Methods of analyzing cellular nucleic acids

The fluidic device with enclosures for single-cell analysis addresses the challenge of monitoring and characterizing individual cells by enabling prolonged observation and nucleic acid sequencing, providing detailed cellular insights.

WO2026236709A1PCT designated stage Publication Date: 2026-11-12CELLANOME INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027447
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-02-17
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing methods for single-cell analysis struggle to efficiently monitor and characterize individual cells due to heterogeneity in cell populations, lacking the ability to track changes at the single-cell level and requiring improved methods for enclosing, monitoring, and characterizing cells.

Method used

A method involving a fluidic device that forms at least 500 enclosures, each containing one or more cells, allowing for monitoring and imaging these enclosures for extended periods, followed by nucleic acid release and sequencing, with unique barcodes for data association.

Benefits of technology

Enables detailed monitoring and characterization of individual cells, capturing longitudinal data and interactions, with high cell viability and efficient nucleic acid capture, facilitating comprehensive analysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027447_12112026_PF_FP_ABST
    Figure US2026027447_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed herein are systems and methods for monitoring and performing serial assays on cells within a fluidic device with single-cell resolution.
Need to check novelty before this filing date? Find Prior Art

Description

WSGR Docket No. 59528-739601METHODS OF ANALYZING CELLULAR NUCLEIC ACIDS CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U. S. Provisional Application No. 63 / 803,414, filed May 9, 2025, U. S. Application No. 19 / 542,547, filed February 17, 2026, U. S.Application No. 19 / 318,300, filed September 3, 2025, U. S. Application No. 19 / 318,303, filed September 3, 2025, U. S. Application No. 19 / 318,284, filed September 3, 2025, U. S.Application No. 19 / 318,293, filed September 3, 2025, and U. S. Application No. 19 / 318,296, filed September 3, 2025, each of which is incorporated herein by reference in its entirety.BACKGROUND

[0002] In the field of cellular biology, single-cell analysis can include the study of genomics, transcriptomics, proteomics, metabolomics, and cell-cell interactions at the single-cell level. Due to the heterogeneity seen in both eukaryotic and prokaryotic cell populations, analyzing a single cell can make it possible to discover mechanisms not seen when studying a bulk population of cells. In single-cell analysis, changes in single cells can be tracked or observed at the level of genes, proteins, or other cellular components. In addition, there is a need to develop improved methods for enclosing, monitoring, and characterizing cells.SUMMARY

[0003] In one embodiment, the present disclosure provides a method, comprising: (a) introducing a plurality of cells to a fluidic device; (b) subsequent to (a), forming at least 500 enclosures, wherein each enclosure of the at least 500 enclosures comprises one or more cells of the plurality of cells; and (c) subsequent to (b), monitoring each enclosure of the at least 500 enclosures for at least about 10 minutes.In one embodiment, the present disclosure provides a method, comprising: (a) providing a fluidic device, wherein: the fluidic device comprises at least 500 enclosures, each enclosure of the at least 500 enclosures has an interior volume, the interior volume comprises a fluid, a cell of the plurality of cells is entirely located within the interior volume of each enclosure of the at least 500 enclosures, and the cell of a plurality of cells within each enclosure is not immobilized within the interior volume the enclosure; and (b) subsequent to (a), monitoring each enclosure of the at least 500 enclosures for at least about 10 minutes.

[0004] In one aspect, the plurality of cells comprises from about 500 to about 5×105cells. In some aspects, (b) comprises forming from about 1000 to about 100000 enclosures. In anotherWSGR Docket No. 59528-739601aspect, (b) comprises forming from about 1000 to about 40000 enclosures. In a further aspect, (b) comprises forming from about 2000 to about 20000 enclosures.

[0005] In a particular aspect, the method comprises monitoring each enclosure of the at least 500 enclosures for at least about one day. In an additional aspect, the method comprises monitoring each enclosure of the at least 500 enclosures for about 1 day to about 50 days. In a further aspect, the distribution of numbers of cells comprised by individual enclosures of the at least 500 enclosures is not a Poisson distribution.

[0006] In certain aspects, each of the at least 500 enclosures comprises a single cell. In further aspects, the plurality of cells are in a quiescent medium during (b). In additional aspects, the monitoring comprises imaging the at least 500 enclosures. In particular aspects, the monitoring comprises performing one or more image-based phenotypic assays on at least one cell of the plurality of cells. In select aspects, the monitoring comprises performing at least two imaging-based phenotypic assays. In further aspects, the one or more imaging-based phenotypic assays comprises monitoring a morphology, proliferation, surface marker expression, cytokine secretion, or a combination thereof of at least one cell of the plurality of cells. In certain aspects, the one or more imaging-based phenotypic assays comprises monitoring an interaction between a first cell of the plurality of cells and a second cell of the plurality of cells. In some such aspects, i) the interaction comprises killing, ii) the interaction comprises activation, iii) the interaction comprises junction formation, iv) the interaction comprises phagocytosis, or v) a combination thereof. In additional aspects, the first cell and the second cell are co-enclosed within an enclosure of the at least 500 enclosures. In further aspects, the first cell is enclosed within a first enclosure of the at least 500 enclosures, and the second cell is enclosed within a second enclosure of the at least 500 enclosures. In other aspects, the first cell is enclosed within a first enclosure of the at least 500 enclosures, and the second cell is not enclosed within an enclosure.

[0007] In a particular aspect, the method further comprises, subsequent to (c): (d) releasing one or more nucleic acids from a cell of the one or more cells, wherein the one or more nucleic acids are captured in an enclosure of the at least 500 enclosures. In one such aspect, (d) comprises lysing the cell. In another aspect, the method further comprises sequencing the one or more nucleic acids, a derivative of the one or more nucleic acids, or a complement of the derivative of the one or more nucleic acids. In additional aspects, the method further comprises linking data generated from the sequencing to data generated from the monitoring. In certain aspects, the one or more nucleic acids are captured on nucleic acid capture probes,WSGR Docket No. 59528-739601and wherein the nucleic acid capture probes comprise barcodes that are uniquely associated with an enclosure of the at least 500 enclosures.

[0008] In some aspects, (c) comprises generating unique longitudinal data for each of the at least 500 enclosures. In further aspects, (b) comprises selectively polymerizing one or more polymer precursors in the fluidic device. Polymerization may occur upon application of energy to the fluidic device. Energy can include thermal energy, radiant energy (including light), chemical energy, plasma energy, mechanical energy, elastic energy, or acoustic energy, for example. In certain aspects, the selectively polymerizing is performed using a spatial light modulator to direct light into the fluidic device, wherein the light photopolymerizes the one or more polymer precursors.

[0009] In certain aspects, the forming generates the at least 500 enclosures at a rate of about 50 to about 1500 enclosures per minute. In some aspects, the forming is performed in less than about 30 minutes. In further aspects, walls of the at least 500 enclosures comprise pores, wherein the pores are sufficiently large to allow passage of proteins including a molecular weight of 150 kDa or less through the walls of the at least 500 enclosures, and wherein the pores block passage of the one or more cells through the walls of the at least 500 enclosures. In particular aspects, the at least 500 enclosures comprise fixed positions within the fluidic device.

[0010] In one aspect, at least about 90% of the one or more cells are alive during the monitoring of (c). In another aspect, a density of the at least 500 enclosures over an area of the fluidic device is about 50 to about 6000 enclosures per cm2. In a certain aspect, (c) comprises detecting a state transition of a cell of the one or more cells.

[0011] In another embodiment, the present disclosure provides a method, comprising: (a) introducing a plurality of cells to a fluidic device; (b) subsequent to (a), forming at least 500 enclosures, wherein each enclosure of the at least 500 enclosures comprises one or more cells of the plurality of cells; (c) subsequent to (b), performing one or more imaging assays in the at least 500 enclosures; and (d) subsequent to (c), performing one or more molecular assays on the one or more cells or on a subset of the one or more cells.

[0012] In another embodiment, the present disclosure provides a method, comprising: (a) providing a fluidic device, wherein: the fluidic device comprises at least 500 enclosures, each enclosure of the at least 500 enclosures has an interior volume, the interior volume comprises a fluid, a cell of a plurality of cells is entirely located within the interior volume of each enclosure of the at least 500 enclosures, and the cell of the plurality of cells within each enclosure is not immobilized within the interior volume of the enclosure comprises a cell ofWSGR Docket No. 59528-739601the plurality of cells; (b) subsequent to (a), performing an imaging assay in the at least 500 enclosures; and (c) subsequent to (b), performing a molecular assay on at least a subset of the plurality of cells.

[0013] In one aspect, the plurality of cells comprises from about 500 to about 5 x 105cells. In another aspect, (b) comprises forming from about 1000 to about 40000 enclosures. In an additional aspect, (b) comprises forming from about 2000 to about 20000 enclosures. In a further aspect, the method comprises monitoring each enclosure of the at least 500 enclosures for about 1 day to about 50 days. In a certain aspect, each of the at least 500 enclosures comprises a single cell. In a particular aspect, the plurality of cells are in a quiescent medium during (b). In a further aspect, the molecular assay comprises releasing one or more nucleic acids from a cell of the one or more cells, wherein the one or more nucleic acids are captured in an enclosure of the at least 500 enclosures, and wherein the molecular assay comprises sequencing the one or more nucleic acids. In another aspect, the one or more imaging assays generate unique longitudinal data for each of the at least 500 enclosures. In a particular aspect, (b) comprises selectively polymerizing one or more polymer precursors in the fluidic device. In another aspect, the forming generates the at least 500 enclosures at a rate of about 50 to about 1500 enclosures per minute.

[0014] In another embodiment, the present disclosure provides a method, comprising: (a) selectively encapsulating at least 100 cells such that in a fluidic device such that each cell of the at least 100 cells is spatially constrained to a unique area of the fluidic device, wherein each of the unique areas is no more than 285,000 μm2; and (b) monitoring each cell of the at least 100 cells for at least 10 minutes, thereby obtaining longitudinal data unique to each cell of the at least 100 cells.

[0015] In some aspects, (a) comprises selectively encapsulating from about 2000 to about 20000 cells. In further aspects, each unique area is about 700 to about 30000 μm2. In particular aspects, each unique area is contained within a unique enclosure.

[0016] In a further embodiment, the present disclosure provides a method, comprising: (a) introducing a plurality of cells to a fluidic device comprising a surface; and (b) selectively encapsulating or isolating a subset of cells of the plurality of cells such that each cell of the subset of cells is physically separated from other cells of the subset of cells, wherein at least about 1.5 cells are encapsulated per mm2of the surface.

[0017] In a particular aspect, from about 2 to about 60 cells are encapsulated or isolated per mm2of the surface. In another aspect, (b) comprises forming a plurality of enclosures, wherein each enclosure of the plurality of enclosures comprises a cell of the subset of cells.WSGR Docket No. 59528-739601In a further aspect, during (b), the plurality of enclosures are formed at a rate of about 50 to about 1500 enclosures per minute. In an additional aspect, during (b), the subset of cells are encapsulated at a rate of about 50 to about 1500 cells per minute. In a certain aspect, an additional subset of cells of the plurality of cells are not selectively encapsulated during (b), and wherein the method comprises removing the additional subset of cells from the fluidic device. In an additional aspect, the subset of cells are in chemical communication following (b).

[0018] An additional embodiment of the present disclosure provides a method, comprising: (a) introducing a plurality of cells to a fluidic device; and (b) selectively encapsulating a subset of cells of the plurality of cells such that each cell of the subset of cells is physically separated from other cells of the subset of cells, wherein during the encapsulating, the plurality of cells are in a quiescent fluid.

[0019] In a further embodiment, the present disclosure provides a method, comprising: (a) introducing a plurality of cells to a fluidic device; and (b) subsequent to (a), forming a plurality of enclosures, wherein each enclosure of the plurality of enclosures comprises one or more cells of the plurality of cells, and wherein one or more secretions of the plurality of cells can flow between the plurality of enclosures.

[0020] In some aspects, during (b) the plurality of cells are in a quiescent fluid. In certain aspects, walls of the enclosures comprise pores, wherein the pores are sufficiently large to allow passage of the secretions through the walls of the enclosures, and wherein the pores block passage of the one or more cells through the walls of the enclosures. In particular aspects, the secretions comprise cytokines.

[0021] Another embodiment of the present disclosure provides a method, comprising: (a) selectively encapsulating a subset of adherent cells of a plurality of adherent cells disposed on a surface of a fluidic device such that each adherent cell of the subset of adherent cells is physically separated from other adherent cells of the subset of adherent cells; and (b) monitoring the subset of adherent cells for at least 10 minutes.

[0022] Further embodiments of the present disclosure provide a fluidic device, comprising: at least 1000 enclosures, wherein at least 75% of the 1000 enclosures comprise a living adherent cell in its adherent state.

[0023] In another embodiment, the present disclosure provides a method for analyzing a cell, comprising: performing at least 3 assays on a plurality of cells, wherein each of the at least 3 assays generates data associated with the plurality of cells, and wherein the method furtherWSGR Docket No. 59528-739601comprises associating a subset of the data from each of the at least 3 assays with individual cells of the plurality of cells.

[0024] In certain aspects, the at least 3 assays are performed in about 1 to about 30 minutes. In particular aspects, an assay of the at least 3 assays generates the data on the plurality of cells simultaneously. In select aspects, the method comprises performing from 4 to 8 assays on the plurality of cells. In some aspects, the at least 3 assays comprise an imaging assay and a molecular assay. In further aspects, the at least 3 assays comprise cytotoxicity, proliferative capacity, proliferation rate, activation status, cellular identity, purity, gene expression profile, transcriptome, surface marker expression, soluble factor secretion, activation status, epigenetic profile, sequence copy number, morphology, subcellular localization, intracellular protein expression, or a combination thereof. In additional aspects, the method further includes enclosing the plurality of cells within a plurality of enclosures.

[0025] Additional embodiments of the present disclosure provide a method for analyzing a cell, comprising: performing at least 3 assays on a plurality of cells, wherein the plurality of cells comprises the cell, wherein each of the at least 3 assays simultaneously generates data associated with the plurality of cells, and wherein the method further comprises associating a subset of the data from each of the at least 3 assays with the cell.

[0026] In a particular aspect, at least two assays of the plurality of assays are performed at different times. In an additional aspect, the method comprises performing from 4 to 8 assays on the plurality of cells. In a further aspect, the plurality of cells are enclosed within a plurality of enclosures.

[0027] In certain embodiments, the present disclosure provides a method for analyzing a plurality of cells, comprising: dispersing a plurality of cells over a planar surface; imaging the plurality of cells, thereby generating a plurality of cell images; performing a molecular assay on the plurality of cells or a subset of the plurality of cells, thereby generating a plurality of molecular assay results; and associating at least one cell image of the plurality of cell images and at least one molecular assay result of the plurality of molecular assay results with each cell of the plurality of cells or the subset of the plurality of cells.

[0028] In some aspects, the plurality of cells comprises at least about 500 cells. In additional aspects, the imaging comprises collecting images of the plurality of cells at multiple time points. In certain aspects, the multiple time points span at least 10 minutes. In further aspects, the imaging comprises collecting multiple images of the cells, wherein the multiple images are collected at different wavelengths. In particular aspects, the at least 3 measurementsWSGR Docket No. 59528-739601comprise at least three images collected at different wavelengths. In select aspects, the multiple images are collected in about 0.2 to about 5 seconds.

[0029] Further embodiments of the present disclosure provide a method for analyzing a plurality of cells over a period of time, comprising: collecting a first image of the plurality of cells, wherein the first image comprises a plurality of fields of view, and wherein the collecting the first image comprises moving a detector over the plurality of fields of view; applying annotations to at least a subset of the plurality of cells in the first image; collecting a second image of the plurality of cells, wherein the second image is collected after the first image, wherein the second image comprises the plurality of fields of view, and wherein the collecting the second image comprises moving the detector over the plurality of fields of view; and applying the annotations to the plurality of cells or the subset of the plurality of cells in the second image, wherein each cell of the plurality of cells or the subset of the plurality of cells received the same annotation in the first image and the second image.

[0030] In one aspect, at least a subset of the plurality of cells move in between the collecting the first image and the collecting the second image. In another aspect, the method further comprises forming a plurality of enclosures, wherein the plurality of enclosures enclose the plurality of cells.

[0031] In an additional embodiment, the present disclosure provides a method for analyzing a cell, comprising: imaging a plurality of cells, wherein the plurality of cells are at least partially enclosed within a plurality of enclosures; at least partially based on the imaging, selecting a first subset of enclosures of the plurality of enclosures, wherein the first subset of enclosures comprises a first subset of cells of the plurality of cells; and subjecting the first subset of cells to a molecular assay. In a particular aspect, the method further comprises degrading a second subset of enclosures of the plurality of enclosures, wherein the second subset of enclosures comprises a second subset of cells of the plurality of cells.

[0032] In some embodiments, the present disclosure provides a method for isolating cells, comprising: collecting an image of a plurality of cells; using the image, identifying at least about 500 cells from the image of the plurality of cells; and generating a plurality of enclosures, wherein the plurality of enclosures at least partially enclose the at least about 500 cells, wherein the method is performed in less than about 30 minutes, and wherein the plurality of cells are in a quiescent medium during the generating.

[0033] In further embodiments, the present disclosure provides a method for isolating cells, comprising: collecting an image of a plurality of cells; using the image, identifying at least about 20 cells from the image of the plurality of cells; and generating a plurality ofWSGR Docket No. 59528-739601enclosures, wherein the plurality of enclosures at least partially enclose the at least about 20 cells, wherein the method is performed in less than about 5 seconds.

[0034] In some aspects, the plurality of cells are in a quiescent medium during the generating. In further aspects, the method further comprises identifying additional cells from the image of the plurality of cells, wherein the plurality of enclosures do not enclose or partially enclose the additional cells. In particular aspects, the at least about 20 cells are in a native state, an adhered state, or a combination thereof. In certain aspects, the generating comprises: i) controlling the minimum number of cells of the at least 20 cells in each enclosure, ii) controlling the maximum number of cells of the at least 20 cells in each enclosure, or iii) a combination thereof.

[0035] In a further aspect, the method further comprises controlling environments inside of the plurality of enclosures. In another aspect, the method further comprises applying a treatment to the at least 20 cells. In an additional aspect, each enclosure of the plurality of enclosures comprises a fixed location within a fluidic device. In a further aspect, the distribution of numbers of cells of the at least 20 cells enclosed by individual enclosures of the plurality of enclosures is not a Poisson distribution.

[0036] In another embodiment, the present disclosure provides a method for isolating cells, comprising: receiving one or more parameters relating to one or more characteristics of an enclosure; generating a plurality of instances of the enclosure, wherein the plurality of instances of the enclosure enclose at least 500 cells, and wherein each of the plurality of instances of the enclosure comprises the one or more characteristics.

[0037] In certain aspects, the one or more characteristics comprise: i) an enclosure dimension, ii) an enclosure wall thickness, iii) an enclosure shape, iv) a minimum distance between an enclosure wall inner surface and a cell, v) a minimum distance between an enclosure wall outer surface and a cell, vi) a number of openings in the enclosure, vii) a maximum percentage of an area that can be covered by the plurality of instances of the enclosure, viii) a minimum percentage of an area that can be covered by the plurality instances of the enclosure, or ix) a combination thereof.

[0038] In certain aspects, the cells in an analysis method or device are from a subject. In some such aspects, the subject is a human subject. In particular aspects, a disclosed method further includes identifying a health status of the subject at least in part based on data generated during the method. In further aspects, the identifying the health status includes a probability of the subject having the health status a) at the time of the sample collection of the cells or b) at a time in the future at certain time interval. In further aspects, the method ofWSGR Docket No. 59528-739601identifying the health status of the subject includes inputting at least a portion of the data into a trained machine learning model. The method of training the trained machine learning model may include using data generated with cells that were not used in the analysis method. The machine learning model may be trained before using the cells in the analysis method.

[0039] In an aspect, the monitoring comprises detecting a cell state transition of a cell of the plurality of cells located in an enclosure of the at least 500 enclosures.

[0040] In another aspect, provided herein is a method, comprising: (a) introducing at least 100 cells to a channel of a fluidic device, wherein the introducing the at least 100 cells to the fluidic device comprises introducing the at least 100 cells through an inlet of the fluidic device; (b) selectively enclosing the at least 100 cells in a plurality of unique enclosures in the channel of the fluidic device such that each cell of the at least 100 cells is spatially constrained to a unique area of a plurality of unique areas of the channel of the fluidic device, wherein each unique area of the plurality of unique areas comprises a unique enclosure of the plurality of unique enclosures, wherein each unique area of the plurality of unique areas is no more than 285,000 square micrometers (μm2), and wherein the selectively enclosing is performed at a rate of at least 250 unique enclosures per minute; (c) subsequent to the selectively enclosing in (b), performing a cellular or molecular assay on the at least 100 cells to determine a cellular characteristic, wherein the cellular characteristic comprises cytotoxicity, proliferative capacity, proliferation rate, cellular identity, purity, gene expression profile, transcriptome, surface marker expression, soluble factor secretion, activation status, epigenetic profile, sequence copy number, morphology, subcellular localization, intracellular protein expression, DNA sequence variation, or a combination thereof; (d) identifying at least a subset of the at least 100 cells; and (e) monitoring the at least 100 cells or the subset of the at least 100 cells in the plurality of unique enclosures for at least 10 minutes, thereby obtaining longitudinal data unique to each cell of the at least 100 cells or the subset of the at least 100 cells, wherein at least 90% of the at least 100 cells or the subset of the at least 100 cells are viable after the at least 10 minutes, wherein the monitoring comprises imaging the at least 100 cells or the subset of the at least 100 cells to generate a plurality of images across a plurality of fields of view of the channel of the fluidic device, wherein the longitudinal data comprises data from a first time point and a second time point of the at least 10 minutes, and wherein the first time point and the second time point are different.

[0041] In some cases, at least two of the at least 100 cells are spatially constrained to the same unique area of the plurality of unique areas. In some cases, the at least 100 cells comprises from 2000 to 20000 cells. In some cases, each unique area of the plurality ofWSGR Docket No. 59528-739601unique areas is 700 to 30000 μm2. In some cases, the fluidic device comprises from 1000 to 100000 unique enclosures of the plurality of unique enclosures. In some cases, at least a subset of the plurality of unique enclosures comprises a single cell of the at least 100 cells.

[0042] In some cases, the monitoring comprises performing an image-based phenotypic assay on a cell of the at least 100 cells or the subset of the at least 100 cells. In some cases, the monitoring comprises detecting an interaction between a first cell of the at least 100 cells or the subset of the at least 100 cells and a second cell of the at least 100 cells or the subset of the at least 100 cells. In some cases, (i) the interaction comprises killing the first cell, (ii) the interaction comprises activation of the first cell, (iii) the interaction comprises junction formation, (iv) the interaction comprises phagocytosis of the first cell, or (v) a combination thereof. In some cases, the first cell and the second cell are co-located in a single unique enclosure of the plurality of unique enclosures. In some cases, the first cell is located in a first unique enclosure of the plurality of unique enclosures, and the second cell is located in a second unique enclosure of the plurality of unique enclosures.

[0043] In some cases, the method further comprises, subsequent to (e), (f) releasing a nucleic acid from a cell of the at least 100 cells, wherein the nucleic acid is captured on a surface located in the unique area of the fluidic device that the cell of the at least 100 cells is spatially constrained to. In some cases, the method further comprises sequencing the nucleic acid, a derivative of the nucleic acid, or a complement of the derivative of the nucleic acid, and linking data generated from the sequencing to the longitudinal data obtained in (e).

[0044] In some cases, the at least 100 cells are from a human subject, and the method further comprises identifying a health status of the human subject at least in part based on the monitoring of (e).

[0045] In another aspect, provided herein is a method, comprising: (a) introducing a plurality of cells to a channel of a fluidic device, wherein the introducing the plurality of cells to the fluidic device comprises introducing the plurality of cells through an inlet of the fluidic device, wherein the fluidic device comprises a surface; (b) selectively enclosing a subset of cells of the plurality of cells in a plurality of unique enclosures in the channel of the fluidic device such that each cell of the subset of cells is physically separated from other cells of the subset of cells of the plurality of cells, wherein at least about 1.5 cells are enclosed per micrometer squared (μm2) of the surface, and wherein the selectively enclosing is performed at a rate of at least 250 unique enclosures per minute; and (c) subsequent to the selectively enclosing in (b), performing a cellular or molecular assay on the plurality of cells or the subset of the plurality of cells to determine a cellular characteristic, wherein the cellularWSGR Docket No. 59528-739601characteristic comprises cytotoxicity, proliferative capacity, proliferation rate, cellular identity, purity, gene expression profile, transcriptome, surface marker expression, soluble factor secretion, activation status, epigenetic profile, sequence copy number, morphology, subcellular localization, intracellular protein expression, DNA sequence variation, or a combination thereof.

[0046] In some cases, from 2 to 60 cells are enclosed per mm2of the surface. In some cases, each unique enclosure of the plurality of unique enclosures comprises a cell of the subset of cells. In some cases, during (b), an additional subset of cells of the plurality of cells are not selectively enclosed during (b), and the method further comprises removing the additional subset of cells from the fluidic device. In some cases, the subset of cells are in chemical communication following (b).

[0047] In some cases, the method further comprises (d) monitoring the subset of cells for at least 10 minutes, thereby obtaining longitudinal data unique to each cell of the subset of cells. In some cases, the method further comprises, subsequent to (d), (e) releasing a nucleic acid from the cell, wherein the nucleic acid is enclosed with the cell. In some cases, the method further comprises sequencing the nucleic acid, a derivative of the nucleic acid, or a complement of the derivative of the nucleic acid, and linking data generated from the sequencing to data generated from the monitoring in (d).

[0048] In some cases, the subset of cells comprises 2000 to 20000 cells. In some cases, the monitoring in (d) comprises: (i) imaging a cell of the subset of cells; (ii) performing an image-based phenotypic assay on the cell; or (iii) a combination thereof.

[0049] In some cases, the plurality of cells are from a human subject, and the method further comprises identifying a health status of the human subject at least in part based the monitoring of (d).

[0050] In some cases, the method further comprises screening a cell of the at least 100 cells for a genetic mutation. In some cases, the monitoring of (e) comprises measuring a response of a cell of the at least 100 cells to an incubation condition.

[0051] In some cases, the plurality of unique enclosures comprise polymer matrices, and the selectively enclosing comprises projecting light into the channel of the fluidic device. In some cases, the light causes a polymer precursor to crosslink to form the polymer matrices.

[0052] In some cases, the monitoring in (e) comprises monitoring the at least 100 cells or the subset of the at least 100 cells in the plurality of unique enclosures for at least 10 hours. In some cases, the monitoring in (e) comprises monitoring the at least 100 cells or the subset of the at least 100 cells in the plurality of unique enclosures for at least 1 day. In some cases, theWSGR Docket No. 59528-739601cellular characteristic comprises cytotoxicity, proliferative capacity, proliferation rate, cellular identity, purity, gene expression profile, transcriptome, surface marker expression, soluble factor secretion, activation status, morphology, or a combination thereof. In some cases, the selectively enclosing is performed at a rate of 250 unique enclosures per minute to 2500 unique enclosures per minute. In some cases, each unique enclosure of the plurality of unique enclosures has an interior volume, and a cell of the at least 100 cells is entirely located within the interior volume of each unique enclosure of the plurality of unique enclosures. In some cases, the cell of the at least 100 cells within each unique enclosure is not immobilized within the interior volume of the unique enclosure.

[0053] In some cases, at least 95% of the at least 100 cells or the subset of the at least 100 cells are viable after the at least 10 minutes. In some cases, at least 98% of the at least 100 cells or the subset of the at least 100 cells are viable after the at least 10 minutes.

[0054] In some cases, the identifying of the at least the subset of the plurality of cells in (d) is based at least based in part on the cellular characteristic determined in (c). In some cases, the identifying of the at least the subset of the plurality of cells in (d) occurs subsequent to the determining of the cellular characteristic in (c).

[0055] In another aspect, provided herein is a method, comprising: (a) selectively encapsulating at least 100 cells in a fluidic device such that each cell of the at least 100 cells is spatially constrained to a unique area of the fluidic device, wherein each of the unique areas is no more than 285,000 μm2; and (b) monitoring each cell of the at least 100 cells for at least 10 minutes, thereby obtaining longitudinal data unique to each cell of the at least 100 cells.

[0056] In another aspect, provide herein is a method, comprising: (a) introducing a plurality of cells to a fluidic device comprising a surface; and (b) selectively encapsulating a subset of cells of the plurality of cells such that each cell of the subset of cells is physically separated from other cells of the subset of cells, wherein at least about 1.5 cells are encapsulated per mm2of the surface.

[0057] In another aspect, provided herein is a method, comprising: (a) introducing a plurality of cells to a channel of a fluidic device, wherein the introducing the plurality of cells to the fluidic device comprises introducing the plurality of cells through an inlet of the fluidic device; (b) subsequent to (a), forming a plurality of unique enclosures in the channel of the fluidic device, wherein the plurality of unique enclosures comprises at least 1000 unique enclosures, wherein each unique enclosure of the plurality of unique enclosures comprises a cell of the plurality of cells, and wherein the plurality of cells are in a quiescent fluid duringWSGR Docket No. 59528-739601the forming of the plurality of unique enclosures; (c) subsequent to (b), performing a cellular or molecular assay on the plurality of cells or a subset of the plurality of cells to determine a cellular characteristic, wherein the cellular characteristic comprises cytotoxicity, proliferative capacity, proliferation rate, cellular identity, purity, gene expression profile, transcriptome, surface marker expression, secretion, activation status, morphology, or a combination thereof; and (d) monitoring each cell of the plurality of cells or the subset of the plurality of cells in the plurality of unique enclosures for at least 10 minutes, thereby obtaining longitudinal data unique to each cell of the plurality of cells or the subset of the plurality of cells, wherein at least 95% of the plurality of cells or the subset of the plurality of cells are viable after the at least 10 minutes, wherein the monitoring comprises imaging the plurality of cells or the subset of the plurality of cells to generate a plurality of images across a plurality of fields of view of the channel of the fluidic device, wherein the longitudinal data comprises data from a first time point and a second time point of the at least 10 minutes, and wherein the first time point and the second time point are different.

[0058] In another aspect, provided herein is a method, comprising: (a) introducing a plurality of cells to a channel of a fluidic device, wherein the introducing the plurality of cells to the fluidic device comprises introducing the plurality of cells through an inlet of the fluidic device; (b) subsequent to (a), forming a plurality of unique enclosures in the channel of the fluidic device, wherein the plurality of unique enclosures comprises at least 1000 unique enclosures, wherein each unique enclosure of the plurality of unique enclosures comprises a cell of the plurality of cells, and wherein the plurality of unique enclosures are configured to allow secretions from the plurality of cells to flow between the plurality of unique enclosures; (c) subsequent to (b), performing a cellular or molecular assay on the plurality of cells or a subset of the plurality of cells to determine a cellular characteristic, wherein the cellular characteristic comprises cytotoxicity, proliferative capacity, proliferation rate, cellular identity, purity, gene expression profile, transcriptome, surface marker expression, secretion, activation status, morphology, or a combination thereof; and (d) monitoring each cell of the plurality of cells or the subset of the plurality of cells in the plurality of unique enclosures for at least 10 hours, thereby obtaining longitudinal data unique to each cell of the plurality of cells or the subset of the plurality of cells, wherein at least 90% of the plurality of cells or the subset of the plurality of cells are viable after the at least 10 hours, wherein the monitoring comprises imaging the plurality of cells or the subset of the plurality of cells to generate a plurality of images across a plurality of fields of view of the channel of the fluidic device, wherein the longitudinal data comprises data from a first time point and a second time pointWSGR Docket No. 59528-739601of the at least 10 hours, and wherein the first time point and the second time point are different.

[0059] In some cases, an additional subset of cells of the plurality of cells are not selectively enclosed during (b), and the method further comprises removing the additional subset of cells from the fluidic device.

[0060] In some cases, (b) comprises selectively enclosing at least 2000 cells of the plurality of cells. In some cases, a first cell of the plurality of cells in a first unique enclosure of the plurality of unique enclosures and a second cell of the plurality of cells in a second unique enclosure of the plurality of unique enclosures are in chemical communication following (b). In some cases, the method further comprises releasing a nucleic acid from a cell of the plurality of cells or the subset of the plurality of cells, wherein the nucleic acid is located in a unique enclosure of the plurality of unique enclosures with the cell. In some cases, the method further comprises sequencing the nucleic acid, a derivative of the nucleic acid, or a complement of the derivative of the nucleic acid, and linking data generated from the sequencing to data generated from the monitoring in (d). In some cases, the nucleic acid is captured on a nucleic acid capture probe, and the nucleic acid capture probe comprises a barcode that is uniquely associated with the unique enclosure of the plurality of unique enclosures.

[0061] In some cases, the plurality of cells are from a human subject, and the method further comprises identifying a health status of the subject at least in part based on the cellular characteristic determined in (c) and the longitudinal data obtained in (d).

[0062] In some cases, during (b) the plurality of cells are disposed in a quiescent fluid. In some cases, walls of the plurality of unique enclosures comprise pores, and the pores are sufficiently large to allow passage of the secretions through the walls of the plurality of unique enclosures. In some cases, the pores block passage of the plurality of cells through the walls of the plurality of unique enclosures. In some cases, the secretions comprise cytokines.

[0063] In some cases, (b) comprises forming from 1000 to 100000 unique enclosures. In some cases, the monitoring in (d) comprises monitoring a morphology, proliferation, surface marker expression, cytokine secretion, or a combination thereof of each cell of the plurality of cells or the subset of the plurality of cells.

[0064] In some cases, the plurality of cells are from a human subject, and the method further comprises predicting a probability of a response from the human subject to a drug treatment or regimen.WSGR Docket No. 59528-739601

[0065] In some cases, the monitoring comprises measuring an intercellular interaction between two or more cells of the plurality of cells or the subset of the plurality of cells. In some cases, the method further comprises screening the plurality of cells or the subset of the plurality of cells for a genetic mutation.

[0066] In some cases, the plurality of unique enclosures comprise polymer matrices, and the forming comprises projecting light into the fluidic device, and wherein the light causes a polymer precursor to crosslink to form the polymer matrices.

[0067] In some cases, the monitoring in (d) comprises monitoring the plurality of cells or the subset of the plurality of cells in the plurality of unique enclosures for at least 10 hours. In some cases, the monitoring in (d) comprises monitoring the plurality of cells or the subset of the plurality of cells in the plurality of unique enclosures for at least 1 day. In some cases, the plurality of unique enclosures are formed at a rate of at least 250 unique enclosures per minute. In some cases, each unique enclosure of the plurality of unique enclosures has an interior volume, and a cell of the plurality of cells is entirely located within the interior volume of each unique enclosure of the plurality of unique enclosures. In some cases, the cell of the plurality of cells within each unique enclosure is not immobilized within the interior volume of the unique enclosure.

[0068] In some cases, at least 95% of the plurality of cells or the subset of the plurality of cells are viable after the at least 10 minutes or the at least 10 hours. In some cases, at least 98% of the plurality of cells or the subset of the plurality of cells are viable after the at least 10 minutes or the at least 10 hours.

[0069] In another aspect, provided herein is a method, comprising: (a) introducing a plurality of cells to a fluidic device; and (b) selectively encapsulating a subset of cells of the plurality of cells such that each cell of the subset of cells is physically separated from other cells of the subset of cells, wherein during the encapsulating, the plurality of cells are in a quiescent fluid.

[0070] In another aspect, provided herein is a method, comprising: (a) introducing a plurality of cells to a fluidic device; and (b) subsequent to (a), forming a plurality of enclosures, wherein each enclosure of the plurality of enclosures comprises a cell of the plurality of cells, and wherein the plurality of enclosures are configured to allow secretions from the plurality of cells to flow between the plurality of enclosures.

[0071] In another aspect, provided herein is a method for analyzing a plurality of cells over a period of time, comprising: collecting a first image of the plurality of cells, wherein the first image comprises a plurality of fields of view, and wherein the collecting the first image comprises moving a detector over the plurality of fields of view; applying annotations to atWSGR Docket No. 59528-739601least a subset of the plurality of cells in the first image; collecting a second image of the plurality of cells, wherein the second image is collected after the first image, wherein the second image comprises the plurality of fields of view, and wherein the collecting the second image comprises moving the detector over the plurality of fields of view; and applying the annotations to the plurality of cells or the subset of the plurality of cells in the second image, wherein each cell of the plurality of cells or the subset of the plurality of cells received the same annotation in the first image and the second image.

[0072] In another aspect, provided herein is a method, comprising: (a) selectively encapsulating a subset of adherent cells of a plurality of adherent cells disposed on a surface of a fluidic device such that each adherent cell of the subset of adherent cells is physically separated from other adherent cells of the subset of adherent cells; and (b) monitoring the subset of adherent cells for at least 10 minutes.

[0073] In some cases, (a) comprises selectively encapsulating from about 2000 to about 20000 adherent cells. In some cases, (a) comprises forming a plurality of enclosures, wherein each enclosure of the plurality of enclosures comprises an adherent cell of the subset of adherent cells. In some cases, during (a) the plurality of enclosures are formed at a rate of about 50 to about 1500 enclosures per minute. In some cases, during (a), the subset of adherent cells are encapsulated at a rate of about 50 to about 1500 adherent cells per minute.

[0074] In some cases, an additional subset of adherent cells of the plurality of adherent cells are not selectively encapsulated during (a), and the method comprises removing the additional subset of adherent cells from the fluidic device. In some cases, the subset of adherent cells are in chemical communication following (a).

[0075] In some cases, the method further comprises, subsequent to (c): (d) releasing a nucleic acid from an adherent cell of the subset of adherent cells, wherein the nucleic acid is selectively encapsulated with the adherent cell. In some cases, the method further comprises sequencing the nucleic acid, a derivative of the nucleic acid, or a complement of the derivative of the nucleic acid, and linking data generated from the sequencing to data generated from the monitoring in (b).

[0076] In some cases, the monitoring in (b) comprises: (i) imaging at least one adherent cell of the subset of adherent cells; (ii) performing an image-based phenotypic assay on an adherent cell of the subset of adherent cells; or (iii) a combination thereof.

[0077] In some cases, (a) comprises forming at least 1000 enclosures, wherein each enclosure of the at least 1000 enclosures comprises an adherent cell of the subset of adherent cells.WSGR Docket No. 59528-739601

[0078] In some cases, in (b), at least 75% of the at least 1000 enclosures comprises a living adherent cell in its adherent state. In some cases, the surface comprises (i) fibronectin, (ii) laminin, (iii) poly-L-ornithine, or (iv) a combination thereof.

[0079] In another aspect, provided herein is a fluidic device, comprising: at least 1000 enclosures, wherein at least 75% of the 1000 enclosures comprise a living adherent cell in its adherent state.

[0080] In some cases, the living adherent cells are adhered to a surface of the fluidic device. In some cases, the surface comprises (i) fibronectin, (ii) laminin, (iii) poly-L-ornithine, or (iv) a combination thereof. In some cases, the living adherent cells are from a single human subject.

[0081] In another aspect, provided herein is a method, comprising: performing at least 3 assays on a plurality of cells, wherein each of the at least 3 assays generates data associated with the plurality of cells, and wherein the method further comprises associating a subset of the data from each of the at least 3 assays with individual cells of the plurality of cells.

[0082] In some cases, the at least 3 assays are performed in about 1 to about 30 minutes. In some cases, at least one assay of the at least 3 assays simultaneously generates data for at least a subset of the plurality of cells. In some cases, the method comprises performing from 4 to 8 assays on the plurality of cells. In some cases, the at least 3 assays comprise (i) an imaging assay and (ii) a molecular assay. In some cases, the imaging assay comprises monitoring a morphology, proliferation, surface marker expression, cytokine secretion, or a combination thereof of at least one cell of the plurality of cells. In some cases, the molecular assay comprises: releasing a nucleic acid from a cell of the plurality of cells, and sequencing the nucleic acid, a derivative of the nucleic acid, or a complement of the derivative of the nucleic acid.

[0083] In some cases, at least about 90% of the plurality of cells are alive during the imaging assay. In some cases, the imaging assay comprises monitoring the plurality of cells for at least about 10 minutes. In some cases, the at least 3 assays measure: cytotoxicity, proliferative capacity, proliferation rate, activation status, cellular identity, purity, gene expression profile, transcriptome, surface marker expression, soluble factor secretion, activation status, epigenetic profile, sequence copy number, morphology, subcellular localization, intracellular protein expression, or a combination thereof of at least one cell of the plurality of cells.WSGR Docket No. 59528-739601

[0084] In some cases, the method further comprises enclosing the plurality of cells within a plurality of enclosures. In some cases, at least 2 assays of the at least 3 assays are performed at different times.

[0085] In another aspect, provided herein is a method for analyzing a plurality of cells, comprising: (a) dispersing the plurality of cells over a planar surface; (b) while the plurality of cells is dispersed over the planar surface, imaging at least a subset of the plurality of cells, thereby generating a plurality of cell images, wherein a cell image of the plurality of cell images comprises an image of a cell of the plurality of cells, wherein the plurality of cell images is collected over a plurality of fields of view of the planar surface; (c) while the plurality of cells is dispersed over the planar surface, releasing a nucleic acid molecule from the cell of the plurality of cells and capturing the nucleic acid molecule with a capture probe; (d) performing at least a portion of a nucleic acid assay on the nucleic acid molecule or a derivative thereof, thereby generating a nucleic acid assay result, wherein the nucleic acid assay result identifies at least a portion of the capture probe that is associated with the cell of the plurality of cells; and (e) associating the cell image with nucleic acid assay result via at least the capture probe.

[0086] In some cases, the imaging is performed at multiple time points, and wherein the multiple time points span at least 10 minutes. In some cases, the plurality of cell images comprise cell images collected at different wavelengths. In some cases, the plurality of cell images are collected at three or more wavelengths. In some cases, the cell image is collected in about 0.2 to about 5 seconds.

[0087] In some cases, the method further comprises enclosing the plurality of cells or the subset of the plurality of cells within a plurality of enclosures, wherein the cell is enclosed within an enclosure of the plurality of enclosures. In some cases, the plurality of enclosures comprises from about 1000 to about 100000 enclosures. In some cases, at least a subset of the plurality of enclosures comprise single cells of the plurality of cells. In some cases, the plurality of enclosures comprise polymer matrices, and the enclosing comprises projecting light into a fluidic device. In some cases, the fluidic device comprises the planar surface, and wherein the light causes a polymer precursor to crosslink to form the polymer matrices.

[0088] In some cases, the nucleic acid assay comprises screening the plurality of cells or the subset of cells for a mutation. In some cases, the method further comprises using the cell image, the nucleic acid assay result, or the combination thereof to measure a response of the cell to an incubation condition.WSGR Docket No. 59528-739601

[0089] In some cases, at least two cell images of the plurality of cell images are generated simultaneously. In some cases, the planar surface is a surface of a fluidic device, and the fluidic device comprises an additional planar surface that opposes the planar surface. In some cases, the planar surface and the additional planar surface at least partially define a fluidic space that comprises the plurality of cells.

[0090] In some cases, the capture probe comprises a spatially addressable tag, and associating the plurality of cell images with the nucleic acid result comprises detecting the spatially addressable tag. In some cases, at least 90% of the plurality of cells are viable during (b). In some cases, at least 90% of the plurality of cells are viable during (b). In some cases, at least 90% of the plurality of cells are viable during (b). In some cases, detecting the spatially addressable tag comprises sequencing the spatially addressable tag. In some cases, the planar surface comprises a plurality of unique areas, and each cell of the plurality of cells is dispersed into a unique area of the plurality of unique areas. In some cases, each unique area of the plurality of unique areas is no more than 285,000 square micrometers (“pm2”).

[0091] In another aspect, provided herein is a method for isolating cells, comprising: (a) collecting an image of a plurality of cells; (b) using the image, identifying at least about 20 cells of the plurality of cells from the image; and (c) generating a plurality of enclosures, wherein the plurality of enclosures at least partially enclose the at least about 20 cells, wherein (a), (b), and (c) are performed in less than about 5 seconds.

[0092] In another aspect, provided herein is a method for isolating cells, comprising: receiving a parameter relating to a characteristic of an enclosure; generating a plurality of instances of the enclosure, wherein the plurality of instances of the enclosure enclose at least 500 cells, and wherein each of the plurality of instances of the enclosure comprises the characteristic.BRIEF DESCRIPTION OF THE DRAWINGS

[0093] The novel features of the invention are set forth with particularity in the appended claims. Abetter understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also “Figure” and “FIG.” herein), of which:

[0094] FIG. 1 is a schematic illustration of a portion of a channel disposed in a fluidic device, according to some embodiments.WSGR Docket No. 59528-739601

[0095] FIG. 2A is an illustration of a portion of a system as provided herein including an energy source, according to some embodiments.

[0096] FIG. 2B is an illustration of a polymer matrix being formed around a biological component in a portion of a system as provided herein, according to some embodiments.

[0097] FIG. 2C is an illustration of a method of forming a polymer matrix around a biological component in a system as provided herein, according to some embodiments.

[0098] FIG. 3A is an illustration of a top view of the bottom layer of a flow cell.

[0099] FIG. 3B is an illustration of a top view of the spacer layer with a cut-out region suitable for use as part of the flow cell.

[0100] FIG. 3C is an illustration of a top view of the top layer of the flow cell where the top layer has an inlet and outlet opening.

[0101] FIG. 3D is an illustration of a cross-sectional side view of a top layer and a bottom layer sandwiching a spacer layer to form multiple channels of a flow cell.

[0102] FIG. 3E is an illustration of a bottom view of the top layer of a flow cell where the top layer has an inlet and outlet opening, arrays of nucleic acid capture probes, and fluorescent fiducial markers.

[0103] FIG. 3F is an illustration of a bottom view of the top layer of a flow cell coupled to a spacer layer of a flow cell.

[0104] FIG. 3G is an illustration of an array of nucleic acid capture probes arranged in discrete sites and fluorescent fiducial markers along a surface of a fluidic device.

[0105] FIG. 4A is an illustration of a system with a flow cell and an imaging apparatus that are capable of implementing methods of the present disclosure.

[0106] FIG. 4B is an illustration of a flow cell, including a blown-up view of a portion of a channel containing cells disposed in hydrogel chambers.

[0107] FIG. 5 is a schematic of a computer system 1501 that is configured to perform methods described herein.

[0108] FIG. 6 is a flow chart depicting a workflow for assessing health or planning a treatment regimen for a subject.

[0109] FIG. 7 A shows a portion of another embodiment of a fluidic device including a sealable aperture.

[0110] FIG. 7B shows a method of trapping biological components in a portion of a fluidic device, according to some embodiments.

[0111] FIGs. 8A-8C show an example of a method for forming a compartment using a stimulus-responsive polymer. FIG. 8A illustrates a cross-sectional side view of a fluidicWSGR Docket No. 59528-739601device showing the stimulus-responsive polymer disposed on a top layer of the fluidic device in a retracted state. FIG. 8B illustrates a bottom view of the fluidic device showing the stimulus-responsive polymer. FIG. 8C illustrates a cross-sectional side view of a fluidic device showing the stimulus-responsive polymer in an expanded closed state enclosing a biological material along with surface bound discrete sites that include nucleic acid capture probes.

[0112] FIG. 9 is an illustration of a method for capturing a nucleic acid and using the nucleic as a template for extension of a nucleic acid capture probe.

[0113] FIG 10 is a schematic of a workflow for selecting enclosure locations.

[0114] FIG. 11 is an illustration of an isometric view of a surface, a well protruding downward from the surface, a biological component disposed within the well, a polymer matrix wall enclosing a top opening of the well.DETAILED DESCRIPTION

[0115] The present disclosure provides rapid, highly multiplexed assays that enable multiple types of data to be collected on and associated with individual cells. Multiple forms of assay data may be generated for tens to hundreds of thousands of cells. The data may be collected over an extended period of time, and can thus be used to monitor cell responses to incubation conditions, treatment regimens, or intercellular interactions.

[0116] In some embodiments, the presently disclosed methods include forming enclosures around cells. In one such embodiment, the present disclosure provides a method that includes: (a) introducing a plurality of cells into a fluidic device; (b) subsequent to (a), forming at least 500 enclosures, wherein each enclosure of the at least 500 enclosures includes one or more cells of the plurality of cells; and (c) subsequent to (b), monitoring each enclosure of the at least 500 enclosures for at least about 10 minutes.

[0117] The plurality of cells may include from about 5xl02to about 5xl03cells, from about 5xl02to about 104cells, from about 5xl02to about 5xl04cells, from about 5xl02to about 105cells, from about 5xl02to about 5×105cells, from about 103to about 104cells, from about 103to about 5xl04cells, from about 103to about 105cells, from about 103to about 5×105cells, from about 5xl03to about 5xl04cells, from about 5xl03to about 105cells, from about 5xl03to about 5×105cells, from about 104to about 105cells, from about 104to about 5×105cells, or from about 5xl04to about 5×105cells. The plurality of cells may include at least about 5xl02, at least about 103, at least about 5xl03, at least about 104, at least about 5xl04, at least about 105or at least about 5×105cells. The plurality of cells may include atWSGR Docket No. 59528-739601most about 5×105, at most about 105, at most about 5xl04, at most about 104, at most about 5xl03, at most about 103, or at most about 5xl02cells. The plurality of cells may, for example, be contained within a single fluidic device or within a single fluidic space (e.g., a single fluidic device channel that is fluidically isolated from other fluidic device channels).

[0118] In some aspects, the enclosures may enclose from about 0.1% to about 1%, from about 0.1% to about 5%, from about 0.1% to about 10%, from about 0.1% to about 20%, from about 0.1% to about 40%, from about 0.1% to about 60%, from about 0.1% to about 80%, from about 0.1% to about 90%, from about 0.1% to about 99%, from about 1% to about 5%, from about 1% to about 10%, from about 1% to about 20%, from about 1% to about 40%, from about 1% to about 60%, from about 1% to about 80%, from about 1% to about 90%, from about 1% to about 99%, from about 5% to about 10%, from about 5% to about 20%, from about 5% to about 40%, from about 5% to about 60%, from about 5% to about 80%, from about 5% to about 99%, from about 10% to about 20%, from about 10% to about 40%, from about 10% to about 60%, from about 10% to about 80%, from about 10% to about 90%, from about 10% to about 99%, from about 20% to about 40%, from about 20% to about 60%, from about 20% to about 80%, from about 20% to about 90%, from about 20% to about 99%, from about 40% to about 60%, from about 40% to about 80%, from about 40% to about 90%, from about 40% to about 99%, from about 60% to about 80%, from about 60% to about 90%, from about 60% to about 99%, from about 80% to about 90%, from about 80% to about 99%, or from about 90% to about 99% of cells of the plurality of cells. The enclosures may enclose at least about 0.1%, at least about 1%, at least about 5%, at least about 10%, at least about 20%, at least about 40%, at least about 60%, at least about 80%, at least about 90%, at least about 95%, or at least about 99% of cells of the plurality of cells. The enclosures may enclose at least about 5xl02, at least about 103, at least about 5xl03, at least about 104, at least about 5xl04, at least about 105or at least about 5×105cells of the plurality of cells. The enclosures may enclose at most about 5×105, at most about 105, at most about 5xl04, at most about 104, at most about 5xl03, at most about 103, or at most about 5xl02cells of the plurality of cells. The enclosure may enclose from about 5xl02to about 5xl03cells, from about 5xl02to about 104cells, from about 5xl02to about 5xl04cells, from about 5xl02to about 105cells, from about 5xl02to about 5×105cells, from about 103to about 104cells, from about 103to about 5xl04cells, from about 103to about 105cells, from about 103to about 5×105cells, from about 5xl03to about 5xl04cells, from about 5xl03to about 105cells, from about 5xl03to about 5×105cells, from about 104to about 105cells, from about 104to about 5×105cells, or from about 5xl04to about 5×105cells of the plurality of cells.WSGR Docket No. 59528-739601

[0119] In certain aspects, the enclosures may enclose a low proportion of the plurality of cells. A subset of the plurality of cells may be selected for enclosure based on one or more imaging characteristics such as morphology or fluorescence profile. The imaging characteristics may indicate a cell state (e.g., a cell may exhibit a morphology consistent with an adherent state), expression profile (e.g., a cell may exhibit fluorescence that indicates surface marker expression), type (e.g., a class of cells such as immune cells or a specific cell type such as RORyt+Thl7), state (e.g., naive, diseased, etc.), transfection status, or a combination thereof. The enclosed cells may thus be of a particular state or type.

[0120] In particular aspects, a method may include measuring a cell state transition. The cell state transition may be measured using an imaging modality such as brightfield imaging, fluorescence imaging (e.g., to measure fluorescent surface marker stains), or a combination thereof. The measurement may include a time-resolved component. The imaging may acquire sequential images of cells over a period of time, thereby enabling identification of morphological features associated with distinct cell states and transitions therebetween. Such features may include, for example, changes in cell size, shape, intracellular structure, intracellular organization, opacity, and the like. Image data may be processed using automated image analysis algorithms to segment, track, and classify individual cells or populations of cells as disclosed elsewhere herein, and to generate quantitative representations (e.g., feature vectors or embeddings) corresponding to cell states or transitions between cell states. In certain aspects, cell state monitoring may include fluorescence imaging. The fluorescence imaging may detect endogenous fluorophores such as fluorescent cofactors (such as NADH, FAD, and tryptophan), exogenous fluorophores such as fluorescently labeled antibodies coupled to surface markers on cells, or a combination thereof. As a non-limiting example, transitions between proliferative and quiescent states may be identified based on changes in cell size, nuclear morphology, and division events observable in time-lapse brightfield image sequences. As a further example, differentiation processes such as stem cell transitions to specific lineages may be identified by detecting gradual changes in cell shape, substrate adhesion, and surface markers. As another example, epithelial-to-mesenchymal transitions may be detected through the loss of epithelial cell-cell junctions, changes in apical-basal polarity, acquisition of elongated spindle-like morphology, increased motility, decreased epithelial marker expression (e.g., E-cadherin), and increased mesenchymal marker expression (e.g., vimentin or N-cadherin). In some methods, a plurality of cells may be monitored in parallel for cell-state transitions. An additional example of a cell state transition is adipogenesis, and more specifically pre-adipocyte differentiation intoWSGR Docket No. 59528-739601adipocytes, and it may be detected using boron-dipyrromethene (BODIPY) fluorescent dye staining to identify lipid droplet accumulation; by monitoring morphological development from small, elongated fibroblast-like structures to larger, rounder structures; and by detecting CD36 expression. A yet further example of a cell state transition is cellular senescence and it may be detected by measuring senescence gene induction (e.g., CDKN1A, IGFBP4, and / or SERPINE2); by measuring morphological changes such as cytoplasmic granularity, vacuolization, and cytoskeletal remodeling; and by detecting senescence-associated markers such as pl 6, CDKN1A, and SA-P-gal. In some cases, cell-state transition measurements include releasing nucleic acids from a cell (e.g., through lysis) and sequencing at least a portion of the nucleic acid. In some cases, cell-state transition measurements are performed on live cells (e.g., prior to lysis and transcriptomic analysis).

[0121] In some aspects, the enclosures enclose from about 0.1% to about 1%, from about 0.1% to about 5%, from about 0.1% to about 10%, from about 0.1% to about 20%, from about 1% to about 5%, from about 1% to about 10%, from about 1% to about 20%, from about 5% to about 10%, from about 5% to about 20%, or from about 10% to about 20% of cells of the plurality of cells. Non-enclosed cells may be removed from the fluidic device, for example following the enclosing.

[0122] The enclosures may also enclose a relatively large proportion of the plurality of cells. In some aspects, the enclosures are generated at positions that maximize the number of enclosed cells. As examples, the enclosures may enclose about 20% to about 50%, about 20% to about 80%, about 20% to about 99%, about 50% to about 80%, about 50% to about 99%, or about 80% to about 99% of the plurality of cells.

[0123] The method may include generating at least about 500 enclosures, at least about 1000 enclosures, at least about 2000 enclosures, at least about 3500 enclosures, at least about 5000 enclosures, at least about 10000 enclosures, at least about 20000 enclosures, at least about 30000 enclosures, at least about 50000 enclosures, at least about 75000 enclosures, at least about 100000 enclosures, at least about 150000 enclosures, at least about 200000 enclosures, at least about 250000 enclosures, at least about 300000 enclosures, or at least about 400000 enclosures. The method may include generating from about 500 to about 1000 enclosures, from about 500 to about 2000 enclosures, from about 500 to about 3500 enclosures, from about 500 to about 5000 enclosures, from about 500 to about 10000 enclosures, from about 500 to about 20000 enclosures, from about 500 to about 30000 enclosures, from about 500 to about 50000 enclosures, from about 500 to about 75000 enclosures, from about 500 to about 100000 enclosures, from about 500 to about 150000 enclosures, from about 500 to aboutWSGR Docket No. 59528-739601200000 enclosures, from about 500 to about 250000 enclosures, from about 500 to about 300000 enclosures, from about 500 to about 400000 enclosures, from about 1000 to about 2000 enclosures, from about 1000 to about 3500 enclosures, from about 1000 to about 5000 enclosures, from about 1000 to about 10000 enclosures, from about 1000 to about 20000 enclosures, from about 1000 to about 30000 enclosures, from about 1000 to about 50000 enclosures, from about 1000 to about 75000 enclosures, from about 1000 to about 100000 enclosures, from about 1000 to about 150000 enclosures, from about 1000 to about 200000 enclosures, from about 1000 to about 250000 enclosures, from about 1000 to about 300000 enclosures, from about 1000 to about 400000 enclosures, from about 2000 to about 3500 enclosures, from about 2000 to about 5000 enclosures, from about 2000 to about 10000 enclosures, from about 2000 to about 20000 enclosures, from about 2000 to about 30000 enclosures, from about 2000 to about 50000 enclosures, from about 2000 to about 75000 enclosures, from about 2000 to about 100000 enclosures, from about 2000 to about 150000 enclosures, from about 2000 to about 200000 enclosures, from about 2000 to about 250000 enclosures, from about 2000 to about 300000 enclosures, from about 2000 to about 400000 enclosures, from about 3500 to about 5000 enclosures, from about 3500 to about 10000 enclosures, from about 3500 to about 20000 enclosures, from about 3500 to about 30000 enclosures, from about 3500 to about 50000 enclosures, from about 3500 to about 75000 enclosures, from about 3500 to about 100000 enclosures, from about 3500 to about 150000 enclosures, from about 3500 to about 200000 enclosures, from about 3500 to about 250000 enclosures, from about 3500 to about 300000 enclosures, from about 3500 to about 400000 enclosures, from about 5000 to about 10000 enclosures, from about 5000 to about 20000 enclosures, from about 5000 to about 30000 enclosures, from about 5000 to about 50000 enclosures, from about 5000 to about 75000 enclosures, from about 5000 to about 100000 enclosures, from about 5000 to about 150000 enclosures, from about 5000 to about 200000 enclosures, from about 5000 to about 250000 enclosures, from about 5000 to about 300000 enclosures, from about 5000 to about 400000 enclosures, from about 10000 to about 20000 enclosures, from about 10000 to about 30000 enclosures, from about 10000 to about 50000 enclosures, from about 10000 to about 75000 enclosures, from about 10000 to about 100000 enclosures, from about 10000 to about 150000 enclosures, from about 10000 to about 200000 enclosures, from about 10000 to about 250000 enclosures, from about 10000 to about 300000 enclosures, from about 10000 to about 400000 enclosures, from about 20000 to about 30000 enclosures, from about 20000 to about 50000 enclosures, from about 20000 to about 75000 enclosures, from about 20000 to about 100000 enclosures, from about 20000 to about 150000WSGR Docket No. 59528-739601enclosures, from about 20000 to about 200000 enclosures, from about 20000 to about 250000 enclosures, from about 20000 to about 300000 enclosures, from about 20000 to about 400000 enclosures, from about 30000 to about 50000 enclosures, from about 30000 to about 75000 enclosures, from about 30000 to about 100000 enclosures, from about 30000 to about 150000 enclosures, from about 30000 to about 200000 enclosures, from about 30000 to about 250000 enclosures, from about 30000 to about 300000 enclosures, from about 30000 to about 400000 enclosures, from about 50000 to about 75000 enclosures, from about 50000 to about 100000 enclosures, from about 50000 to about 150000 enclosures, from about 50000 to about 200000 enclosures, from about 50000 to about 250000 enclosures, from about 50000 to about 300000 enclosures, from about 50000 to about 400000 enclosures, from about 75000 to about 100000 enclosures, from about 75000 to about 150000 enclosures, from about 75000 to about 200000 enclosures, from about 75000 to about 250000 enclosures, from about 75000 to about 300000 enclosures, from about 75000 to about 400000 enclosures, from about 100000 to about 150000 enclosures, from about 100000 to about 200000 enclosures, from about 100000 to about 250000 enclosures, from about 100000 to about 300000 enclosures, from about 100000 to about 400000 enclosures, from about 150000 to about 200000 enclosures, from about 150000 to about 250000 enclosures, from about 150000 to about 300000 enclosures, from about 150000 to about 400000 enclosures, from about 200000 to about 250000 enclosures, from about 200000 to about 300000 enclosures, from about 200000 to about 400000 enclosures, from about 250000 to about 300000 enclosures, from about 250000 to about 400000 enclosures, from about 300000 to about 400000 enclosures. In some cases, all of the enclosures are contained within a single fluidic device. In some cases, all of the enclosures are contained within a single fluidic space (e.g., within a single channel within a fluidic device).

[0124] The enclosures may then be monitored for a period of minutes, hours, days, weeks, or months. As examples, the enclosures may be monitored for at least 30 minutes, at least one hour, at least 5 hours, at least 10 hours, at least one day, at least two days, at least 5 days, at least 10 days, at least 20 days, at least 30 days, at least 50 days, at least 100 days, from about 30 minutes to about 1 day, from about 30 minutes to about 10 days, from about 30 minutes to about 100 days, from about 1 day to about 10 days, from about 1 day to about 20 days, from about 1 day to about 50 days, from about 1 day to about 100 days, from about 10 days to about 50 days, from about 10 days to about 20 days, from about 10 days to about 100 days, or from about 50 days to about 100 days. The monitoring may thus generate longitudinal data. The longitudinal data may be collected independently for individual cells or enclosures.WSGR Docket No. 59528-739601

[0125] The monitoring may be performed continuously or in intervals. For example, the monitoring may include collecting analyzing (e.g., imaging) cells and / or containers about once per minute, about once per every 5 minutes, about once per every 10 minutes, about once per every 20 minutes, about once per every 40 minutes, about once per every 60 minutes, about once per every 90 minutes, about once per every 120 minutes, about once per every 150 minutes, about once per every 300 minutes, about once per every 600 minutes, about once per every day, about once per every two days, about once per every three days, about once per every five days, or about once per every week. The monitoring can include analyzing (e.g., imaging) one or more cells and / or containers about once per minute to about once per every 60 minutes, about once per every minute to about once per every 150 minutes, about once per every minute to about once per every 300 minutes, about once per every minute to about once per every day, about once per every minute to about once per every week, about once per every 60 minutes to about once per every 150 minutes, about once per every 60 minutes to about every 300 minutes, about once per every 60 minutes to about once per every day, about once per every 60 minutes to about once per every week, about once per every 150 minutes to about once per every 300 minutes, about once per every 150 minutes to about once per every day, about once per every 150 minutes to about once per every week, about once per every 300 minutes to about once per every day, about once per every 300 minutes to about once per every week, or about once per every day to about once per every week.

[0126] Monitoring may generate longitudinal data for a biological component. The longitudinal data may be generated by monitoring the biological component. The longitudinal data may include data from a plurality of time points. A first time point and a second time point of the plurality of timepoints may be different. For example, when the monitoring is performed in intervals, the monitoring may be performed about 2 to about 5, about 2 to about 10, about 2 to about 50, about 2 to about 100, about 2 to about 500, about 2 to 1000, about 2 to about 5000, about 5 to about 10, about 5 to about 50, about 5 to about 100, about 5 to about 500, about 5 to about 1000, about 5 to about 5000, about 10 to about 50, about 10 to about 100, about 10 to about 500, about 10 to about 1000, about 10 to about 5000, about 50 to about 100, about 50 to about 500, about 50 to about 1000, about 50 to about 5000, about 100 to about 500, about 100 to about 1000, about 100 to about 5000, about 500 to about 1000, about 500 to about 5000, or about 1000 to about 5000 times during the monitoring period. Similarly, the monitoring may be performed at least about 2, at least about 5, at leastWSGR Docket No. 59528-739601about 10, at least about 50, at least about 100, at least about 500, at least about 1000, or at least about 5000 times during the monitoring period.

[0127] Multiple optional features of the enclosures can facilitate long-term incubation and monitoring. First, the enclosures may be fixed at defined locations along a surface or within a fluidic device. The enclosures may be formed by selectively polymerizing a polymer precursor at defined locations over a surface and / or within a fluidic device. As the enclosures form, the enclosures may polymerize onto the surface or to a portion of the fluidic device, which may fix the enclosures to defined locations. Accordingly, measurements taken at multiple time points can be associated with individual enclosures. Second, the enclosures may include walls that physically prevent cell exit from or entry into a formed enclosure. One or more cells within a particular enclosure can thus be confined to an area of a surface or volume of a fluidic device so that, even if the one or more cells move, the one or more cells can be monitored independently of cells outside of the particular enclosure. Third, the enclosures may be porous, and may therefore permit dynamic nutrient and waste exchange with a surrounding fluid (e.g., cell media) wherein nutrients flow into the enclosures and waste flows out of the disclosures. Whereas cells can rapidly deplete nutrients from enclosures that rely on nutrient diffusion through dense polymers or across phase boundaries-for example, cells can deplete oxygen from droplets within 20 minutes of droplet formation (see, e.g., Mahler et al., RSC Adv. 2015, 5, 101871) and can deplete oxygen from microwells within 10 minutes of microwell deposition (see, e.g., Molter et. al., Sens Actuators B Chem.2009, 135(2), 678)-the presently disclosed enclosures can have pores that allow nutrient concentrations to equilibrate to surrounding levels. Enclosed cells can thus remain viable for days, weeks, or months within an enclosure. Enclosure pore size may be controlled as disclosed elsewhere herein, for example by adjusting porogen size, porogen concentration, crosslinker concentration, and polymerization conditions (e.g., irradiation time when an enclosure is formed through photopolymerization).

[0128] The number of cells contained within individual enclosures may be controlled during enclosure formation. The plurality of cells may be imaged prior to chamber formation. The locations of individual cells may be determined from an image of the plurality of cells, and enclosure locations and / or dimensions may be selected to capture a desired number of cells per container. In some aspects, the enclosures contain an average of about one cell per enclosure. In other aspects, the enclosures contain an average of more than about one cell per enclosure, for example about two, about three, about four, or about five cells. A method may include selecting upper and / or lower bounds for the number of cells within individualWSGR Docket No. 59528-739601enclosures. For example, enclosure positions and / or dimensions may be selected to ensure that each chamber encloses between about one and about two cells, between about one and about five cells, between about one and about ten cells, between about two and about five cells, between about two and about ten cells, or between about ten and about five cells.

[0129] In some aspects, the distribution of numbers of cells enclosed by enclosures is not a Poisson distribution. By imaging the plurality of cells and then forming the enclosures at locations with a desired number of cells, the numbers of cells per enclosure may be strictly controlled, and may be described by a constant number or collection of numbers, wherein all enclosures or essentially all enclosures contain designated numbers of cells, and approximately zero enclosures contain non-designated numbers of cells. Cell enclosure methods may utilize a machine learning algorithm as disclosed herein to attain uniformity in numbers of cells per enclosure. For example, in a method that forms enclosures with one cell, at least 98%, at least 99%, at least 99.5%, or at least 99.9% of enclosures can include one cell, and less than 2%, less than 1%, less than 0.5%, or less than 0.1% of enclosures can include zero cells or two or more cells. Similarly, in a method that forms enclosures with two, three, or four cells, at least 98%, at least 99%, at least 99.5%, or at least 99.9% of enclosures can include two, three or four cells, and less than 2%, less than 1%, less than 0.5%, or less than 0.1% of enclosures can include fewer than two or greater than four cells. The ability to generate enclosures with non-Poisson distributions of cells addresses a fundamental limitation of many cell partitioning methods, which generate enclosures with statistical distributions of numbers of cells. In such methods, enclosures with undesired numbers of cells may obfuscate assays by returning results that are unrepresentative of enclosures with desired numbers of cells. For example, in a proliferation assay, enclosures with a greater than an intended number of cells may exhibit proliferation rates that appear anomalously fast relative to enclosures with the intended number of cells.

[0130] The plurality of cells may be in a quiescent medium during enclosure formation. For example, the plurality of cells can be loaded into a fluidic device in a fluid. Fluid flow within the fluidic device can then be suspended for a period of time that allows the fluid to become quiescent. The cells may then be enclosed while they are in the quiescent fluid, for example by polymerizing polymer precursors in the fluid to form the enclosures. Polymerization may occur upon application of energy to the fluidic device. Energy can include thermal energy, radiant energy (including light), chemical energy, plasma energy, mechanical energy, elastic energy, or acoustic energy, for example.WSGR Docket No. 59528-739601

[0131] In some aspects, the monitoring includes performing one or more image-based phenotypic assays. As used herein, an “image-based phenotypic assay,” or an “imaging assay,” may be an assay that generates an image of a cell or a portion of a cell. Examples of imaging assays include morphological analysis with brightfield imaging; and surface marker analysis using fluorescence imaging to detect fluorescently labeled antibodies coupled to surface markers on cells. In some aspects, the monitoring comprises performing at least two imaging-based phenotypic assays. As examples, the imaging-based phenotypic assays can detect a morphology, proliferation, surface marker expression, cytokine secretion, or a combination thereof of one or more cells. The imaging-based assays may detect state transitions of individual cells. The imaging-based assays may also detect an interaction between a first cell and a second cell. The interaction may include killing, activation, junction formation, phagocytosis, or a combination thereof. Two interacting cells may be co-enclosed within a single enclosure. Alternatively, an interaction may be between cells in different enclosures. In such cases, the enclosures may be within sufficient proximity (e.g., less than about 30 microns, less than about 50 microns, or less than about 80 microns) for cytokines secreted by the cells to diffuse between their enclosures. Alternatively, one or more of the cells may project growths such as neurites out of their enclosures to contact another enclosed cell. A cell within an enclosure may also interact with a cell that is not enclosed, for example through cytokine secretions or neurite growth.

[0132] One or more cells may also be subjected to a molecular assay. As used herein, a molecular assay may be an assay that analyzes a molecule collected from a cell. Examples of molecular assays include genomic assays, transcriptomic assays, and mass spectrometric assays on biomolecules collected from cells. In particular aspects, the monitoring includes sequencing one or more nucleic acids from a cell (or a derivative of the one or more nucleic acids, or a complement of the derivative of the one or more nucleic acids). Such a method can include releasing one or more nucleic acids from the cell (e.g., by lysing the cell), capturing the nucleic acids on capture probes, extending the capture probes using the captured nucleic acids or portions of the captured nucleic acids as templates to generate extended capture probes, and sequencing the extended capture probes. Similarly, such a method can include releasing one or more nucleic acids from the cell (e.g., by lysing the cell), capturing the nucleic acids on capture probes, extending the nucleic acids using the capture probes or portions of the capture probes as templates to generate extended nucleic acids, and sequencing the extended nucleic acids. The nucleic acid capture probes can include barcodes that are uniquely associated with an enclosure of the at least 500 enclosures.WSGR Docket No. 59528-739601

[0133] Data from a molecular assay can be linked to data from an imaging assay. Molecular assays are typically challenging to link with imaging assays. In many molecular assays, for example, target molecules are collected by lysing a population of cells, pooling lysate from the cells, and analyzing target molecules within the pooled lysate, such that the identities of cells from which individual target molecules are derived is lost. In select aspects, the present disclosure addresses this challenge by enclosing cells within spatially addressed enclosures that include barcodes associated with enclosure locations. The barcodes may be coupled to biomolecules or copies or complements of biomolecules derived from cells, thereby allowing the biomolecules to be associated with a particular cell or enclosure.

[0134] In some aspects, enclosure formation includes selectively polymerizing one or more polymer precursors in the fluidic device. Polymerization may occur upon application of energy to the fluidic device. Energy can include thermal energy, radiant energy (including light), chemical energy, plasma energy, mechanical energy, elastic energy, or acoustic energy, for example. As detailed further herein, the selectively polymerizing can be performed using a spatial light modulator to direct light into the fluidic device, wherein the light photopolymerizes the one or more polymer precursors. The selectively polymerizing can also include determining locations of the one or more cells (or, in some aspects, cell aggregates, tissue samples, organoids, organelles, or other biological components disclosed herein) and using the locations to form enclosures around the one or more cells. In some cases, the cells are disposed over a surface, and the selectively polymerizing forms polymer matrix walls that extend perpendicularly from the surface. For example, when the cells are disposed over a planar surface, the polymer matrix walls may extend upwards from the planar surface and optionally to an additional surface that opposes the planar surface. The polymer matrix walls may surround and at least partially enclose an open interior space that contains at least one cell, for example as illustrated by polymer matrices 208 and 209 in FIG. 2A.

[0135] In some aspects, the selectively polymerizing may form a polymer matrix wall over at least a portion of an opening to a well, a pen, a trap, or a portion thereof. An example of such a configuration is illustrated in FIG. 11. This figure provides an isometric view of a biological material (1103) disposed inside of a well (1100). The well (1100) is defined by a bottom surface (1100A) and side walls (1100B), and projects downwards from a planar substrate (1101). A top opening of the well (1100) is capped by a polymer matrix wall ( 1104). As illustrated in FIG. 11, the uppermost portion of polymer matrix wall (1104) is coincident with the planar substrate (1101). The polymer matrix wall (1104) may be selectively formed at the top of the well (1100), for example by inputting light or heat or applying an electricalWSGR Docket No. 59528-739601potential at the opening of the well (1100). The polymer matrix wall (1104) may be formed after the biological material (1103) diffuses or deposits into the well (1100). The polymer matrix wall (1104) may be selectively formed, for example, only after the biological material (1103) is detected in the well (1100) and a characteristic of the biological material (1103) such as cell type or size is detected. The biological material (1103) may be detected, for example, by brightfield imaging, fluorescence imaging, impedance measurements in the well (1100), or a combination thereof. The polymer matrix wall (1104) may block the biological material (1103) from exiting the well (1100), and may similarly block additional biological materials that are not in the well (1100) from entering the well (1100). The polymer matrix wall (1104) may include pores that allow nutrients and / or reagents to flow into the well (1100) and waste products from the biological material (1103) to flow out of the well (1100). It is worth noting that some methods utilize switches or other actuated enclosing mechanisms to form barriers over enclosures. For example, upon receiving an image of a biological material in a well, a computing device may send an electrical signal to actuate a switch to close an opening of the well. In such configurations, the opening may be partially closed so as to allow reagents, nutrients, and waste to flow into and out of the well but to also prevent the biological material from exiting the well.

[0136] The forming can generate enclosures at a rate of about 10 to about 25 enclosures per minute, about 10 to about 50 enclosures per minute, about 10 to about 100 enclosures per minute, about 10 to about 150 enclosures per minute, about 10 to about 250 enclosures per minute, about 10 to about 500 enclosures per minute, about 10 to about 750 enclosures per minute, about 10 to about 1000 enclosures per minute, about 10 to about 1500 enclosures per minute, about 10 to about 2000 enclosures per minute, about 10 to about 2500 enclosures per minute, about 25 to about 50 enclosures per minute, about 25 to about 100 enclosures per minute, about 25 to about 150 enclosures per minute, 25 to about 250 enclosures per minute, about 25 to about 500 enclosures per minute, about 25 to about 750 enclosures per minute, about 25 to about 1000 enclosures per minute, about 25 to about 1500 enclosures per minute, about 25 to about 2000 enclosures per minute, about 25 to about 2500 enclosures per minute, about 50 to about 100 enclosures per minute, about 50 to about 150 enclosures per minute, about 50 to about 250 enclosures per minute, about 50 to about 500 enclosures per minute, about 50 to about 750 enclosures per minute, about 50 to about 1000 enclosures per minute, about 50 to about 1500 enclosures per minute, about 50 to about 2000 enclosures per minute, about 50 to about 2500 enclosures per minute, about 100 to about 150 enclosures per minute, about 100 to about 250 enclosures per minute, about 100 to about 500 enclosures per minute,WSGR Docket No. 59528-739601about 100 to about 750 enclosures per minute, about 100 to about 1000 enclosures per minute, about 100 to about 1500 enclosures per minute, about 100 to about 2000 enclosures per minute, about 100 to about 2500 enclosures per minute, about 250 to about 500 enclosures per minute, about 250 to about 750 enclosures per minute, about 250 to about 1000 enclosures per minute, about 250 to about 1500 enclosures per minute, about 250 to about 2000 enclosures per minute, about 250 to about 2500 enclosures per minute, about 500 to about 1000 enclosures per minute, about 500 to about 1500 enclosures per minute, about 500 to about 2000 enclosures per minute, about 500 to about 2500 enclosures per minute, about 750 to about 1500 enclosures per minute, about 750 to about 2000 enclosures per minute, about 750 to about 2500 enclosures per minute, about 1000 to about 1500 enclosures per minute, about 1000 to about 2000 enclosures per minute, about 1000 to about 2500 enclosures per minute, or about 1500 to about 2500 enclosures per minute. The forming can generate enclosures at a rate of at least about 10, at least about 50, at least about 100, at least about 150, at least about 250, at least about 500, at least about 750, at least about 1000, at least about 1500, at least about 2000, or at least about 2500 enclosures per minute. In some aspects, enclosure formation rate is the number of enclosures formed in a fluidic device or subspace thereof (e.g., a fluidic channel) divided by the time required to form the enclosures. Enclosure formation rate may account for both time used to form the enclosures (e.g., polymerizing a polymer precursor, actuating a switch to close an opening to a well or pen, or partitioning aqueous media into an oil phase to form a droplet) and time used to facilitate enclosure formation, such as locating cells, selecting enclosure locations, and moving a field of view of a detector and / or energy source. Such a rate may optionally be referred to as an “average” enclosure formation rate. In certain specifically denoted aspects, enclosure formation rate may instead refer exclusively to the duration of a single enclosure formation step. For example, a polymer chamber formed during 5 seconds of photopolymerization may have an enclosure formation rate of 5 seconds, and a well that switches closed 100 microseconds after electrical actuation may have an enclosure formation rate of 100 microseconds.

[0137] During a method, a plurality of enclosures may be formed in less than about 150 minutes, less than about 120 minutes, less than about 90 minutes, less than about 60 minutes, less than about 45 minutes, less than about 30 minutes, less than about 25 minutes, less than about 20 minutes, less than about 15 minutes, less than about 12 minutes, less than about 10 minutes, less than about 8 minutes, less than about 6 minutes, less than about 5 minutes, less than about 4 minutes, or less than about 3 minutes. For example, a plurality of enclosuresWSGR Docket No. 59528-739601formed during a method may be formed in about 3 to about 6, about 3 to about 12, about 3 to about 20, about 3 to about 30, about 3 to about 60, about 3 to about 90, about 3 to about 120, about 3 to about 150, about 6 to about 12, about 6 to about 20, about 6 to about 30, about 6 to about 60, about 6 to about 90, about 6 to about 120, about 12 to about 20, about 12 to about 30, about 12 to about 60, about 12 to about 90, about 12 to about 150, about 20 to about 30, about 20 to about 60, about 20 to about 90, about 20 to about 120, about 20 to about 150, about 30 to about 60, about 30 to about 90, about 30 to about 120, about 30 to about 150, about 60 to about 90, about 60 to about 120, about 60 to about 150, about 90 to about 120, about 90 to about 150, or about 120 to about 150 minutes.

[0138] As detailed elsewhere herein, walls of the enclosures can include pores. The pores may be sufficiently large for reagents and cell secretions to diffuse through, but prohibitively small for cells to move through. For example, the pores may permit passage of proteins with including a molecular weight of about 250 kDa or less, about 200 kDa or less, about 150 kDa or less, about 100 kDa or less, about 75 kDa or less, about 50 kDa or less, or about 25 kDa or less. Accordingly, cells may be trapped within enclosures, but fluid and solutes within enclosures may dynamically exchange with surrounding media. Cells in different enclosures can be in chemical communication, wherein molecules from the interior of a first enclosure (e.g., molecules secreted by a cell in the first enclosure) diffuse out of the first enclosure and into the interior of a second enclosure, and molecules from the interior of the second enclosure diffuse out of the second enclosure and into the first enclosure.

[0139] The enclosures can have fixed positions within a fluidic device. For example, the enclosures may be formed by polymerizing a polymer precursor, and the polymer precursor may adhere to a fluidic device surface during polymerization. The enclosures remain fixed in place when liquid is flowed through the fluidic device.

[0140] The cells may remain viable during enclosure and monitoring. In some cases, at least about 60%, at least about 70% at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or at least about 99.5% of cells may be alive following enclosure. In some cases, at least about 60%, at least about 70% at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or at least about 99.5% of cells may be alive for the duration of monitoring.

[0141] The enclosures may have a density of about 10 to about 50 enclosures per cm2, about 10 to about 100 enclosures per cm2, about 10 to about 200 enclosures per cm2, about 10 to about 500 enclosures per cm2, about 10 to about 1000 enclosures per cm2, about 10 to about 1500 enclosures per cm2, about 10 to about 3000 enclosures per cm2, about 10 to about 6000WSGR Docket No. 59528-739601enclosures per cm2, about 10 to about 9000 enclosures per cm2, about 50 to about 100 enclosures per cm2, about 50 to about 200 enclosures per cm2, about 50 to about 500 enclosures per cm2, about 50 to about 1000 enclosures per cm2, about 50 to about 1500 enclosures per cm2, about 50 to about 3000 enclosures per cm2, about 50 to about 6000 enclosures per cm2, about 50 to about 9000 enclosures per cm2, about 100 to about 200 enclosures per cm2, about 100 to about 500 enclosures per cm2, about 100 to about 1000 enclosures per cm2, about 100 to about 1500 enclosures per cm2, about 100 to about 3000 enclosures per cm2, about 100 to about 6000 enclosures per cm2, about 100 to about 9000 enclosures per cm2, about 200 to about 500 enclosures per cm2, about 200 to about 1000 enclosures per cm2, about 200 to about 1500 enclosures per cm2, about 200 to about 3000 enclosures per cm2, about 200 to about 6000 enclosures per cm2, about 200 to about 9000 enclosures per cm2, about 500 to about 1000 enclosures per cm2, about 500 to about 1500 enclosures per cm2, about 500 to about 3000 enclosures per cm2, about 500 to about 6000 enclosures per cm2, about 500 to about 9000 enclosures per cm2, about 1000 to about 1500 enclosures per cm2, about 1000 to about 3000 enclosures per cm2, about 1000 to about 6000 enclosures per cm2, about 1000 to about 9000 enclosures per cm2, about 1500 to about 3000 enclosures per cm2, about 1500 to about 6000 enclosures per cm2, about 1500 to about 9000 enclosures per cm2, about 3000 to about 6000 enclosures per cm2, about 3000 to about 9000 enclosures per cm2, or about 6000 to about 9000 enclosures per cm2.

[0142] In another embodiment, the present disclosure provides a method for analyzing a cell that includes: performing at least 3 assays on a plurality of cells, wherein each of the at least 3 assays generates data associated with the plurality of cells, and wherein the method further comprises associating a subset of the data from each of the at least 3 assays with individual cells of the plurality of cells. In some aspects, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 assays are performed on the cell. In other aspects, between 3 and 10, between 4 and 10, between 5 and 10, between 4 and 8, or between 4 and 6 assays are performed on the cell. The assays may be performed in about 1 minute to 15 minutes, from about 1 minute to 30 minutes, from about 1 minute to about 60 minutes, from about 1 minute to about 90 minutes, from about 1 minute to about 120 minutes, from about 1 minute to about 180 minutes, from about 1 minute to about 240 minutes, from about 1 minute to about 300 minutes, from about 15 minutes to about 30 minutes, from about 15 minutes to about 60 minutes, from about 15 minutes to about 120 minutes, from about 15 minutes to about 180 minutes, from about 15 minutes to about 240 minutes, from about 15 minutes to about 300 minutes, from about 30 minutes to about 60 minutes, from about 30 minutes to about 90WSGR Docket No. 59528-739601minutes, from about 30 minutes to about 120 minutes, from about 30 minutes to about 180 minutes, from about 30 minutes to about 240 minutes, from about 30 minutes to about 300 minutes, from about 60 minutes to about 90 minutes, from about 60 minutes to about 120 minutes, from about 60 minutes to about 180 minutes, from about 60 minutes to about 240 minutes, from about 60 minutes to about 300 minutes, from about 90 minutes to about 180 minutes, from about 90 minutes to about 240 minutes, from about 90 minutes to about 300 minutes, from about 120 minutes to about 240 minutes, or from about 120 minutes to about 300 minutes.

[0143] The plurality of cells may be contained within a single fluidic device. In such cases, the plurality of cells may be contained within a single fluidic space (such as a single channel) within the fluidic device, or within multiple fluidic spaces (such as multiple channels) within the fluidic device. In certain aspects, the method includes associating a subset of the data from each of the assays with each of the plurality of cells or with a subset of the plurality of cells. For example, subsets of the data from each of the assays may be associated with about 10% to about 90%, about 50% to 90%, about 10% to about 100%, about 50% to about 100%, or about 90% to about 100% of cells of the plurality of cells.

[0144] In a further embodiment, the present disclosure provides a method for isolating cells that includes: collecting an image of a plurality of cells; using the image, identifying at least about 20 cells from the image of the plurality of cells; and generating a plurality of enclosures, wherein the plurality of enclosures at least partially enclose the at least about 20 cells, wherein the method is performed in less than about 5 seconds. The enclosures may be generated by polymerizing one or more polymer precursors. Polymerization may occur upon application of energy to the fluidic device. Energy can include thermal energy, radiant energy (including light), chemical energy, plasma energy, mechanical energy, elastic energy, or acoustic energy, for example. The at least about 20 cells may be present within a single field of view of a detector. The detector may collect an image of the cells, after which time a machine learning algorithm may rapidly identify the cells. A spatial light modulator such as a digital micromirror device may then project light into the field of view to generate enclosures. This process may be performed in less than about 20 seconds, less than about 15 seconds, less than about 10 seconds, less than about 8 seconds, less than about 6 seconds, less than about 5 seconds, less than about 4 seconds, less than about 3 seconds, or less than about 2.5 seconds. Such rapid enclosure can allow precise cell and enclosure positioning within fluidic devices, as enclosure formation can be rapid relative to cell diffusion and motility, andWSGR Docket No. 59528-739601can therefore be performed on cells with desired locations or on groups of cells with desired intercellular distances.

[0145] An additional embodiment of the present disclosure provides a method for analyzing a plurality of cells over a period of time, wherein the method includes: collecting a first image of the plurality of cells, wherein the first image comprises a plurality of fields of view, and wherein the collecting the first image including moving a detector over the plurality of fields of view; applying annotations to at least a subset of the plurality of cells in the first image; collecting a second image of the plurality of cells, wherein the second image is collected after the first image, wherein the second image comprises the plurality of fields of view, and wherein the collecting the second image comprises moving the detector over the plurality of fields of view; and applying the annotations to the plurality of cells or the subset of the plurality of cells in the second image, wherein each cell of the plurality of cells or the subset of the plurality of cells received the same annotation in the first image and the second image. As used herein, an annotation may be a unique identifier or label that is provided to a cell, enclosure, or other object (e.g., a fluorescent bead) that can tracked across longitudinal and multimodal datasets.Enclosures

[0146] The term “enclosure,” as used herein, generally, refers to a space or volume that may be suitable to contain one or more species or conduct one or more reactions. An enclosure may be a physical compartment. The enclosure may isolate a space or volume from another space or volume. An enclosure may comprise one or more other (inner) enclosures. In some aspects, it should be noted that the space or volume of an enclosure can be an open space or open volume that is occupied by air or liquid. An enclosure can have an open space or open volume that is defined by a wall. In various examples, the open space or open volume is not filled with a polymeric material. The wall can be made of a polymer that has an outer surface and inner surface where the inner surface forms at least a part of the boundary of the open space or open volume and the outer surface forms at least a part of the boundary to the area outside of the enclosure. In some aspects, an enclosure may include one or more polymeric chambers. The one or more chambers may enclose the one or more cells with nucleic acid capture probes that are configured to capture one or more cellular nucleic acids from a cell.

[0147] In some embodiments disclosed herein, the one or more chambers are comprised of one or more polymer matrices formed with the fluidic space. As used herein, the term "polymer matrix" generally refers to a phase material (e.g. continuous phase material) that comprises at least one polymer. In some embodiments, the polymer matrix refers to the atWSGR Docket No. 59528-739601least one polymer as well as the open interstitial space within the polymer. A polymer matrix may be composed of one or more types of polymers. A polymer matrix may include linear, branched, and crosslinked polymer units. A polymer matrix may also comprise non-polymeric species intercalated within its interstitial spaces not occupied by polymer chains. The intercalated species may be solid, liquid, or gaseous species. For example, the term "polymer matrix" may encompass desiccated hydrogels, hydrated hydrogels, and hydrogels comprising glass fibers. A polymer matrix may comprise a polymerized form of a polymer precursor, which generally refers to one or more molecules that upon activation can trigger or initiate a polymeric reaction. A polymer precursor can be activated by electrochemical energy, photochemical energy, a photon (i.e., light), magnetic energy, or any other suitable energy. Energy can include thermal energy, radiant energy, chemical energy, plasma energy, mechanical energy, elastic energy, or acoustic energy, for example. As used herein, the term "polymer precursor" includes monomers (e.g., that are polymerized to produce a polymer matrix) and / or crosslinking compounds, which may include photo-initiators, other compounds necessary or useful for generating polymer matrices (e.g., porogen).

[0148] In particular embodiments, the one or more chambers comprise a hydrogel. As used herein, the term “hydrogel” can refer to a polymeric material that is not water soluble or is poorly water soluble but can contain water (e.g., at least 10% by weight) when hydrated.

[0149] FIGS. 2A-C illustrate an example method for forming an enclosure (in this example a chamber) that encloses one or more biological components in a fluidic device disclosed herein. FIG. 2A shows a portion of a system as provided herein (e.g., comprising a fluidic device as disclosed herein) including an energy source forming a polymer matrix around biological components 50 and 51. FIG. 2B shows a polymer matrix being formed around another biological component 52 in a portion of a system as provided herein. FIG. 2C is a top view schematic showing top view of a channel with a polymer matrix formed around a biological component in a system as provided herein. As illustrated in FIGS. 2A-2C, in some embodiments, the one or more chambers have cylindrical shapes that extend from the bottom layer to the top layer of a fluidic device.

[0150] With continued reference to FIG. 2A, the channel 200 of the system may include a first surface 201 provided by the bottom layer and a second surface 202 provided by the top layer of the fluidic device. The energy source 203 may comprise one or more energy emitting portions (e.g., an energy emitting portion 205). In some embodiments, the energy source 203 may comprise one or more non-emitting portions (e.g., a non-emitting portion 204). The nonemitting portion 204 does not emit energy for forming a polymer structure, but can beWSGR Docket No. 59528-739601configured at a later time to emit energy. In some embodiments, the emitting portion 205 can emit energy in the form of electromagnetic waves (e.g., microwaves, light, heat, etc.) to at least a portion of the fluidic device. For example, the energy source may comprise an LED array in which individual LEDs can be selectively activated (e.g., act as an energy emitting portion 205) to create light projections with specified patterns.

[0151] In further reference to FIG. 2A, the polymer matrix 208, 209, or at least a portion of the polymer matrix 208, 209, may be coupled to the first surface 201, the second surface 202, or both surfaces 201, 202. The polymer matrix 208, 209 may enclose an interior space 220 that contains a biological component 50. In various embodiments, the polymer matrix 208, 209 may extend from the first surface 201 to the second surface 202 (e.g., through at least a portion of a lumen of the channel 200) such that the polymer matrix surrounds, or substantially surrounds, the biological component 50. FIG. 2B shows polymer matrices 218, 219 formed surrounding the biological component 52. Biological component 53 was separated from biological component 52, and is not present in FIG. 2B. In some embodiments, separation of the biological components is achieved through fluidic pressure, flow pulsation, dielectrophoresis, optothermal flow, or some combination thereof. FIG. 2C provides a top-down view of the channel 200 depicted in FIG. 2B, wherein the cylindrical shapes of the polymer matrix define a compartment 220 surrounding the biological component 50. Additional biological components 55, 56, 57, which are not enclosed within polymer matrices, are shown in FIG. 2C.

[0152] In some embodiments, the generation of a polymer matrix within the fluidic device is performed using a spatial light modulator (SLM) (i.e. a spatial energy modulation element that is capable of generating desired light intensity pattern spatially). In some embodiments, the SLM is a digital micromirror device (DMD). In some embodiments, the SLM is a laser beam steered using a galvanometer. In some embodiments, the SLM is liquid crystal based. In some embodiments, the fluidic channel may be coupled to or disposed on a movable stage. In other embodiments, light may be projected to or onto at least a portion of the first fluidic channel to generate one or more polymer matrices. The light may be directed to various parts of the first fluidic channel. The energy source (e.g., light source) may be coupled to the fluidic device via an objective (e.g., a microscope objective or lens). The energy source may be directed to a portion of the fluidic channel (e.g., via a movable objective). In some cases, the light source, the objective, and / or the fluidic channel are movable to allow emission of energy to the fluidic channel so as to generate a pattern on at least a portion of a surface ofWSGR Docket No. 59528-739601the fluidic device. The polymer matrix may be formed similarly or complementary to the pattern of energy emission.

[0153] In some embodiments, such chambers have annular-like cross-sections. As used herein, the term "annular-like cross-section" means a cross section topologically equivalent to an annulus. In some embodiments, the inner space, or interior, of a chamber has an inner diameter from 5 μm to 500 μm and a volume in the range of from about 1 nanoliter to 100 nanoliters, or from about 1 nanoliter to 10 nanoliters. In some embodiments, the polymer matrix wall has a thickness of at least 1 μm (micrometer) to about 30 μm or about 5 to about 15 μm. In some embodiments, a chamber extends from a bottom surface to a top surface of a fluidic device. In some embodiments, a chamber has a height of about 10 μm to about 500 μm. In some embodiments, a polymer matrix wall having an annular-like cross-section has an aspect ratio (i.e., height / width) of 1 or less. In some embodiments, aspect ratio and polymer matrix wall thickness are selected to maximize chamber stability against forces, such as reagent flow through the channel, washings, and the like.

[0154] In some embodiments, the generation of a polymer matrix within the fluidic device comprises exposing the one or more polymer precursors to an energy source. In some embodiments, the energy source is a light generating device. In some embodiments, the light generating device generates light ranging from about 350 nm to about 800 nm. In some embodiments, the generation of the polymer matrix comprises from about 1 to about 50 seconds of illumination or from about 2 to about 4 seconds of illumination.

[0155] Optionally, a first chamber of the one or more chambers can be disposed inside of a second chamber of the one or more chambers. This design can be utilized to separately partition two species (e.g., a cell and a reagent or two cells) within close proximity. This design can also be used to control the timing with which two species are contacted. For example, a method can include forming a first chamber around a cell, flowing a bead (or other assay reagent incapable of diffusing into the first chamber) adjacent to the cell, forming a second chamber surrounding the first chamber and enclosing the bead, and selectively degrading the first chamber to allow the cell and bead to come into contact within the second chamber.

[0156] In some embodiments, a functional group can be coupled to one or more chambers. Some non-limiting examples of functional group may include a capture reagent (e.g., pyridinecarboxaldehyde (PCA)), an acrylamide, an agarose, a biotin, a streptavidin, a strep-tag II, a linker, a functional group comprising an aldehyde, a phosphate, a silicate, an ester, an acid, an amide, an aldehyde dithiolane, PEG, a thiol, an alkene, an alkyne, an azide, or aWSGR Docket No. 59528-739601combination thereof. In some cases, the functionalized chamber may be used to capture a biomolecule enclosed therein, thereby trapping the biomolecule in proximity to a biological component (e.g., a cell) enclosed within the chamber. The biomolecule may be produced by the biological component (e.g., secretome from a cell). The functionalized surface of the polymer matrix inside the compartment may be used to capture reagents or molecules from outside the compartment. The functionalized surface may increase surface area covered by a reagent, a molecular sensor, or any molecule of interest (e.g., an antibody).

[0157] A fluidic device disclosed herein can include a detector that is configured to detect one or more locations of one or more biological components contained within a channel. Returning to FIGS. 2A-B, in certain embodiments, the energy source 203 can comprise, be coupled to, or be in communication with a detector that detects, or is configured to detect, a location of a biological component in the fluidic device. In some embodiments, the image may be obtained from a camera (e.g., a digital camera, fluorescent imaging camera, etc.). In some embodiments, the camera may be coupled to, connected to, or in communication with the energy source 203. For example, the camera (not shown) may be in electrical communication with the energy source 203. In some embodiments, the energy source 203 may comprise the camera. In various embodiments, the energy source 203 may comprise a microscope (e.g., a fluorescence microscope, a confocal microscope, lens-free imaging system, a transmission electron microscopy (TEM), a scanning electron microscope (SEM), etc.). The microscope may be used to detect one or more positions of one or more biological components (e.g., in combination with the detector).

[0158] In some embodiments, one or more chambers has sufficiently large pores to allow movement or transfer of a reagent (e.g., an enzyme, a chemical compound, a small molecule, an antibody, etc.) therethrough, but sufficiently small so as to retain biological components (e.g., cells). Alternatively or additionally (e.g., when two or more chambers are synthesized with different polymer precursors or radiation powers), one or more chambers can have sufficiently small pores to inhibit movement or transfer of a reagent and / or biological component (e.g., DNA, RNA, a protein, a cell, etc.) through the walls of the chamber. In some embodiments, the pores have a diameter from 5 nm to 100 nm. In some embodiments, the pores have a diameter smaller than 5 nm. Pore size may be selected based on the sizes of reagents and analytes in an assay. For example, pore size may be modulated by adjusting polymer precursor formulation, porogen size, pH, salt concentration, photopolymerization light duration and light intensity, and the like. In some embodiments, the average diameter of pores of a chamber prevent passage of molecules having a molecular weight of 25WSGR Docket No. 59528-739601kiloDaltons (kDa) or greater; or having a molecular weight of 50 kDa or greater; or having a molecular weight of 75 kDa or greater; or having a molecular weight of 100 kDa or greater; or having a molecular weight of 150 kDa or greater. In some embodiments, the pores of a chamber are sufficiently large for 150 kDa species such as antibodies, as well as smaller reagents, to flow through, but prohibitively small for cells or beads to flow through. In some embodiments, DNA or RNA retained have lengths that are sequencable using conventional sequencing-by-synthesis techniques. For example, such DNA or RNA comprise at least 50 nucleotides, or in some embodiments, at least 100 nucleotides. In some embodiments, the pores may have an average diameter from 5 nm to 100 nm.

[0159] In some cases, the analysis channel may include polymer matrix structures for capturing or trapping a biological component or a molecule or compound produced by the biological component (e.g., prior to introduction of the biological components into the fluidic device) For example, a user may obtain an analysis channel that includes polymer matrix structures. That is, the user may not form the polymer matrix structures. In various cases, the analysis channel may be configured to include polymer matrix, structures for capturing or trapping a biological component or a molecule or compound produced by the biological component. For example, in such embodiments, subsequent to introduction of the biological components into the fluidic device and the analysis channel, one or more polymer matrix structures may be formed in the analysis channel. The analysis channel may be configured for a screening process, a library preparation, or another suitable process. In some embodiments, the screening process may be for drug screening, antibiotic screening, culture conditions screening, or CRISPR screening. In certain cases, a plurality of samples may be placed into a plurality of channels. The plurality of samples may be screened against a variety of conditions in other signal-containing channels.

[0160] The sealable aperture may be configured to transition from a sealed state to an open state. For example, a sealable aperture may comprise a heat sensitive polymer that can melt, for example, upon receiving heat and render the sealable aperture open. In some cases, the passage of the biological component through the sealable aperture may be inhibited in the sealed state. In certain cases, the passage of the biological component through the sealable aperture may be allowed in the open state. In some cases, the sealable aperture may be sealed with an agarose gel, a temperature-soluble polymer, an N-isopropylacrylamide (NIP AAm) polymer, a wax compound, an alginate, or any other suitable compound or material.

[0161] FIGS. 7A and 7B show a portion of a fluidic device configured to trap a biological component 50. The fluidic device may comprise a flow channel or chamber 651, an analysisWSGR Docket No. 59528-739601channel or chamber 652, and a layer or wall 653 disposed between at least a portion of the flow channel 651 and the analysis channel 652. The layer 653 may comprise one or more sealable apertures or openings 654. Additionally, one or more flow inhabitation elements 655 may inhibit or prevent, or be configured to inhibit or prevent, the biological component 50 from flowing along the flow channel 611. A flow inhibition element 655 may be configured to stop or trap the biological component 50 adjacent to a sealable aperture 654. As described herein, the sealable aperture 614 may be configured to transition from a sealed state (e.g., a closed state) or configuration to an open state or configuration. FIG. 7 A shows an example of the sealable aperture 614 in a sealed state. FIG. 7B shows an example of the sealable aperture 654 in an open state. Upon transitioning to a sealed state to an open state, the sealable aperture 654 may allow or permit passage of the biological component 50 from at least a portion of the flow channel 651 to at least a portion of the analysis channel 652. In certain instances, the analysis channel 652 may be placed, or configured to be placed, below the flow channel 651 to allow the biological component 50 to be transferred to the analysis channel 652 from the flow channel 651 by a force provided (e.g., via gravity, high pressure pulse by pressurizing a flow in the flow channel, and generating negative pressure in the analysis channel). In some embodiments, the fluidic device may be spun or centrifuged to disposed the one or more biological components from the flow channel to the analysis channel. Reagents can be disposed or passed through at least a portion of the analysis channel 652, for example, to conduct analyses or experiments are provided herein.

[0162] As shown in FIG. 7 A, the flow inhibition element 655 may be disposed within at least a portion of the flow channel 651 to inhibit or prevent flow of a biological component (e.g., biological component 50) in the flow channel 651. The flow inhibition element 655 may be configured to capture or trap the biological component 50 in at least a portion of the flow channel 651. In some cases, the flow inhibition element 655 may extend from a surface (e.g., surface 669) of the flow channel 651. In some cases, the surface 669 may be disposed opposite of a flow channel surface 661, which is adjacent to the layer 653.

[0163] In various cases, the analysis channel 652 may comprise a surface 659 disposed opposite of the analysis channel surface 663, which is adjacent to or a surface ofthe layer 653. The analysis channel 652 may comprise one or more polymer matrices 656. The analysis channel 652 may comprise one or more polymer precursors. For example, one or more polymer precursors may be disposed in at least a portion of the analysis channel 652. ’The one or more polymer matrices 656 may be formed using an energy source whichWSGR Docket No. 59528-739601provides energy to the one or more polymer precursors in the analysis channel 602. The energy source may be in optical communication, electrochemical communication, electromagnetic communication, thermal communication, or microwave communication with the fluidic device or the analysis channel 652. In some cases, the energy source may be a light generating device, a heat generating device, an electrochemical generating device, an electrode, a microwave device, or a combination thereof. The energy source may selectively provide energy to the analysis channel 652 to form polymer matrices at predefined locations. A spatial energy modulating element may be used to selectively provide energy to the analysis channel 652.

[0164] In some cases, the spatial energy modulating element may comprise a photolithographic mask, a DMD system, or other suitable mask. The one or more polymer matrices 656 may be formed before the sealable aperture 654 transitions to an open state (e.g., as shown in FIG 7A). For example, a polymer matrix may be formed and aligned with the sealable aperture such that the biological component 650 held by the inhibition element 655 may directed (e.g., fall by gravity or by fluid pressure) intoa compartment 620 when the sealable aperture 654 is rendered open. The one or more polymer matrices 656 may be formed after the sealable aperture 654 transitions to an open state (e.g., as shown in FIG. 7B). The one or more polymer matrices 656 may form an analysis chamber or compartment 620, as described herein.

[0165] In some aspects, a compartment may be formed by expanding a stimulus-responsive polymer to enclose a biological material. As used herein, the terms biological material and biological component may be used interchangeably. The stimulus-responsive polymer may expand from a contracted state to an expanded state in response to a stimulus such as temperature, osmolarity, pH, or a combination of stimuli thereof. In the contracted state, the stimulus-responsive polymer may form a portion of a compartment that includes an opening through which a biological material such as a cell may flow through. After a biological material flows into the opening, the stimulus responsive polymer may be expanded, which may shrink or close the opening to form a compartment with the biological material trapped therein. The stimulus may be applied in a spatially controlled manner, for example by using light directed from a spatial light modulator to selectively heat (e.g., in the presence of thermoresponsive particles) individual stimulus-responsive polymers within a fluidic device. The stimulus may also be applied throughout a fluidic device or a portion of a fluidic device, for example by heating or replacing a buffer in a fluidic device or an individual fluidic channel within a fluidic device. Examples of stimulus-responsive polymers consistent withWSGR Docket No. 59528-739601the present disclosure include poly(N-isopropylacrylamide) (PNIPAM), poly(N-vinylcaprolactam) (PVCL), poly(acrylic acid) (PAA), poly(methacrylic acid) (PMAA), poly(itaconic acid) (PIA), poly(glutamic acid) (PGA), poly(aspartic acid) (PASP), a poly(β-amino ester) (PBAE), poly(L-histidine) (PLH), poly(2-vinylpyridine) (P2VP), poly(4-vinylpyridine) (P4VP), poly(dimethylaminoethyl methacrylate) (PDMAEMA), poly(diethylaminoethyl methacrylate) (PDEAEMA), poly(allylamine hydrochloride) (PAH), poly(styrene sulfonate) (PSS), poly(acrylamide-co-acrylic acid) (PAM-co-PAA), poly(acrylamide-co-dimethylaminoethyl methacrylate) (PAM-co-PDMAEMA), poly(acrylamide-co-diethylaminoethyl methacrylate) (PAM-co-PDEAEMA), as well as combinations thereof.

[0166] An example of a method for forming a compartment using a stimulus-responsive polymer is illustrated in FIGS. 8A-C. FIG. 8A provides a cross-sectional side-on view of a portion of a fluidic device (700). The fluidic device (700) may include a bottom surface (700A) and a top surface (700B) that opposes (e.g., is substantially parallel to) the bottom surface (700A). In this example, the top surface (700B) includes a discrete site (703 A) with nucleic acid capture probes as described elsewhere herein. In this figure, the stimulus-responsive polymer (701) is in a contracted state, and only extends partway from the top surface (700B) along the height of the fluidic device (700). Such a structure may be fabricated, for example, by forming the stimulus-responsive polymer (701) on the top surface prior to fluidic device (700) fabrication.

[0167] With continued reference to FIG. 8A, biological materials (702A, 702B) may be input into the fluidic device (700). In this example, a first biological material (702A) may diffuse into a region that is circumscribed or otherwise surrounded by the stimulus-responsive polymer

[0168] (701). A second biological material (702B) remains outside of the area occupied or surrounded by the stimulus-responsive polymer (701). For example, the stimulus-responsive polymer can be formed by a controlled photopolymerization or 3D printing or by a physical printing process to transfer the stimulus-responsive polymer to the top surface (700B).

[0169] FIG. 8B provides a bottom view of the portion of the fluidic device (700) depicted in FIG. 8A. From this view, the shape of the stimulus-responsive polymer (701) coupled to the top surface (700B) is visible. The first biological material (702A) is inside of a region surrounded by the stimulus-responsive polymer (701), while the second biological material (702B) is outside of this region.WSGR Docket No. 59528-739601

[0170] Next, as shown in FIG. 8C, which is an illustration of the cross-sectional side-on view of the fluidic device (700) as shown in FIG. 8A, a stimulus may be applied to the stimulus-responsive polymer (701), causing the stimulus-responsive polymer (701) to transition from its contracted state to its expanded state. The expanded stimulus-responsive polymer (701) extends from the top surface (700B) to the bottom surface (700A), thereby, along with the top surface (700A) and the bottom surface (700B), defining a compartment that encloses the first biological material (702A). The second biological material (702B) is not enclosed in the compartment, and may optionally be washed out of the fluidic device (700) while the first biological material (700 A) is trapped within the compartment. It should be noted that the stimulus-responsive polymer (701), the top surface (700A) and the bottom surface (700B) cooperate to form an open interior volume that contains the first biological material (702A) and discrete site (703 A)

[0171] In some cases, the enclosures are droplets. A droplet can serve as a reaction chamber for one or more cells. The droplet may be a first phase (e.g., aqueous phase) in a second phase (e.g., oil) immiscible with the first phase. The droplet may be a first phase in a second phase that does not phase separate from the first phase, such as, for example, a capsule or liposome in an aqueous phase. In some cases, the droplets are encapsulated in oil. In some cases, the droplets comprise one or more beads. In some cases, each droplet comprises a single bead. A bead can be a gel bead. In some cases, a bead comprises one or more oligonucleotides. The oligonucleotides can be used to capture one or more components from a cell in the droplet. The oligonucleotides can include a barcode unique to the bead which they are disposed on. Within each droplet, a cell can be lysed, and nucleic acids from the cell (including messenger RNA) can bind to a unique barcode on the gel bead, which can then be used to identify the cell of origin. In some cases, the droplets are formed by mixing cells and barcoded gel beads with oil to create the droplets. Enclosing a nucleic acid molecule or a derivative thereof or a cell comprising the nucleic acid molecule or a derivative thereof and one or more reagents may comprise flowing a first phase comprising an aqueous fluid, the cell, and the one or more reagents and a second phase comprising a fluid that is immiscible with the aqueous fluid toward a junction. Upon interaction of the first and second phases, a discrete droplet of the first phase comprising the nucleic acid molecule or a derivative thereof or a cell comprising the nucleic acid molecule or a derivative thereof and the one or more reagents may be formed. In some cases, the enclosure may comprise a single cell. The cell may be lysed or permeabilized within the enclosure (e.g., droplet) to provide access to the nucleic acid molecule of the cell. In some cases, reagents (including reverse transcriptionWSGR Docket No. 59528-739601reagents) are also included during droplet formation. One or more reagents may be coenclosed with a nucleic acid molecule or a derivative thereof or a cell comprising the nucleic acid molecule or a derivative thereof. For example, a nucleic acid molecule or a derivative thereof or a cell comprising the nucleic acid molecule or a derivative thereof may be coenclosed with one or more reagents selected from the group consisting of lysis agents or buffers, permeabilizing agents, enzymes (e.g., enzymes capable of digesting one or more RNA molecules, extending one or more nucleic acid molecules, reverse transcribing an RNA molecule, permeabilizing or lysing a cell, or carrying out other actions), fluorophores, oligonucleotides, primers, probes, barcodes, nucleic acid barcode molecules (e.g., nucleic acid barcode molecules comprising one or more barcode sequences), buffers, deoxynucleotide triphosphates, detergents, reducing agents, chelating agents, oxidizing agents, nanoparticles, beads, and antibodies. In some cases, a nucleic acid molecule or a derivative thereof, or a cell comprising the nucleic acid molecule or a derivative thereof, may be co-enclosed with one or more reagents selected from the group consisting of temperaturesensitive enzymes, pH-sensitive enzymes, light-sensitive enzymes, reverse transcriptases, proteases, ligase, polymerases, restriction enzymes, nucleases, protease inhibitors, exonucleases, and nuclease inhibitors. Droplets may have overall volumes that are less than about 1000 picoliters (pL), 900 pL, 800 pL, 700 pL, 600 pL, 500 pL, 400pL, 300 pL, 200 pL, 100 pL, 50 pL, 20 pL, 10 pL, 1 pL, or less.

[0172] As described herein, one or more processes may be performed in an enclosure, which may be a well. The well may be a well of a plurality of wells of a substrate, such as a microwell of a microwell array or plate, or the well may be a microwell or microchamber of a device (e.g., microfluidic device) comprising a substrate. The well may also be a nanowell. The well may be a well of a well array or plate, or the well may be a well or chamber of a device (e.g., fluidic device). Accordingly, the wells or microwells may assume an “open” configuration, in which the wells or microwells are exposed to the environment (e.g., contain an open surface) and are accessible on one planar face of the substrate, or the wells or microwells may assume a “closed” or “sealed” configuration, in which the microwells are not accessible on a planar face of the substrate. In some instances, the wells or microwells may be configured to toggle between “open” and “closed” configurations. For instance, an “open” microwell or set of microwells may be “closed” or “sealed” using a membrane (e.g., semi-permeable membrane), an oil (e.g., fluorinated oil to cover an aqueous solution), or a lid. The well may have a volume of less than 1 milliliter (mL). For instance, the well may beWSGR Docket No. 59528-739601configured to hold a volume of at most 1000 microliters (pL), at most 100 pL, at most 10 pL, at most 1 pL, at most 100 nanoliters (nL), at most 10 nL, at most 1 nL, at most 100 picoliters (pL), at most 10 (pL), or less. The well may be configured to hold a volume of about 1000 pL, about 100 pL, about 10 pL, about 1 pL, about 100 nL, about 10 nL, about 1 nL, about 100 pL, about 10 pL, etc. The well may be configured to hold a volume of at least 10 pL, at least 100 pL, at least 1 nL, at least 10 nL, at least 100 nL, at least 1 pL, at least 10 pL, at least 100 pL, at least 1000 pL, or more. The well may be configured to hold a volume in a range of volumes listed herein, for example, from about 5 nL to about 20 nL, from about 1 nL to about 100 nL, from about 500 pL to about 100 pL, etc. The well may be of a plurality of wells that have varying volumes and may be configured to hold a volume appropriate to accommodate any of the partition volumes described herein.

[0173] In some instances, a microwell array or plate comprises a single variety of microwells. In some instances, a microwell array or plate comprises a variety of microwells. For instance, the microwell array or plate may comprise one or more types of microwells within a single microwell array or plate. The types of microwells may have different dimensions (e.g., length, width, diameter, depth, cross-sectional area, etc.), shapes (e.g., circular, triangular, square, rectangular, pentagonal, hexagonal, heptagonal, octagonal, nonagonal, decagonal, etc.), aspect ratios, or other physical characteristics. The microwell array or plate may comprise any number of different types of microwells. For example, the microwell array or plate may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more different types of microwells. A well may have any dimension (e.g., length, width, diameter, depth, cross-sectional area, volume, etc.), shape (e.g., circular, triangular, square, rectangular, pentagonal, hexagonal, heptagonal, octagonal, nonagonal, decagonal, other polygonal, etc.), aspect ratios, or other physical characteristics described herein with respect to any well. In certain instances, the microwell array or plate comprises different types of microwells that are located adjacent to one another within the array or plate. For instance, a microwell with one set of dimensions may be located adjacent to and in contact with another microwell with a different set of dimensions. Similarly, microwells of different geometries may be placed adjacent to or in contact with one another. The adjacent microwells may be configured to hold different articles; for example, one microwell may be used to contain a cell, cell bead, or other sample (e.g., cellular components, nucleic acid molecules, etc.) while the adjacent microwell may be used to contain a microcapsule, droplet, bead, or other reagent. In some cases, the adjacentWSGR Docket No. 59528-739601microwells may be configured to merge the contents held within, e.g., upon application of a stimulus, or spontaneously, upon contact of the articles in each microwell.

[0174] In some cases, cells can be enclosed using optofluidic technology. A fluidic device can include one or more distinct regions, which can be at least partially physically separated from each other. In some cases, these distinct regions may be referred to as “pens.” For example, a fluidic device can include a channel in fluidic communication with a plurality of pens. A pen may be open on a side of the pen that abuts or is adjacent to a channel. Cells can be loaded into the channel. Energy, including light, can be applied to the fluidic device. The projected light can change electrical properties of certain regions of the fluidic device to create electrical fields that push or pull cells. This light energy can be used to pick up single cells or a certain number of cells, move the single cell or cells, and place the single cell or cells in a specific pen within the fluidic device. This can result in a pen of a fluidic device comprising a single cell. Once isolated, cells may remain in the pen and kept alive with controlled media flow. The pens within a fluidic device can be continuously monitored. As described elsewhere herein, any type of assay may be performed on a single cell or multiple cells within a pen (functional assays, imaging assays, morphology assays, proteomic assays, metabolic assays, etc.). Nucleic acids can be released from the cells and contained within the pen.

[0175] In some cases, cells are spatially constrained to a unique area of the fluidic device, with or without a physical enclosure. In some cases, each of the unique areas is no more than 285,000 μm2, 200,000 pm2, 150,000 pm2, 100,000 pm2, 50,000 pm2, 25,000 pm2, 20,000 pm2, 15,000 pm2, 12,000 pm2, 11,000 pm2, 5,000 pm2, 1,000 pm2, 500 pm2, 100 pm2, 10 pm2, or 1 pm2. In some cases, a physical enclosure as described elsewhere herein is used to constrain the area a cell can move. In some cases, a cell is constrained to an area without the use of a physical enclosure. The present disclosure also provides systems including one or more capture elements for immobilizing and / or compartmentalizing one or more biological components (including cells). The system can include a fluidic device. The fluidic device can include or contain one or more biological components. In some embodiments, the fluidic device can include a first surface (e.g., in a channel and / or chamber of the fluidic device). The fluidic device can include one or more capture elements. The capture elements can immobilize, or be configured to immobilize, at least one of the one or more biological components at a location on or adjacent to the first surface (or any suitable surface).Immobilization or coupling of a biological component to a capture element can form anWSGR Docket No. 59528-739601immobilized biological component. In some embodiments, the one or more capture elements comprise a physical trap (including a divot), a geometric trap, a well, an electrochemical trap, a chemical affinity trap, one or more magnetic particles, an electrophoretic trap, adielectrophoretic trap, or a combination thereof. In some embodiments, the chemical affinity trap comprises streptavidin, an antibody, or a combination thereof. In some embodiments, the electrochemical trap comprises a gold electrode, a platinum electrode, an indium tin oxide (ITO) electrode, or other suitable electrochemical trap. In some embodiments, the one or more capture elements are disposed in a pattern on the first surface. In some embodiments, the one or more capture elements comprises a well as described elsewhere herein. For example, a cell can be constrained to a specific area of a fluidic device by using a capture element. A biological component (including a cell) can couple to a capture element on a surface, for example. Once coupled to the capture element, the biological component may be constrained to a specific area of the fluidic device. As described elsewhere herein, any number and combination of assays can be performed on a spatially constrained biological component.Use of Trained Machine Learning Algorithms for Enclosure Placement

[0176] Determining optimal enclosure locations can be computationally intensive, and can add seconds or minutes to enclosure formation over each field-of-view over a fluidic device. Determining a suitable set of enclosure locations given a set of biological material positions can be prohibitively computationally demanding and time intensive for methods that generate or manipulate (e.g., actuating openings to pens) hundreds, thousands, or tens of thousands of enclosures within a fluidic device. In some cases, a computationally intensive model such as a repeated random sampling algorithm may be capable of identifying optimized cage positions, but may require minutes to determine cage locations for an image containing hundreds of biological materials, and may therefore communicate instructions to generate or manipulate enclosures after cells have diffused outside of cage locations. Furthermore, when a fluidic device contains hundreds or thousands of fields of view from a particular imaging apparatus, enclosure locations may need to be determined in less than one minute for each field of view to permit media refreshment or incubation steps useful for promoting cell viability.

[0177] In some aspects, the present disclosure addresses these challenges with a trained machine learning algorithm. The trained machine learning algorithm may utilize images of biological components to select enclosure locations. The trained machine learning algorithm may speed up the process of enclosure formation by rapidly selecting enclosure locations,WSGR Docket No. 59528-739601thereby saving seconds to minutes per field-of-view of a fluidic device and allowing enclosures to be formed, for example, at rates of about 50 to about 2500 enclosures per minute. The enclosure locations can fulfill user-defined parameters such as enclosure size, enclosure shape, inter-enclosure spacing, number of biological components per enclosure, type or types of biological components to be enclosed, and the like.

[0178] An example of a method that utilizes a trained machine learning algorithm is outlined in FIG. 10. In step 1001, a computing device may receive an image of a fluidic device. The image may include a brightfield image, a fluorescence image, or a combination thereof. The image may include a field-of-view of a portion of a fluidic device. The method may be repeated over multiple fields-of-view of the fluidic device.

[0179] As outlined in step lOOlAof FIG. 10, a user may input a parameter. The parameter may define an aspect of the enclosures such as size, inter-enclosure spacing, number of enclosures, and the like. The parameter may also define an aspect of biological materials to be enclosed or excluded from enclosures, such as type, size, or fluorescence profile. Next, in optional step 1002 of FIG. 10, the computing device may implement the trained machine learning algorithm (or an additional trained machine learning algorithm) to identify biological components in images of a fluidic device. During this step, biological materials may be distinguished from other objects such as dust particles. The contours (i.e., outer edges) of the biological materials may also be identified. When multiple biological particles overlap or are clustered within an image, the trained machine learning algorithm may distinguish individual biological components and provide total counts of biological components within discrete areas of the fluidic device. The machine learning algorithm may be trained to identify biological components from low magnification images.

[0180] In reference to step 1002A of FIG. 10, the machine learning algorithm may be trained using manually annotated images of biological components, wherein a human identifies and labels biological components in images and uploads the labeled images as training data for the machine learning algorithm. The biological components may include cells, and the cells may labeled by individual cell type and optionally according to other features such as cell cycle phase and / or state. The biological materials may optionally be further characterized according size, morphology (e.g., shape, eccentricity, protrusion size, number of protrusions, etc.), optical characteristics (e.g., opacity), and / or fluorescence profile (e.g., signals from a fluorescent probe targeted to a surface marker or a panel of fluorescent probes targeted to a panel of surface markers). In some cases, a subset of the biological materials, for example a particular type of cell from among a mixture of cell types, may be selected for enclosure. InWSGR Docket No. 59528-739601some cases, a subset of the biological materials, for example terminally differentiated cells or cells exhibiting high degrees of thermal or oxidative stress, may be excluded from enclosure.

[0181] With further reference to FIG. 10 step 1002A, the machine learning algorithm may also be trained to identify biological components from images generated using magnification of less than 40X and / or exposure times of less than 10 seconds. The machine learning algorithm may thus speed up enclosure formation by diminishing imaging time required for enclosure formation. As one example, the machine learning algorithm may utilize images with magnification of about 2X (i.e., 3-fold increase in apparent size in an image relative to real size of an object) to about 4X, about 2X to about 10X, about 2X to about 20X, about 2X to about 40X, about 4X to about 10X, about 4X to about 20X, about 4X to about 40X, about 10X to about 20X, about 10X to about 40X, or about 20X to about 40X. The magnification may be at most about 40X, at most about 20X, at most about 10X, at most about 4X, or at most about 2X. Magnification within these ranges may allow large portions of a fluidic device to be imaged within individual fields of view, thereby diminishing the number of images that are analyzed to form enclosures (e.g., to form polymeric chambers) or otherwise enclose biological materials (e.g., actuate openings into wells or pens) throughout the fluidic device. The machine learning algorithm may be capable of identifying biological components in images generated using exposure times of less than about 10 seconds that, in some cases, may have lower resolution than images generated using exposure times of greater than about 10 seconds. The machine learning algorithm may use images generated in less than about 10 seconds, less than about 5 seconds, less than about 2 seconds, less than about 1 second, less than about 0.5 seconds, less than about 0.1 seconds, less than about 0.05 seconds, less than about 0.01 seconds, less than about 0.005 seconds, or less than about 0.001 seconds. The images may be generated in about 0.001 to about 0.01 seconds, about 0.001 to about 0.1 seconds, about 0.001 to about 1 seconds, about 0.001 to about 10 seconds, about 0.01 to about 0.1 seconds, about 0.01 to about 1 second, about 0.01 to about 10 seconds, about 0.1 to about 1 second, about 0.1 to about 10 seconds, or about 1 to about 10 seconds. The images may include brightfield images generated by collecting light that passes through the fluidic device. The images may include fluorescence images generated by irradiating the fluidic device with light of a first wavelength and then detecting light of a second wavelength emitted from the fluidic device.

[0182] Moving to step 1003 of FIG. 10, the computing device may then analyze the image in order to determine an optimal set of enclosure locations. During this step, the computing device may utilize the trained machine learning algorithm of step 1002 (trained in stepWSGR Docket No. 59528-7396011002 A) or the computing device may utilize an additional trained machine learning algorithm. The trained machine learning algorithm or the additional trained machine learning algorithm may select a set of enclosure locations. As an example, the trained machine learning algorithm or the additional trained machine learning algorithm may generate an enclosure centered around each biological material from step 1002. If any two enclosures overlap, the second machine learning model may move an enclosure (e.g., so that the enclosure still encloses but is no longer centered over a biological material) remove an overlapping enclosure. Enclosure locations may then be adjusted in order to maximize interenclosure distances. Alternatively, the trained machine learning algorithm or the additional trained machine learning algorithm may provide a starting set of enclosure locations to a deterministic or other classical algorithm for optimization. The optimal enclosure locations may, for example, maximize the number of enclosed biological components or may balance multiple parameters such as inter-enclosure spacing and enclosure overlap with discrete sites.

[0183] In reference to step 1003 A of FIG. 10, the machine learning algorithm used in step 1003 may be trained to rapidly identify enclosure positions that satisfy a set of input parameters. The data used for this training step may include biological components along with enclosure locations determined using a computationally intensive algorithm (e.g., an algorithm that utilizes about 1 to 10 minutes of computing time to determine enclosure locations). This process may train the machine learning model or the additional machine learning model to quickly select enclosure locations (e.g., an algorithm that utilizes about 0.1 to about 10 seconds of computing time to determine enclosure locations). The trained machine learning model or the additional trained machine learning model may also be trained on a computationally intensive algorithm that is configured to produce a set of enclosure locations. The computationally intensive algorithm may be impracticably slow for use on biological components, but may reliably generate suitable enclosure locations for a given set of biological material positions and input parameters. The trained machine learning model or the additional trained machine learning model may be less complex than the algorithm, and may thus select enclosure positions faster than the algorithm.

[0184] Finally, at step 1004 of FIG. 10, the computing device may output instructions to enclose specific biological materials. The instructions may be transmitted to an apparatus that is configured to execute the instructions. As one example, the instructions may prompt a light source and a spatial light modulator to project a defined light pattern into the fluidic device to photopolymerize a polymer precursor at irradiated locations. As another example, theWSGR Docket No. 59528-739601instructions may prompt an apparatus to provide electrical signals to actuators to close selected wells or pens to trap biological components positioned therein.Fluidic Device

[0185] A method disclosed herein may be performed within a fluidic device. An example of a fluidic device consistent with the present disclosure is illustrated in FIG. 1, which depicts cells disposed within a channel 100 of a fluidic device. A channel 100 of a fluidic device can also sometimes be referred to as a “flow chamber,” “flow channel,” or “reaction chamber”, and may receive or be configured to receive a biological sample. FIG. 1 shows a simplified schematic cross-sectional side view illustration of a portion of a channel 100 of a fluidic device. The channel 100 may comprise a first surface 101 and a second surface 102 positioned opposite of one another (e.g., as depicted in FIG. 1). In some embodiments, a middle spacer layer of double-sided adhesive with a cut-out portion can be used to position the first surface 101 and second surface 102 in a facing relationship to at least partly form the flow channel 100. The perpendicular distance between the first surface 101 and the second surface depends in part on the nature and size of the biological components to be analyzed. In some embodiments, such as, those adapted to analyzing mammalian cells, the perpendicular distance between a first surface and a second surface may be in the range of from 10 pm to 500 pm, or in the range of from 50 pm to 250 pm. In some embodiments, the perpendicular distance between a first surface and a second surface may be in the range of from twice the average size of the biological component to be analyzed to five times the average size of the biological component to be analyzed. In some embodiments, the first surface 101 may be a lower surface. In certain embodiments, the second surface 102 may be an upper surface. In some embodiments, the first surface 101 and second surface 102 are substantially parallel, so that the perpendicular distance between them is substantially the same throughout the channel, for example, where chambers are formed. The perpendicular distance may vary by less than + / - 10%, 5%, 1%, or 0.1% throughout the channel 100. The channel 100 may receive a biological sample comprising one or more biological components 50, 51. The channel 100 may receive one or more polymer precursors. As illustrated in FIG.1, the biological components 50, 51 may include cells. However, as discussed herein, biological components enclosed and / or analyzed in the disclosed methods may include tissues, proteins, nucleic acids, etc.

[0186] In particular cases, a method of the present disclosure may utilize a tissue sample. Tissue samples suitable for the systems and methods disclosed herein may include intact tissue sections (e.g., generated during tissue biopsies), partially dissociated tissue samples,WSGR Docket No. 59528-739601and engineered tissue samples. A tissue sample may be placed in a fluidic device or on a surface of the present disclosure. In some aspects, the tissue sample may comprise an excised specimen, such as a tumor biopsy, epithelial tissue, organ slice, or other primary tissue obtained from a subject. The tissue sample may include sub-millimeter, millimeter, or centimeter scale dimensions. The tissue sample may include live cells. The tissue sample may be dead (e.g., fixed). In certain embodiments, the tissue is used substantially intact and immobilized for imaging or analysis, while in other embodiments the tissue is embedded within or supported by a matrix material, such as a hydrogel or extracellular matrix analog, to maintain structural integrity or to form engineered three-dimensional constructs (e.g., cardiac, muscle, connective, or composite tissues). In certain aspects, the tissue sample may be subjected to mechanical and / or enzymatic processing to yield smaller fragments, cell clusters, or single-cell suspensions for downstream analysis. In some aspects, an entire tissue sample may be enclosed within a single enclosure.

[0187] A method of the present disclosure may also utilize a cell aggregate. Examples of cell aggregates suitable for use with the disclosed microfluidic devices may include multicellular spheroids, organoids, embryoid bodies, and neurospheres. Such aggregates may comprise homogeneous or heterogeneous populations of cells, including combinations of parenchymal, stromal, and / or immune cell types, and may exhibit defined structural features such as proliferative outer layers, quiescent or hypoxic cores, and extracellular matrix deposition. Representative sizes may range from tens of micrometers to several hundred micrometers in diameter, for example about 10 pm to about 500 pm. In some cases, a single cell aggregate may be enclosed within a single enclosure.

[0188] In some embodiments, the first surface 101 and / or second surface 102 can be optically transmissive so that visible and UV light can transmit through one or both of the surface for the generation of polymeric hydrogels, imaging of the flow cell, and the measurement of the analyte and biological components.

[0189] In certain cases, a channel may have a cross-sectional area that is rectangular, circular, semi-circular, or oval. Accordingly, the channel may have a single, internal surface. In some cases, a channel may have a triangular, square, rectangular, polygonal, or other cross-section. Accordingly, the channel may have three or more internal surfaces. One or more of the internal surfaces may be couple or receive, or be configured to couple or receive, the one or more biological components.

[0190] In certain cases, a channel may have a cross-sectional area that is rectangular, circular, semi-circular, or oval. Accordingly, the channel may have a single, internal surface. In someWSGR Docket No. 59528-739601cases, a channel may have a triangular, square, rectangular, polygonal, or other cross-section. Accordingly, the channel may have three or more internal surfaces. One or more of the internal surfaces may be couple or receive, or be configured to couple or receive, the one or more biological components.

[0191] The first surface 101, the second surface 102, or both surfaces 101, 102 may be functionalized, for example with a coating. As a non-limiting example, a surface coating may be a surface polymer. Some non-limiting examples of surface coatings may include a capture reagent (e.g., pyridinecarboxaldehyde (PCA)), a functional group to capture one or more moi eties (e.g., a chemical moiety), an acrylamide, an agarose, a biotin, a streptavidin, a strep-tag II, a linker, a functional group comprising an aldehyde, a phosphate, a silicate, an ester, an acid, an amide, an alkyne, an azide, an aldehyde dithiolane, or a combination thereof. In various embodiments, the surface coating may include a functional group to capture one or more moieties. For example, the acrylamide, the agarose, etc. may include such a functional group. In certain embodiments, the surface polymer may comprise polyethylene glycol (PEG), a thiol, an alkene, an alkyne, an azide, or combinations thereof. In various embodiments, the surface polymer may comprise a silane polymer derivatized with N-hydroxysuccinimide. In some embodiments, the surface polymer may be functionalized with at least one of an oligonucleotide, an antibody, a cytokine, a chemokine, a protein, an antibody derivative, an antibody fragment, a carbohydrate, a toxin, or an aptamer. In particular embodiments, the surface coating comprises a material for which adherent cells have a binding affinity, such as fibronectin, laminin, poly-L-ornithine, or combinations thereof.

[0192] FIGS. 3A-G illustrate an example of a fluidic device consistent with the present disclosure. The channel 100 of FIG. 1 may correspond to any one of the cut-out regions (405 A, 405B, 405C) of FIG. 3D. FIGS. 3A-D figures depict the components of a flow cell comprised of a bottom layer 400 (FIG. 3A), a spacer layer 402 (FIG. 3B), and top layer 404 (FIG. 3C). The bottom layer (400) and the top layer (404) can both independently be a glass or plastic material. In some cases, the top layer (404) is optically transparent or translucent. In some cases, the bottom layer (400) is optically transparent or translucent. In many cases, the top layer (404) and the bottom layer (400) are optically transparent or translucent. The top layer (404) and / or the bottom layer (400) may be planar. The bottom layer (400), the top layer (404), or the bottom layer (400) and the top layer (404) can include a physical fiducial marker such as a laser etched cross. The physical fiducial marker may be utilized as a reference point during fluidic device imaging to measure the orientation of the fluidic device; to estimateWSGR Docket No. 59528-739601locations of channels, discrete sites, fluorescent fiducial markers (e.g., element 416 in FIG.3E), or other fluidic device features; to focus an optical system on the fluidic device; or a combination thereof.

[0193] With continued reference to FIG. 3B, the spacer layer (402) can be a double-sided pressure sensitive adhesive with one or more cut-out regions (405A, 405B, 405C). In this design, the one or more cut-out regions of the spacer layer are sandwiched between the bottom layer and the top layer to form one or more channels. In various embodiments, the spacer layer (402) includes a core plastic (e.g., PET) layer with pressure sensitive adhesive coating on its top and / or bottom sides that contact the top (404) and bottom (400) layers. Examples of adhesive coatings consistent with the present disclosure include siloxane, silicone, acrylate, acrylamide, polyvinyl, polyurethane, epoxy, polyphenol, polyester, polyamide, polyimide, polytetrafluoroethylene, polyethylene, polypropylene, polycarbamate, polycarbonate, polyacrylic acid, sulfonated polyester, and combinations thereof. The spacer layer (402) may be gas-permeable, and may thereby allow gas diffusion in and out of sample-filled channels to facilitate long-term cell viability. More specifically, the spacer layer (402) may permit O2 to diffuse into cell-containing fluid in cut-out regions (405A, 405B, 405C) and waste gas such as CO2 to diffuse out of cell-containing fluid in the cut-out regions (405 A, 405B, 405C). Examples of gas-permeable materials suitable for the spacer layer include siloxane, silicone, acrylate, acrylamide, polyvinyl, polyurethane, epoxy, polyphenol, polyester, polyamide, a polyimide, polytetrafluoroethylene, polyethylene, polypropylene, polycarbamate, polycarbonate, polyethylene terephthalate, cyanoacrylates, as well as combinations thereof.

[0194] Referring to FIG. 3B, a peripheral portion (407) of the spacer layer (402) provides a boundary for one or more cut-out regions (405A, 405B, 405C) with defined widths (406A) and lengths (406B). In many designs disclosed herein, the spacer layer (402) adheres to the top (404) and bottom (400) layers, such that a cut-out region or plurality of cut-out regions (405A, 405B, 405C) define a channel or a plurality of channels. The spacer layer (402), bottom layer (400), and / or top layer (404) can be water (or optionally more generally liquid) impermeable such that a first aqueous sample in a first cut-out region (e.g., 405A) is isolated from a second aqueous sample in a second cut-out region (e.g., 405B). Biological components and reagents in a first cut-out region (e.g., 405A) may similarly be isolated from other cut-regions (405B, 405C). The one or more cut-out regions (405A, 405B, 405C) can thus define flow cell channels with defined dimensions.WSGR Docket No. 59528-739601

[0195] A channel defined by a cut-out region (405A, 405B, 405C) can be operably coupled to an inlet (408) and / or an outlet (410) in the top layer (404), through which, for example, a gas, liquid, sample, or reagent may flow. In various embodiments, the inlet (408) and outlet (410) can both be represented as through holes in the top layer (404). However, the inlet (408) and / or outlet (410) can be disposed within other components of the flow cell, such as the bottom layer (400) or spacer layer (402).

[0196] With respect to FIG. 3D, the top layer (404) can have a height of about 0.7 mm and the bottom layer can have a height of about 0.5 mm. The first cut-out region (406) can have a height (406C) defined by the distance between opposing faces of the top layer (404) and the bottom layer (400). The spacer layer can have a height ranging from about 50 microns to about 200 microns, and preferably, from about 70 microns to about 130 microns. The cut-out region can have dimensions of about 10.3 cm length y about 0.7 cm width.

[0197] Moving to FIG. 3E, nucleic acid capture probes can be coupled to a surface (e.g., bottom surface 400 from FIG. 3A or top surface 404 from FIG. 3C) of a fluidic device. The surface may include a plurality of discrete sites, wherein at least a portion of nucleic acid capture probes within a particular discrete site include share a common spatial barcode sequence that is associated with that discrete site. Discrete sites may be arranged in arrays (414) along the surface (404). Each array may include, for example, about 100 to about 500, about 100 to about 1000, about 100 to about 2500, about 100 to about 5000, about 500 to about 1000, about 500 to about 2500, about 500 to about 5000, about 1000 to about 2500, about 1000 to about 5000, or about 2500 to about 5000 discrete sites. Each discrete site along the surface (404) can be associated with a unique spatial barcode sequence. Alternatively, each discrete site within a row of arrays (414) can be associated with a unique spatial barcode sequence relative to other discrete sites within the row. In some cases, each discrete site within a particular array (414) can be associated with a unique spatial barcode sequence relative to other discrete sites within the array (414). In such cases, a discrete site in a first array (414) may share a spatial barcode sequence in common with another discrete site in another array (414). In particular cases, a particular spatial barcode sequence may be associated with one discrete site or at least one discrete site within each array (414) on the fluidic device surface (404). In some cases, each discrete site within a particular array (414) is associated with a common spatial barcode sequence that distinguishes the array from at least a subset of other arrays in the fluidic device. In such cases, at least a subset of discrete sites within the particular array (414) may be associated with additional spatial barcodeWSGR Docket No. 59528-739601sequences that distinguish the discrete sites from other discrete sites within the particular array (414).

[0198] With continued reference to FIG. 3E, a fluidic device surface (404) may include fluorescent fiducial markers (416). A set of fluorescent fiducial markers (416) may surround and partially enclose an array (414). The set of fluorescent fiducial markers (416) may define the edges of a square, rectangle, or other geometric shape. In the example shown in FIG. 3E, the fluorescent fiducial markers (416) may define the edges of a square that surrounds the array (414). Each array (414) may be encompassed by a set of fluorescent fiducial markers (416) in this manner. In other embodiments, the surface (404) of the fluidic device may include a single set of fluorescent fiducial markers (416) that may, for example, be positioned at the outer edges of the collection of arrays (414) on the surface (404) or may be positioned at a single location along the fluidic device surface (404). Alternatively, each row of arrays (414) may include a single set of fluorescent fiducial markers (416) that may, for example, define the edges of a geometric shape that encompasses the row of arrays. View 412 encompasses an array (414) and an associated set of fluorescent fiducial markers (416) and is shown in greater detail in FIG. 3G.

[0199] FIG. 3F shows the top surface (404) of the fluidic device coupled to the spacer layer (402). Each of the arrays (414) and fluorescent fiducial markers (416) is exposed through a cutout region (405A, 405B, 405C) of the spacer layer (402). In this example, the cutout regions (405A, 405B, 405C) correspond to channels within the fluidic device, and each cutout region (405A, 405B, 405C) coincides with 15 sets of arrays (414) and fluorescent fiducial markers (416), one inlet (408), and one outlet (410). However, the cutout regions (405A, 405B, 405C) may include any numbers of arrays (414), fluorescent fiducial markers (416), inlets (408), and outlets (410). Two cutout regions (405 A, 405B, 405C) in the spacer layer (402) may coincide with the same number or different numbers of arrays (414), fluorescent fiducial markers (416), inlets (408), and outlets (410) on the top layer (404).

[0200] FIG. 3G provides a blown up view of field 412 from FIGS. 3E-F. This view covers a single array (414) and set of fluorescent fiducial markers (416). As illustrated in FIG. 3G, four subsets of the set of fluorescent fiducial markers (416) can be arranged such that they are proximate to each vertex of the array (414). The array (414) may include a plurality of discrete sites (414A), which can be arranged in a uniform or regular pattern, such as a hexagonal or rectangular array. The discrete sites (414A) can have a common size and / or shape. For example, the discrete sites (414A) can have areas of about 500 to about 1000, about 500 to about 2500, about 500 to about 5000, about 500 to about 10000, about 500 toWSGR Docket No. 59528-739601about 25000, about 1000 to about 2500, about 1000 to about 5000, about 1000 to about 10000, about 1000 to about 25000, about 2500 to about 5000, about 2500 to about 10000, about 2500 to about 25000, about 5000 to about 10000, about 5000 to about 25000, or about 10000 to about 25000 pm2. Within the array (414), the discrete sites (414A) can have a pitch of about 1.25 to about 1.5, about 1.25 to about 2, about 1.25 to about 2.5, about 1.25 to about 5, about 1.5 to about 2, about 1.5 to about 2.5, about 1.5 to about 5, about 2 to about 5, or about 2.5 to about 5 times a mean diameter or width of a discrete site (414A). For example, when the discrete sites (414A) are 80 pm diameter circles, the pitch between discrete sites may be about 100 pm to about 400 pm. The discrete sites (414A) can be annular, circular, square, rectangular, hexagonal, or another polygonal shape. At least a subset of the discrete sites (414A) are associated with one or more nucleic acid capture probe sequences. For example, each discrete site (414A) may contain nucleic acid capture probes that are uniquely associated with the discrete site (414A) in which they are located.

[0201] With continued reference to FIG. 3G, the fluorescent fiducial markers (416) may include a collection of discrete fluorescent spots (416A). The discrete fluorescent spots (416A) may have similar or identical sizes and / or shapes as the discrete sites (414A). The discrete fluorescent spots (416A) may be applied by the same droplet spotter or other fabrication device utilized to generate the discrete sites (414A). When the discrete sites (414A) are arranged in a regular pattern or grid, the discrete fluorescent spots (416A) may reside in locations that coincide with the pattern or grid (i.e., if the array (414) were larger, the fluorescent fiducial spots (416A) would reside at locations within the array (414) pattern or grid). A fluorescent fiducial marker (416) may define two orthogonal axes. For example, fluorescent fiducial spots (416A) within a fluorescent fiducial marker (416) may be disposed in a bracket-like pattern as shown in FIG. 3G. A set of fluorescent fiducial markers (416) surrounding an array (414) may be arranged along common axes.

[0202] Examples of fluorophores that are suitable for fabricating fluorescent fiducial markers (416) consistent with the present disclosure include organic dyes, fluorescent proteins, and fluorescent particles. In some cases, the fluorescent fiducial markers (416) include a fluorescent dye selected from carboxy tetramethylrhodamine (TAMRA), carboxy-HEX, NAN, Cl-FLAN, TET, JOE, ZOE, rhodamine, isomers of carboxyrhodamine, dichlorofluorescein, dichlororhodamines, isomers thereof, or combinations thereof. The fluorophores utilized for fluorescent fiducial marker (416) fabrication may be selected to avoid overlap with absorbance or emission spectra of fluorophores utilized in assays disclosed herein.WSGR Docket No. 59528-739601

[0203] In further reference to FIGS. 3E-G, the fluorescent fiducial markers (416) may be utilized to identify positions of discrete sites (414A) within a fluidic device, for example during a method for biological analysis disclosed herein. Such a method may include: (i) disposing the fluidic device on a platform or holder within an optical system (e.g., the optical system depicted in FIG. 4A); (ii) detecting a fluorescence signal from one or more fluorescent fiducial markers (416) in the fluidic device; (iii) using the fluorescence signals, determining locations of the one or more fluorescent fiducial markers (416) in the fluidic device; and (iv) using the locations of the fluorescent fiducial markers (416), determining: locations of at least a subset of the discrete sites (414A), an orientation of an array (414) of the discrete sites (414A), or a combination thereof. In some cases, prior to detecting the fluorescent signal from one or more fluorescent fiducial markers (416); the method further includes detecting a location of a physical fiducial marker (409) in the fluidic device, and using the location of the physical fiducial marker (409) to: (a) determine locations of at least a subset of the fluorescent fiducial markers (416); (b) determine an orientation of the fluidic device; (c) determine an orientation of an array (414) of discrete sites (414A); or (d) a combination thereof. In some cases, the determining the locations of the one or more fluorescent fiducial markers (416) comprises detecting a plurality fluorescent fiducial markers (416) that partially surround the array (414) of the discrete sites (414A). In some cases, the method comprises forming one or more chambers in the fluidic device, wherein locations of the one or more chambers are determined using the locations of the discrete sites (414A) or the locations of the subset of the discrete sites (414A). In some cases, projecting light into the fluidic device such that the projected light causes cross-linking of the polymer precursor to form a polymer matrix that at least partially surrounds the discrete site at the identified location, whereby the identifying the location of the discrete site beforehand allows for a precise alignment of the discrete site and a pattern of the polymer matrix.Polymer Precursors

[0204] In some aspects, an enclosure may be formed from one or more polymer precursors. For example, a channel of a fluidic device (e.g., the channel) can comprise one or more polymer precursors for forming chambers. The polymer precursor may be light activatable. For example, synthesizing one or more chambers can comprise projecting light into the channel with a spatial energy modulating element such that the projected light causes crosslinking of one or more polymer precursors to at least partially form the one or more chambers. As discussed in further detail below, a wide variety of photo-synthesizable gels and degradable gels are available for implementing the systems and methods described herein. InWSGR Docket No. 59528-739601some embodiments, photo-synthesized gels are formed using a photo-initiator for radical polymerization. In some embodiments, photo-initiators comprise 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure 2959), lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP), or Eosin- Y. In some embodiments, one or more polymer precursors comprise hyaluronic acid, chitosan, alginate, polyethylene glycol (PEG), multi-arm PEG, polyethylene glycol)-b-poly(propylene oxide)-b-poly(ethylene glycol) (PEG-PPO-PEG), poly(lactic acid-co-glycolic acid)-b-poly(ethylene glycol)-b-poly(lactic acid-co-glycolic acid) (PLGA-PEG-PLGA), and poly(vinyl alcohol). In some embodiments, polymer precursors comprise PEG or multi-arm PEG. In some embodiments, the polymer precursors comprise an enzymatically degradable cross-linker. In some embodiments, such an enzymatically degradable cross-linker is degradable by an esterase or a peptidase. In some embodiments, polymer precursors comprise a photo-degradable cross-linker. In some embodiments, such a photo-degradable cross-linker comprises a nitrobenzyl group. In some embodiments, such photo-degradable cross-linker comprises a coumarin moiety.

[0205] In some embodiments, the one or more polymer precursors are added to the fluidic device along with the one or more cells. In various embodiments, the one or more cells and the one or more polymer precursors can be pre-mixed and then added to the fluidic device at the same time; the one or more cells and the one or more polymer precursors can be added to the fluidic device at the same time; the one or more cells can be added to the fluidic device first and then the one or more polymer precursors can be added to the fluidic device second; the one or more cells can be added to the fluidic device first allowing the one or more cells couple to a surface in the fluidic device, and then the one or more polymer precursors can be added to the fluidic device second; or the one or more polymer precursors can be added to the fluidic device first and then the one or more cells can be added to the fluidic device second.

[0206] Polymer precursors may be selected from a wide variety of compounds including, but not limited to, polyethylene glycol (PEG)-thiol, PEG-acrylate, acrylamide, N, N'-bis(acryloyl)cystamine, PEG, polypropylene oxide (PPO), polyacrylic acid, poly(hydroxyethyl methacrylate) (PHEMA), poly(methyl methacrylate) (PMMA), poly(N-isopropyl acrylamide) (PNIPAAm), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), poly(L-aspartic acid), poly(L-glutamic acid), polylysine, agar, agarose, alginate, alginate sulfate, dextran sulfate, hyaluronan, pectin, carrageenan, gelatin, chitosan, cellulose, collagen, bisacrylamide, diacrylate, diallylamine, triallylamine, divinyl sulfone, diethyleneglycol diallyl ether, ethyleneglycol diacrylate, polymethyleneglycol diacrylate, polyethyleneglycol diacrylate, trimethylopropoaneWSGR Docket No. 59528-739601trimethacrylate, ethoxylated trimethylol triacrylate, or ethoxylated pentaerythritol tetraacrylate, or combinations or mixtures thereof. Representative crosslinkers useful for polymer synthesis are listed in Tables 1 A and IB. Degradation agents that may be used to degrade chambers formed from particular polymer precursors are indicated in column 4 of Table 1 A (column 4).Table 1ATable IBWSGR Docket No. 59528-739601WSGR Docket No. 59528-739601WSGR Docket No. 59528-739601WSGR Docket No. 59528-739601WSGR Docket No. 59528-739601WSGR Docket No. 59528-739601WSGR Docket No. 59528-739601WSGR Docket No. 59528-739601WSGR Docket No. 59528-739601

[0207] A polymer precursor can further comprise additional reagents that affect polymerization and polymer matrix properties. As examples, a polymer precursor can include a crosslinker, a porogen, a viscosity-modifying agent, an acid, a base, a catalyst, a salt, a photoinitiator, or a combination thereof. As another example, polymer precursors can include a crosslinker, a porogen, a photoinitiator, and a buffer.

[0208] As used herein, the term “crosslinker” denotes a species with two or more polymerizable groups. For example, where the polymerizable group is an ethylenicallyWSGR Docket No. 59528-739601unsaturated group, a crosslinker would contain two or more ethylenically unsaturated groups. In another example, a crosslinker can contain three or more reactive centers for bifunctional polymer synthesis (e.g., the three methoxy groups of trimethoxybenzene in the context of polyester synthesis).

[0209] As used herein, the term “porogen” can denote a species that modulates the porosity of a polymer matrix. A porogen can be dispersed with the reactants before the polymerization process of forming the polymer matrix. Porogens typically diffuse out of polymer matrices following polymerization, leaving pores in the regions that they occupied. Porogen size, concentration, hydrophobicity, and hydrophilicity can thus influence pore density and pore size in polymer matrices. Examples of porogens consistent with the present disclosure include particles (e.g., polymeric, ceramic, metal, metal oxide, or hydrogel particles), polymers such as polyethylene glycol and alginate, and vesicles such as liposomes or micelles.

[0210] As used herein, the term “photoinitiator” can denote a species that generates a radical upon photoexcitation. In many cases, a photoinitiator included in a polymer precursor formulation is a type I photoinitiator, that is a molecule that generates radicals through intramolecular cleavage (e.g., homolysis) upon photoexcitation, or a type II photoinitiator, that is a molecule that abstract an electron or hydrogen atom from a co-initiator following photoexcitation. Examples of photoinitiators utilizable in the present methods include acetophenone, anisoin, anthraquinone, anthraquinone-2-sulfonic acid, benzil, benzoin, benzophenone, 3,3’,4,4’-benzophenonetetracarboxylic dianydride, 4-benzoylbiphenyl, 2-benzyl-2-(dimethylamino)-4’-morpholinobutyrophenone, dibenzosuberenone, 2,2-diethoxyacetophenone, 2-ethylanthraquinone, ferrocene, 2-isopropylthioxanthone, lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate, methyl-2-benzoylbenzoate, and thiooxanthen-9-one.Nucleic Acid Capture Probes

[0211] In some aspects, a method is performed in a fluidic device, wherein one or more surfaces of the fluidic device (e.g., first surface 101, second surface 102, or first and second surfaces 101 and 102 of channel 100 of FIG. 1) contains one or more nucleic acid capture probes. One or more surfaces may contain, for example, about 1 to about 50,000,000 barcodes. The barcodes or subsets of the barcodes may be different from one another (e.g., each barcode may be unique). In some cases, a barcode (or a portion / subset of barcodes) may be associated with the location of the barcode on a surface (location coordinates (e.g., x-, y-coordinates) on a surface of a channel). In particular, a barcode may include a sequence thatWSGR Docket No. 59528-739601is unique (“spatially-addressed”) to a region or discrete spot along a surface of the fluidic device. Each region or discrete spot may contain a plurality of nucleic acid capture probes that share a common “spatially-addressed” sequence, while different discrete spots may be associated with different spatially-addressed sequences. Accordingly, the spot or region of origin of a barcode may be determined based on its spatially-addressed sequence. A discrete spot or region that contains barcodes with common “spatially-addressed” sequences may cover an area, for example, of about 10 to about 105pm2along the first or second surface of the fluidic device. The first or second surface of the fluidic device may contain about 10 to about 107discrete spots. In some embodiments, a surface of a channel within a fluidic device may include about 5xl03to about 5xl04discrete spots. In further embodiments, a surface of a channel within a fluidic device may include about 5 to about 102discrete spots per square millimeter. Similarly, the fluidic device may comprise one or more fluidic channels, each of which may include about 50 to 107spots or regions that contain nucleic acid capture probes with unique “spatially-addressed” sequences or spatially-addressed sequences that are associated with a region or discrete spot within each channel.Cellular and Biomolecular Analysis

[0212] “ Cells” that may be cultured and assayed by methods and systems described herein may comprise any biological cells including, but not limited to, vertebrate, non-vertebrate, eukaryotic, mammalian, microbial, protozoan, prokaryotic, bacterial, archaea, insect, or fungal cells. In some embodiments, mammalian cells are assayed by methods and systems described herein. In particular, any population of mammalian cells which may be, or have been, induced, treated, modified or genetically altered (i.e. genetically engineered) for use in a medical, industrial, environmental, or remedial process, may be analyzed by methods and systems described herein. In some embodiments, “cells” as used herein comprise genetically modified cells. In some embodiments, “cells” comprise stem cells that have been induced to differentiate. In some embodiments, “cells” refer to cells modified by CRISPR Cas9 techniques. In some embodiments, “cells” refer to cells of the immune system including, but not limited to, cytotoxic T lymphocytes, regulatory T cells, CD4+ T cells, CD8+ T cells, natural killer cells, antigen-presenting cells, or dendritic cells. In some embodiments, “cells” refer to diseased cells such as cancer cells or virally infected cells.

[0213] A disclosed method can include assays (i.e., one or more forms of cellular analysis). Such assays may optionally be performed on a cell enclosed in a chamber, and may be performed in real-time or at defined timepoints. Accordingly, a single cell that is enclosed within an enclosure can be tracked independently of other cells that are not enclosed and cellsWSGR Docket No. 59528-739601that are enclosed in separate enclosures. The one or more assays can be performed on a single cell sequentially or in tandem. The one or more assays can be separately performed on multiple cells in tandem.

[0214] One or more cellular characteristics determined in a method can be selected from cytotoxicity, proliferative capacity, proliferation rate, activation status, cellular identity, purity, gene expression profile, transcriptome, surface marker expression, soluble factor secretion, activation status, epigenetic profile, sequence copy number (e.g., integrated viral copy number for transduced cells, plasmid copy number for transiently transfected cells, or gene copy number), morphology, subcellular localization, intracellular protein expression, or a combination thereof. Additional assays may include culture contamination assays including, but not limited to, viral, bacterial, yeast, mold, or mycoplasma assays, endotoxin assays, and cellular morphology assays. An assay can include one or more assay components, which may be provided with or as part of a channel include, but are not limited to, capture elements such as nucleic acid capture probes (which may include capture sequences as disclosed elsewhere herein), primers for captured nucleic acid amplification, antibodies, and detectable labels. In some embodiments, such assay components may be attached to a surface of a fluidic device or a polymer matrix wall exclusively, or on combinations of such surfaces, either exclusively, or in combination with other reagents. In some embodiments, assay components may be provided after synthesizing gel chambers. However, assay components may be premixed with cells prior to introduction into a fluidic device, added to a fluidic device simultaneously with cells, added to a fluidic device after the addition of cells to the fluidic device, added to a fluidic device before the introduction of cells to the fluidic device, or a combination thereof. Assay components include, but are not limited to, lysing reagents, transcription reagents, reverse transcription reagents, antibodies, polymerases, primers, beads, and the like. In some embodiments, cellular or assay components may be attached or captured by capture elements on a polymer matrix wall.(i) Morphological Analysis

[0215] In some aspects, a method includes identifying a morphological feature of a cell. The cell may be imaged, and one or more features of the cell may be discerned from the image. In some cases, the imaging includes brightfield imaging. However, morphological features can also be identified with fluorescence imaging, which may utilize dyes that localize, partition, or intercalate into specific cellular structures such peroxisomes or lipid membranes.Examples of morphological features include size, shape, circumference, opacity, andWSGR Docket No. 59528-739601protrusions (e.g., number, size, and shape). In some cases, the morphological feature is flattening or spread associated with cell adherence to a surface.(ii) gRNA Analysis

[0216] A method disclosed herein can include detecting a guide ribonucleic acid (gRNA) associated with a genetic modification of the cell (i.e., gRNA may be the cellular nucleic acid released by the cell, captured on a nucleic acid capture probe, and sequenced). The cell can be transiently or stably transfected with a sequence encoding a gRNA specific for a particular genomic sequence. The guide RNA can be coupled to a barcode, an exogenous messenger RNA (e.g., a selection marker), a capture sequence (e.g., a polyAtail), or a combination thereof. The first cell or the aggregate of the first cells can express a Cas protein that can utilize the gRNA. Alternatively, a Cas protein can be delivered to the cells, for example in a chitosan particle or liposome. Cell growth, movement, or other characteristic or characteristics can then be correlated with a genomic edit imparted by a particular gRNA sequence. In one such method, the cells can be lysed to release guide RNA, the guide RNA can optionally be captured on a nucleic acid capture probe, and then be used as a template for generating a cDNA molecule comprising a complement of the guide RNA sequence, and optionally additional sequences coupled to the guide RNA such as the exogenous mRNA, the barcode, or a combination thereof. The cDNA molecule can be coupled to a spatial location tag corresponding to a unique location within the channel of the fluidic device.(Hi) Proliferation Rate

[0217] In some aspects, determining a characteristic of the one or more cells includes determining a proliferation rate. It is understood that the term “proliferation rate” may include a measure of a lack of proliferation. Proliferation rate can be determined by counting cells at least partially enclosed by the one or more chambers generated during an assay. For example, the one or more cells can be counted periodically (e.g., with fluorescence or brightfield imaging) following at least partial enclosure within the one or more chambers to determine a rate of change in the number of cells. Separate proliferation rates can be determined for each cell or collection of cells enclosed by a unique chamber or collection of chambers. In some embodiments, cells may be stained with a membrane or intracellular dye for determining proliferation by dye dilution so that an independent measure of cell proliferation may be obtained. Intracellular dyes for dye dilution can include, but are not limited to, Hoechst 33342, carboxyfluorescein succinimidyl ester (CFSE), and the like. After counts are recorded for each chamber, further assays may be conducted on the clonal populations within theWSGR Docket No. 59528-739601chambers to identify the cell types, for example, by an assessment of cell surface proteins, cell protein secretions, transcriptome, or the like.(iv) Soluble Factor Analysis

[0218] In some aspects, determining a characteristic of the one or more cells includes detecting a soluble factor secreted by the one or more cells. Soluble factor analysis can include disposing a capture surface (e.g., a bead) comprising an affinity reagent (e.g., an aptamer or an antibody) that binds the soluble factor adjacent to one or more cells and detecting the soluble factor bound to the capture surface. Disposing the capture surface adjacent to the one or more cells can include enclosing or at least partially enclosing the capture surface with the one or more cells within the one or more chambers, and optionally removing non-enclosed capture surfaces from the channel of the fluidic system. The capture surface can be loaded into the channel at a controlled density, for example 1 capture surface per about 100, 50, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, 0.005, or 0.001 mm2of the channel.

[0219] In an embodiment, the capture surface comprises a bead. As used herein, the term “bead” can denote a microparticle or a nanoparticle, such as a ceramic, metal, metal oxide, polymer, or saccharide-based 30 to 10000 pm particle. However, further capture surfaces such as nanotubes, nucleic acid nanostructures, and antibody Fc domains may be used. The capture surface affinity reagent can, as non-limiting examples, include antibodies, antibody fragments, aptamers, affimers, or a combination thereof.

[0220] Soluble factor detection may be performed with a bispecific binding agent capable of simultaneously binding to a cell and to a soluble factor secreted by the cell. The bispecific binding agent can be coupled to a target cell of interest and then used to capture soluble factors secreted by the cell. In this way, the bispecific binding agent may couple the soluble factor to the surface of the cell. The soluble factor may then be detected, for example by coupling a detectable binding agent such as a fluorescent antibody to the soluble factor coupled to the surface of the cell, and measuring the detectable binding agent. Unlike antibody modified beads that reside randomly within the chamber for capturing secretions that happen to diffuse to the beads, bispecific antibodies are coupled to the cell surface allowing for a more efficient capture of secretions emanated from the cell surface.

[0221] As examples, the soluble factor may include a cytokine, an immune active molecule, an interleukin, an interferon, a colony stimulating factor, a tumor necrosis factor, or a granzyme. The cytokine may be interferon-y (IFN-y) and interferon-a (IFN-a), an interleukins such as interleukin- 1 (IL-1), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin- 10 (IL- 10),-n-WSGR Docket No. 59528-739601interleukin- 13 (IL-13), interleukin- 15 (IL-15), interleukin-21 (IL-21), or interleukin-23 (IL-23), a colony stimulating factor (CSFs) such as granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), or a tumor necrosis factors (TNF) such as TNF-a or TNF-p. In another embodiment, the secreted factor comprises an effector molecule such as a granzyme.

[0222] A soluble factor bound to a capture surface (e.g., an affinity reagent of a capture surface) can be detected by contacting the soluble factor bound to the capture surface with a labeled antibody configured to bind to the soluble factor, and detecting the labeled antibody. Multiple soluble factors can be detected in a single assay by providing a capture surface or plurality of capture surfaces that comprise a plurality of affinity reagents configured to bind the plurality of soluble factors, contacting the plurality of soluble factors bound to the capture surface or plurality of capture surfaces with a plurality of labeled antibodies configured to bind to the plurality of soluble factors, and detecting a plurality of labels coupled to the plurality of antibodies.(v) Transcriptomic Analysis

[0223] In some aspects, determining a characteristic of the one or more cells includes sequencing at least a portion of a transcriptome of the one or more cells. The nucleic acid capture probes may then be extended using the mRNA as templates, and the extended nucleic acid capture probes can be eluted from a fluidic device and sequenced. Examples of sequencing methods consistent with the present disclosure include nanopore sequencing, pyrosequencing, sequencing-by-hybridization, sequencing-by-ligation, sequencing-by-synthesis, single-molecule sequencing, digital gene expression, next generation sequencing, shotgun sequencing, Sanger sequencing, ion torrent sequencing, as well as other nextgeneration-sequencing methods known in the art.

[0224] The nucleic acid capture probes may contain spatial barcode sequences that are uniquely associated with the cell and / or the one or more chambers. Accordingly, extended nucleic acid capture probes (which contain the spatial barcodes) and mRNA extended using the nucleic acid capture probes as templates (which contain complements of the spatial barcodes) may be associated with a cell or a chamber. The nucleic acid capture probes may also contain unique molecular identifiers to facilitate mRNA quantitation by normalizing sequencing counts of extended nucleic acid capture probes and / or mRNA extended using the nucleic acid capture probes as templates. For example, during sequencing, the number of instances of each mRNA sequence may be determined based on the number of unique molecular identifier sequences associated with that mRNA sequence.WSGR Docket No. 59528-739601

[0225] In some cases, mRNA and / or nucleic acid capture probe extension involves reverse transcription. Reverse transcription reagents may comprise conventional reagents for reverse transcription; namely, a reverse transcriptase (such as, a Moloney murine leukemia virus (MMLV)), dNTPs, optional RNase inhibitor, buffer.

[0226] The sequencing step may be carried out at the sites of the captured mRNAs (in situ) or cDNAs may include a spatial barcode and be eluted and sequenced on a separate sequencing instrument (“external” sequencing). For in situ sequencing, further steps may include (i) amplifying the complementary DNAs, e.g. by bridge amplification, or like method, (ii) sequencing the amplified complementary DNAs, e.g. by a sequencing-by-synthesis technique, and (iii) determining relative expression of the mRNAs for the cells of each of the chambers. For external sequencing, further steps may include (i) providing capture elements comprising spatial barcodes, (ii) synthesizing cDNAs comprising spatial barcodes, and (iii) eluting and sequencing the cDNAs and correlating each cDNA with a chamber location by its spatial barcode.

[0227] An example of a nucleic acid analysis method is depicted in FIG. 9. This figure illustrates a side-on field-of-view of a top surface (900B) of a fluidic device that is coupled to a nucleic acid capture probe (902) through a linker (902A). The method could also be performed with nucleic acid capture probes (902) coupled to alternate substrates such as fluidic device bottom surfaces or beads. The method depicts the nucleic acid capture probe (902) during extension (920), tempi ate- switch oligonucleotide coupling (930), further extension (940), and cleavage (950) steps. The leftmost portion of the figure depicts the nucleic acid capture probe (902) coupled to a nucleic acid (909), a portion of the top surface (900B) of the fluidic device (900), and the linker (902A) that couples the nucleic acid capture probe (902) to the top surface (900B). In this example, a 5’ end of the nucleic acid capture probe (902) is coupled to the linker (902A), and the nucleic acid capture probe (902) includes, from its 5’ end to its 3’ end, one or more additional sequences (911), a spatial barcode (912), and a capture sequence (913). Examples of one or more additional sequences (911) that may be included in the nucleic acid capture probe (902) include unique molecular identifier (UMI) sequences, primer binding sites, restriction enzyme binding sites, uracil-containing nucleotides, suppressor sequences, chemically-cleavable functional groups, photocleavable functional groups, complements thereof, and combinations thereof.

[0228] With continued reference to FIG. 9, the capture sequence (913) may couple to a capturable sequence (914) of a nucleic acid (909). The nucleic acid (909) may be a nucleic acid derived from a biological material, such as an mRNA, gRNA, shRNA, miRNA, or DNAWSGR Docket No. 59528-739601molecule released from a cell through poration or lysis. As a specific illustrative example, the capture sequence (913) may include a poly(T) sequence that hybridizes to a poly(A) sequence of the nucleic acid (909). The nucleic acid (909) may also include a target sequence (915) upstream or downstream of the capturable sequence (914). For example, the nucleic acid (909) can include a coding sequence, a regulatory sequence, or a combination thereof upstream of a poly(A) capturable sequence (914). While in FIG. 9 the capturable sequence (914) is disposed at a 3’ end of the nucleic acid (909), in other embodiments disclosed herein, the nucleic acid (909) includes one or more elements (e.g., one or more additional sequences) downstream of the capturable sequence (914).

[0229] Next, as depicted in step 920 of FIG. 9, the nucleic acid capture probe (902) may be extended using at least a portion of the nucleic acid (909) as a template. The capture sequence (913) may be disposed at the 3’ end of the nucleic acid capture probe (902) so that an extension sequence (915’), in this example a complement of the target sequence (915) of the nucleic acid (909), generated during extension step 920, may be coupled to the capture sequence (913). The extension step 920 may also generate an overhang (922, in this case an oligoguanine) at a 3’ end of the resultant extended nucleic acid capture probe (921), beyond the end of the nucleic acid (909) template. For example, the extension step (920) may be performed by a reverse transcriptase with terminal transferase activity.

[0230] Next, as shown following step 930 of FIG. 9, a tempi ate- switch oligonucleotide (931) may couple to the extended nucleic acid capture probe (921). The template-switch oligonucleotide (931) may include a complement of the overhang (932) that may couple to the overhang (922) of the extended nucleic acid capture probe (921). The template-switch oligonucleotide (931) may also include a template-switch oligonucleotide sequence (933) such as a primer binding site, a suppressor sequence, or a combination thereof.

[0231] With continued reference to FIG. 9, the extended nucleic acid capture probe (921) may then be further extended in step 940 using at least a portion of the tempi ate- switch oligonucleotide sequence (933) as a template, thereby converting the extended nucleic acid capture probe (921) into a further extended nucleic acid capture probe (941) that includes a further extension sequence (933’), in this case a complement of at least a portion of the template-switch oligonucleotide sequence (933).

[0232] Finally, as depicted in step 950 of FIG. 9, the further extended nucleic acid capture probe (941) may be cleaved from the surface (900B). This step may be achieved by cleaving the linker (902 A) that couples the further extended nucleic acid capture probe (941) to the surface (900B). As a non-limiting example, the linker (902) may include a reductivelyWSGR Docket No. 59528-739601cleavable functional group such as a disulfide that may be cleaved with a reducing agent such as beta-mercaptoethanol or dithiothreitol. The linker (902) may include an oxidatively cleavable functional group such as a vicinal diol that may be cleaved with an oxidizing agent such as sodium periodate. The linker may also include (902) an enzymatically cleavable functional group such as a saccharide (e.g., glucuronic acid for cleavage by P -glucuronidase) or oligopeptide (e.g., a valine-citrulline-containing peptide for cleavage by cathepsin) that may be cleaved by its cognate enzyme.

[0233] With continued reference to FIG. 9, a portion of the further extended nucleic acid capture probe (941) may be cleaved in step 950. Such a process may utilize an endonuclease that targets a double-stranded portion of the further extended nucleic acid capture probe (941). The cleaved portion of the further extended nucleic acid capture probes (941) may be double-stranded, for example by virtue of hybridization to the nucleic acid (909).Alternatively, further extended nucleic acid capture probe cleavage may utilize an enzyme that targets a single-stranded portion of the further extended nucleic acid capture probe (941) such as a CAS9 endonuclease targeted by guide RNA. In some instances, the nucleic acid (909) and / or template-switch oligonucleotide (931) may be melted from further extended nucleic acid capture probe (941).

[0234] With further reference to FIG. 9, it is worth noting that the extended nucleic acid capture probe (921) or a modified version of the extended nucleic acid capture probe (921) may also be cleaved from the surface (900B). Some methods disclosed herein, for example, do not include steps 930 and 940, and may include other steps for modifying extended nucleic acid capture probe (921) such as tagmentation. In such cases, the further extended nucleic acid capture probe (941) may not be generated, and the cleavage step 950 may cleave the extended nucleic acid probe (921) or modified versions of the extended nucleic acid capture probe from the surface (900B).

[0235] Following cleavage step 950 in FIG. 9, the further extended nucleic acid capture probe (941), the extended nucleic acid capture probe (921), the modified extended nucleic acid capture probe (as described above), or a combination thereof may be eluted from the fluidic device for analysis and / or sequencing. The sequencing may include short-read sequencing, long-read sequencing, nanopore sequencing, sequencing-by-synthesis, sequencing-by-hybridization, optical readout, or combinations thereof, and the resulting sequence data may be used, for example, to identify, quantify, or otherwise characterize nucleic acids associated with the biological components processed within the fluidic device. The further extended nucleic acid capture probe (941), the extended nucleic acid captureWSGR Docket No. 59528-739601probe (921), the modified extended nucleic acid capture probe (as described above), or the combination thereof may be further prepared for sequencing by addition of sequencing adapters, indices, or other modifications compatible with a desired sequencing platform. For example, the further extended nucleic acid capture probe (941), the extended nucleic acid capture probe (921), the modified extended nucleic acid capture probe (as described above), or the combination thereof may be subjected to end repair, tailing, adapter ligation, tagmentation, and / or amplification to generate a sequencing-ready nucleic acid library. As examples, such sequencing libraries may comprise adapter sequences suitable for sequencing-by-synthesis platforms, such as Illumina® instruments (e.g., MiSeq®, NextSeq®, or NovaSeq®), including flow-cell binding sequences (e.g., P5 and P7 adapters) and sample index sequences. In other embodiments, sequencing libraries may also be prepared for nanopore sequencing, such as by ligation of adapters comprising motor proteins for use with Oxford Nanopore Technologies® instruments (e.g., MinION®, GridION®, or PromethION®), and in such cases may include barcode sequences for multiplexed analysis. In still other embodiments, nucleic acids may be converted into circular templates, such as SMRTbell® templates, for single-molecule real-time sequencing using Pacific Biosciences® platforms (e.g., Sequel II or Revio).(vi) Cytotoxicity

[0236] In a further aspect, the one or more cells comprises an effector cell, and determining the characteristic of the one or more cells comprises measuring a cytotoxicity of the effector cell. Such a method may be performed by at least partially enclosing one or more target cells with the effector cell, and counting dead cells, viable cells, or a combination thereof from among the one or more target cells. As non-limiting examples, the target cells may comprise a sample of tumor cells of a patient, or target cells may be from a cell line, e.g. tumor cell line, such as, hepatic tumor cell line, SK-HEP-1, Chava et al, J. Vis. Exp., 2020 Feb 22: (156): 10.3791 / 60714. Examples of effector cells include Tel cells, Tc2 cells, Tc9 cells, Tcl7 cells, Tc22 cells, natural killer cells. In some embodiments, the effector cell is engineered for a therapeutic purpose. For example, the effector cell may express a chimeric antigen receptor that confers cytotoxicity against a particular cancer.

[0237] A cytotoxicity assay may include loading the effector cell and target cells into the channel (either simultaneously or sequentially). In some aspects, the target cells are loaded into channel where they optionally adhere to a surface prior to effector cell loading. In other aspects, the effector cell is loaded into the channel prior to target cell loading. The effector cell may be at least partially enclosed with the target cells inside one or more chambers. TheWSGR Docket No. 59528-739601target cells and effector cells are then incubated. The incubation may be performed in the presence of a vital dye that generates an optical signal in response to a characteristic of viable cells or dead cells to facilitate dead cell enumeration. The method may include counting the number of target cells killed per effector cell. The method may also include counting the number of target cells killed per unit time. Alternatively or in addition thereto, the target cells may be pre-treated with a dye that internalizes into the target cells prior to loading into the channel. In addition to target cell killing, effector cells can be identified based on other cellular characteristics disclosed herein, such as their secretome, transcriptome, or the like.(vii) Cellular Activation

[0238] In some aspects, the characteristic of the one or more cells comprises activation. Cellular activation can be detected using numerous assays disclosed herein, including surface marker expression, soluble factor secretion, transcriptomic analysis, proliferation or changes in proliferation, changes in morphology, change in cytotoxicity, or a combination thereof. As non-limiting examples, these methods are broadly amenable to detecting activation caused by contact between a second cell and a cell of the one or more cell, a soluble factor secreted by the second cell and the cell of the one or more cells, and combinations thereof. In a particular aspect of the present disclosure, determining activation comprises detecting a surface marker of the one or more cells. For example, the method can comprise contacting the one or more cells with a binding agent configured to bind to the surface marker and detecting the binding agent.Fluidic and Optical Systems

[0239] FIG. 4A is an example of a system for carrying out the disclosed methods. Flow cell (500) is a component of a fluidic device that provides channels for carrying out a variety of assays and liquid handling components under programmable control for delivering samples and reagents to the channels. In this illustration, four channels (502, 504, 506, and 508) are shown. However, as detailed elsewhere herein, systems of the present disclosure can utilize flow cells with fewer or greater numbers of channels.

[0240] The system of FIG. 4A includes an optical system (521) for photosynthesizing chambers at locations of cells or other analytes in the channels (502, 504, 506, and 508) of the flow cell (500) and for collecting images and other optical signals. The optical system (521) includes a light source (522) that generates a light beam (523) of appropriate wavelength light (e.g. UV light) for synthesizing chambers (e.g., hydrogel chambers) in the flow cell (500). The light beam (523) that passes through an appropriate photo-mask or beamshaping or beam steering (Galvo) system (524) for shaping a beam to synthesize a desiredWSGR Docket No. 59528-739601structure or structures in a channel. For example, the beam shaping system (524) may project circular patterns of light from the light source (522) onto the flow cell (500) to cause a polymer precursor to photopolymerize in the shape of a cylindrical chamber (e.g., chamber 516 in FIG. 4B). In some embodiments, this beam shaping system (524) includes a digital micromirror device (DMD). In other embodiments, a physical photo-mask may be employed. The DMD may contain an array with tens of thousands or more microscopic mirrors. Each mirror may correspond to a pixel in a virtual photomask or an image. Each mirror may be individually rotated between ‘on’ and ‘off’ states. In an ‘on’ state, an individual micromirror may reflect light from the light source (522) onto the flow cell (500). In an ‘off’ state, an individual micromirror may reflect light from the light source (522) away the flow cell (500), thereby preventing the light from reaching the flow cell (500). A micromirror may also generate local grayscale in a position in the flow cell (500) by rapidly rotating between ‘on’ and ‘off’ states, thereby lowering the intensity of light from the light source (522). Reflected light from DMD (524) may be shaped using conventional optics, e.g. collimating optics (528), and is directed through objective lens system (534) into channel 2 segment (510). In other embodiments, the beam shaping system (524) can include a virtual mask (e.g., a computer code or a digital system). The virtual mask may render one or more electrodes, or arrays of electrodes, to produce spatially-modulated energy (e.g., light, electrical current, etc.) to form the patterned polymer matrix in the flow cell (500). The virtual mask may also block a portion of light from the light source (522). When a virtual mask is utilized in this manner, the virtual mask can prevent light from being emitted to a location where analyte (e.g., a cell 518) is present within the flow cell (500). In some embodiments, the light is directed by one or more dichroic mirrors (530 and 531).

[0241] Chamber position, shape and polymer matrix wall thickness is determined at least in part from cell position information determined from images collected by detector (532). Objective (534) and flow cell (500) move relative to one another in the xy-directions (536) to photosynthesize chambers at any position in any of the channels. In some embodiments, the flow cell (500) moves and optical system (521) is stationary. The system may utilize light from a light source (599), such as a homogenized light condenser, that is positioned on an opposite side of the flow cell as the optical system and directs light through the flow cell (500) to the objective (534). To achieve this functionality, the light source positioned on the opposite side of the flow cell (599) can be configured to move in tandem with the optical system (521), or the light source (599) and optical system can be stationary and the flow cell (500) can be moved to the region illuminated by the light source (599) and from which lightWSGR Docket No. 59528-739601is collected by the objective (534). In some embodiments, objective (534) may also direct light beam (527) from light source (529) to targets, such as cells, on first surface (514, see FIG. 4B) and collect optical signals, such as fluorescent signals, from assays taking place on first surface (514). Optical signal collection can also be carried out with a separate objective. Information collected by detector (532), particularly cellular positions in their respective channels, is employed by computer (538) and / or subsidiary controllers to direct DMD (524) and translation devices controlling the relative positions of objective (534) and flow cell (500) to synthesize hydrogel chambers of the appropriate shape and size at the appropriate locations.

[0242] FIG. 4B provides a blown-up view of the channel segment (510) of the flow cell of FIG. 4A. On first surface (514) of channel 2 (504) a plurality of cells, e.g. (518), are each enclosed by a hydrogel chamber, e.g. (516).

[0243] One of ordinary skill in the art would recognize that optical systems with different configurations than those of FIG. 4A and 4B may be employed for carrying out these functions. In some embodiments, a plurality of DMD-objective subsystems for synthesizing hydrogel structures may be employed to increase the speed of synthesis by synthesizing multiple structures simultaneously.Health Assessment and Treatment Planning

[0244] Further disclosed herein are methods for assessing a subject’s health and for planning treatment regimens. Cells from a biological sample from the subject may be analyzed to ascertain a health or disease status of the subject, or a cell state. For example, a cell can be in an exhausted state, an activated state, a suspension state, an adherent state, an inflamed state, a proliferative state, a killer state, a senescent state, or a combination thereof. In addition, the biological sample may be analyzed to determine a probability of having a health or disease status of the subject, or a cell state at the time of the sample collection or in the future and more particularly within a future time interval. The analysis may be performed on multiple biological samples collected from the subject at the same time or at different points in time, facilitating longitudinal health or disease monitoring of the subject. The analysis may be performed on a single type of biological sample or on multiple types of biological samples from the subject. For example, a first biological sample from healthy tissue from the subject may be analyzed to better define the disease type or disease state of a second biological samples collected from diseased tissue from the subject. In some cases, a cell can be contained in a hydrogel enclosure in a flow cell and then monitored using image based measurements at various time intervals (i.e., longitudinal monitoring data), which canWSGR Docket No. 59528-739601optionally be measured with a sequencing measurement like transcriptomics. The hydrogel enclosure can retain cells and allow high molecular weight molecules to pass through (i.e., into and out of the enclosure) such as reverse transcriptase and antibody conjugates, and allow cells to remain alive during the collection of the longitudinal monitoring data. The longitudinal monitoring data and / or the sequencing measurements can be used as an input into the machine learning model.

[0245] By enabling multiomic and multi-biomarker measurements on individual cells, the presently disclosed methods facilitate sensitive health and disease monitoring in subjects. A core challenge in health and disease monitoring is that many changes in health status do not manifest in detectable cellular population-level changes. For example, many early-stage cancers are evidenced by low variant allele frequencies that are undetectable through traditional pooled sample sequencing methods. Similarly, because viral gene expression and changes in native gene expression can be heterogeneous among populations of cells of the same type, viral infection stage and severity can be challenging to measure through population-level cellular analyses. The presently disclosed methods circumvent these issues by enabling massively parallelized multi-biomarker and multi-omic analyses on individual cells, allowing subtle changes to be detected within subpopulations of cells from biological samples to provide a comprehensive view of the subject’s health.

[0246] FIG. 6 is a flow chart that outlines an example of a method for assessing the health of a subject and / or formulating a treatment regimen of the subject. The method may include analyzing a biological sample from the subject, and, based at least in part on data from the analyzing, identifying a health status of the subject The method may utilize a biological sample (3201) from the subject. Examples of biological samples consistent with the present disclosure include whole blood, buffy coat, Ficoll-Paque blood fractions,cerebrospinal fluid, synovial fluid, ductal lavage, nasal fluid, ear fluid, gastric fluid, pancreatic fluid, trabecular fluid, lung lavage, crevicular fluid, prostatic fluid, sputum, bronchial lavage, bronchial aspirants, tissue sections, tissue homogenates, lymphatic fluid, or any combination thereof. The sample may also include a cell line that is a population of cells from a multicellular organism that has been established in culture and can be maintained and proliferate indefinitely or for a prolonged period in vitro. A cell line can be derived from a subject that is human, goat, cow, pig, plant, bacteria, fungus, or combination thereof. The sample may optionally be processed (3202), for example to separate interconnected cells into single cells (e.g., trypsinization), to enrich desired types of cells (e.g., throughWSGR Docket No. 59528-739601immunoprecipitation or pull-down), to deplete undesired cell types, or a combination thereof. The subject may be a human, a mammal, or another type of animal.

[0247] The biological sample may then be subjected to a cell analysis method (3203) of the present disclosure. As disclosed elsewhere herein, cells from the biological sample may be input into a fluidic device (3203 A), compartmentalized (3203B), optionally subjected to a drug or treatment regimen (3203C), and analyzed (3203D) at one or more time points. The cells from the biological sample can be in the native state or genetically modified state (e.g., mutations, methylations, knocked in genes, or knocked out genes. The method may generate genomic data, transcriptomic data, proteomic data, epigenomic data, methylomic data, secretomic data, metabolomic data, optical imaging data, or a combination thereof on cells from the biological sample.

[0248] Data (3204A) from the cell analysis method (3203) may be uploaded to a server (3204) for storage and / or processing. The data can be associated with a single point in time or could be associated with several measurements of the same hydrogel enclosure over a period of time. The data can include imaging data such as segmentation, number of pixels to image a cell, fluorescent intensity at particular wavelengths and location, size, shape, eccentricity, and perimeter of the cell. The data can also include genetic data such as gene type, number of gene types, RNA sequences, and DNA sequences. The server (3204) may be a cloud server. The server (3204) may contain additional data (3204B) associated with the subject such as age, gender, genetic profile, weight, blood pressure, body scans (e.g., positron emission tomography, computed tomography, magnetic resonance imaging, or X-ray imaging), and the like. The server (3204) may also include data from previous cell analysis methods performed on additional biological samples from the subject (e.g., biological samples collected at earlier points in time). One or more processes may be performed on the server (3204), including steps 3205 and 3208, which are discussed below.

[0249] In step 3205, data (3204A, 3204B) may then be input into a machine learning model. The machine learning model may utilize the data (3204A, 3204B) to assess or determine the health status of the subject, to identify a treatment regimen for the subject, or a combination thereof. The data from the server (3204A,3204B) may also then be utilized to determine the probability of the subject having a health status at the time of the sample collection, in the future, or at a future time interval. The subject’s health status, the treatment regimen, or the combination thereof may be provided as an output (3206) from the machine learning model. During step 3205, the subject’s data may be referenced against a database of known disease markers, for example as described in Kolobkov etal., Genes 2022, 13(1), 1168; Chen etal.,WSGR Docket No. 59528-739601MedComm 2023, 7(4), e315; and Hayes etal., Genes 2024, 75(12), 1551, which are hereinafter incorporated by reference for their disclosures of disease markers. The subject may be assessed, for example, for disease status, disease stage, disease risk, disease susceptibility, and combinations thereof. The subject may be screened for a single disease or condition, or for a multitude of diseases and / or conditions.

[0250] With continued reference to step 3205, the subject’s health status may be monitored over time. When biological samples are collected from the subject at multiple points in time (e.g., steps 3201-3203 are performed multiple times), data generated using the biological samples may be compared to detect changes in the subject’s health. Biological samples may be collected from the subject and then analyzed about once per week, about once per month, about once per year, about once per every three years, about once per every five years, about once per every ten years, or about once per every twenty years. Data generated from the subject’s biological samples can be used to determine baseline biomarker levels for the subject. The baseline may be utilized to distinguish subtle changes in biomarker levels that would otherwise be imperceptible from population-level data, for example where a change in biomarker levels in biological samples from a subject is smaller than standard variance within the human population. Data from earlier biological samples (e.g., biological samples collected months or years prior to a present biological sample) may be used to calibrate data from a present biological sample.

[0251] With further reference to step 3205, data from a disclosed method may also be utilized to predict a probability of a subject’s response to a drug or treatment regimen (i.e., the probability of the subject’s response to the drug or treatment regimen may be an output (3206) of the machine learning model). During the method, cells from the subject may be contacted to a drug or subjected to a treatment regimen (e.g., mixed with engineered immune cells), and responses of the cells to the drug or treatment regimen can be measured to assess whether the drug will be efficacious for treating the subject. In some cases, drug treatment efficacy may be predicted by measuring the viability of the subject’s cells in the presence of the drug. In other cases, the drug treatment efficacy may be characterized by a probability of a subject surviving for a predetermined time interval (e.g., % chance of surviving 5 years) or having a tumor that decrease in size after the treatment. Similarly, data from a disclosed method may be utilized to measure the subject’s response to a drug or treatment regimen. Responses to drugs and treatment regimens can be measured at a single-cell level, and may be correlated to genotypic and / or phenotypic features of the cells. Such a method may assess a response by a particular cell type, such as a cancer or immune cell from the subject, to theWSGR Docket No. 59528-739601drug or the treatment regimen. This type of analysis may identify, for example, subpopulations of cells from the subject that are responsive to the drug or that certain genotypic or phenotypic traits are associated with drug responsiveness. The analysis may also determine that an adjunctive or synergistic drug can enhance the effectiveness of a first drug. For example, unresponsiveness to a monotherapy may be found to correlate with activity in a signaling pathway such as PI3K, RAS / MAPK, Notch, or Wnt that can be modulated with an inhibitor such as alpelisib (PI3K inhibitor), RMC-6236 (pan-RAS inhibitor), OMP-59R5 (anti-Notch2 / 3 monoclonal antibody), or LGK-974 (inhibitor of porcupine O-acyltransferase, a Wnt pathway signaling protein).

[0252] With yet further reference to step 3205, drug and treatment regimen efficacy can also be measured on combinations of cells from the subject. Many diseases, including numerous neurodegenerative diseases and cancers, are driven by aberrant intercellular adhesion or signaling. Single-cell and pooled screening methods can thus be incapable of assessing treatment efficacy for these diseases. The present disclosure addresses this challenge by providing methods for co-enclosing two or more cell-types within individual compartments. A drug or treatment regimen may be applied to a subset of compartments (e.g., the drug or treatment regimen can be applied to compartments in a first fluidic device or fluidic channel, and the drug or treatment regimen can be withheld from compartments in a second fluidic device or fluidic channel) to assess whether the drug or treatment regimen affects interactions between the two or more types of cells. Intercellular interactions can be monitored using one or more methods disclosed herein, including with imaging (e.g., to detect contact and / or junction formation between cells), proteomic analysis (e.g., detection of protein secretion or surface protein expression), transcriptomic analysis, or a combination thereof. Cell types may be similarly determined using imaging, proteomic analysis, and / or transcriptomic analysis, and data may be collected only from compartments that include each of the two or more types of cells selected for analysis.

[0253] In continued reference to step 3205, a health or treatment assessment may utilize a machine learning model. The machine learning model may utilize data generated from one or more biological samples from the subject and optionally may utilize additional data such as the subject’s age, height, weight, biometric data (e.g., blood pressure), health status, disease status, and the like. In some cases, the machine learning model includes a trained machine learning model.

[0254] With continued reference to step 3205, the machine learning model may be trained using data generated from a method disclosed herein. For example, the machine learningWSGR Docket No. 59528-739601model may be trained using images of cells within compartments, genomic or transcriptomic data on cells enclosed within compartments, and the like. The training data may be longitudinal data generated from multiple samples from the subject. The training data may also be longitudinal with respect to an individual sample. For example, cells from the sample may be enclosed within compartments and then monitored over a period of minutes, hours, days, or weeks, and longitudinal data from the cells (e.g., phenotypic and / or genotypic data) may then be used to train the machine learning model. The training data may also include additional data associated with the subject such as their age, height, weight, biometric data, health status, disease status, and the like.

[0255] With continued reference to step 3205, in some cases, the machine learning model is fixed. For example, the machine learning model may be a fixed trained machine learning model, that is, a machine learning model that has been trained in a supervised, semisupervised, and / or self-supervised manner, and whose parameters are fixed when it is utilized in a method for assessing health status or selecting a treatment regimen. Examples of machine learning models consistent with the present disclosure linear regression algorithms, logistic regression algorithms, support vector machines (SVMs), decision trees, random forest algorithms, K-nearest neighbor (KNN) algorithms, K-means clustering algorithms, hierarchical clustering algorithms, principal component analysis (PCA) algorithms, t-distributed neighbor embedding (t-SNE) algorithms, artificial neural networks, convolutional neural networks, recurrent neural networks, generative adversarial networks, Bayesian networks, as well as combinations thereof. The machine learning model may be trained utilizing data generated from a method disclosed herein. The machine learning model may be actively updated (3208) with outputs (3206, e.g., health statuses or proscribed treatment regimens generated by the machine learning model during step 3205) and subject outcomes (3207).Computer Systems

[0256] The present disclosure provides computer systems that are programmed to implement methods of the disclosure. FIG. 5 shows a computer system 1501 that may be programmed or otherwise configured to perform methods described herein. The computer system 1501 can regulate various aspects of the present disclosure, such as, for example, identifying a biological component, detecting a barcode, controlling a spatial light modulator to shape a light beam, providing energy from an energy source, or detecting or measuring a local parameter using a sensor. The detector may be a camera (e.g., a fluorescent camera), such as a charged coupled device (CCD) camera capable of collecting optical signals and positionWSGR Docket No. 59528-739601information from a plurality of sources distributed over a planar region. The computer system 1501 can be an electronic device of a user or a computer system that may be remotely located with respect to the electronic device. The electronic device can be a mobile electronic device.

[0257] The computer system 1501 includes a central processing unit (CPU, also “processor” and “computer processor” herein) 1505, which can be a single core or multi core processor, or a plurality of processors for parallel processing. The computer system 1501 also includes memory or memory location 1510 (e.g., random-access memory, read-only memory, flash memory), electronic storage unit 1515 (e.g., hard disk), communication interface 1520 (e.g., network adapter) for communicating with one or more other systems, and peripheral devices 1525, such as cache, other memory, data storage and / or electronic display adapters. The memory 1510, storage unit 1515, interface 1520 and peripheral devices 1525 are in communication with the CPU 1505 through a communication bus (solid lines), such as a motherboard. The storage unit 1515 can be a data storage unit (or data repository) for storing data. The computer system 1501 can be operatively coupled to a computer network (“network”) 1530 with the aid of the communication interface 1520. The network 1530 can be the Internet, an internet and / or extranet, or an intranet and / or extranet that may be in communication with the Internet. The network 1530 in some cases may be a telecommunication and / or data network. The network 1530 can include one or more computer servers, which can enable distributed computing, such as cloud computing. The network 1530, in some cases with the aid of the computer system 1501, can implement a peer-to-peer network, which may enable devices coupled to the computer system 1501 to behave as a client or a server.

[0258] The CPU 1505 can execute a sequence of machine-readable instructions, which can be embodied in a program or software. The instructions may be stored in a memory location, such as the memory 1510. The instructions can be directed to the CPU 1505, which can subsequently program or otherwise configure the CPU 1505 to implement methods of the present disclosure. Examples of operations performed by the CPU 1505 can include fetch, decode, execute, and writeback.

[0259] The CPU 1505 can be part of a circuit, such as an integrated circuit. One or more other components of the system 1501 can be included in the circuit. In some cases, the circuit may be an application specific integrated circuit (ASIC).

[0260] The storage unit 1515 can store files, such as drivers, libraries, and saved programs. The storage unit 1515 can store user data, e.g., user preferences and user programs. TheWSGR Docket No. 59528-739601computer system 1501 in some cases can include one or more additional data storage units that are external to the computer system 1501, such as located on a remote server that may be in communication with the computer system 1501 through an intranet or the Internet.

[0261] The computer system 1501 can communicate with one or more remote computer systems through the network 1530. For instance, the computer system 1501 can communicate with a remote computer system of a user (e.g., a laptop, a personal computer, a tablet, or a mobile phone). Examples of remote computer systems include personal computers (e.g., portable PC), slate or tablet PC’s (e.g., Apple® iPad, Samsung® Galaxy Tab), telephones, Smart phones (e.g., Apple® iPhone, Android-enabled device, Blackberry®), or personal digital assistants. The user can access the computer system 1501 via the network 1530.

[0262] Methods as described herein can be implemented by way of machine (e.g., computer processor) executable code stored on an electronic storage location of the computer system 1501, such as, for example, on the memory 1510 or electronic storage unit 1515. The machine executable or machine readable code can be provided in the form of software.During use, the code can be executed by the processor 1505. In some cases, the code can be retrieved from the storage unit 1515 and stored on the memory 1510 for ready access by the processor 1505. In some situations, the electronic storage unit 1515 can be precluded, and machine-executable instructions are stored on memory 1510.

[0263] The code can be pre-compiled and configured for use with a machine having a processer adapted to execute the code, or can be compiled during runtime. The code can be supplied in a programming language that can be selected to enable the code to execute in a pre-compiled or as-compiled fashion.

[0264] Aspects of the systems and methods provided herein, such as the computer system 1501, can be embodied in programming. Various aspects of the technology may be thought of as “products” or “articles of manufacture” typically in the form of machine (or processor) executable code and / or associated data that may be carried on or embodied in a type of machine readable medium. Machine-executable code can be stored on an electronic storage unit, such as memory (e.g., read-only memory, random-access memory, flash memory) or a hard disk. “Storage” type media can include any or all of the tangible memory of the computers, processors or the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like, which may provide non-transitory storage at any time for the software programming. All or portions of the software may at times be communicated through the Internet or various other telecommunication networks. Such communications, for example, may enable loading of the software from oneWSGR Docket No. 59528-739601computer or processor into another, for example, from a management server or host computer into the computer platform of an application server. Thus, another type of media that may bear the software elements includes optical, electrical and electromagnetic waves, such as used across physical interfaces between local devices, through wired and optical landline networks and over various air-links. The physical elements that carry such waves, such as wired or wireless links, optical links or the like, also may be considered as media bearing the software. As used herein, unless restricted to non-transitory, tangible “storage” media, terms such as computer or machine “readable medium” refer to any medium that participates in providing instructions to a processor for execution.

[0265] Hence, a machine readable medium, such as computer-executable code, may take many forms, including but not limited to, a tangible storage medium, a carrier wave medium or physical transmission medium. Non-volatile storage media include, for example, optical or magnetic disks, such as any of the storage devices in any computer(s) or the like, such as may be used to implement the databases, etc. shown in the drawings. Volatile storage media include dynamic memory, such as main memory of such a computer platform. Tangible transmission media include coaxial cables; copper wire and fiber optics, including the wires that comprise a bus within a computer system. Carrier-wave transmission media may take the form of electric or electromagnetic signals, or acoustic or light waves such as those generated during radio frequency (RF) and infrared (IR) data communications. Common forms of computer-readable media therefore include for example: a floppy disk, a flexible disk, hard disk, magnetic tape, any other magnetic medium, a CD-ROM, DVD or DVD-ROM, any other optical medium, punch cards paper tape, any other physical storage medium with patterns of holes, a RAM, a ROM, a PROM and EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wave transporting data or instructions, cables or links transporting such a carrier wave, or any other medium from which a computer may read programming code and / or data. Many of these forms of computer readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution.

[0266] The computer system 1501 can include or be in communication with an electronic display 1535 that comprises a user interface (UI) 1540 for providing, for example, an image of a biological component, a barcode, a signal or measurement of a local parameter.Examples of UI’s include, without limitation, a graphical user interface (GUI) and web-based user interface.WSGR Docket No. 59528-739601

[0267] Methods and systems of the present disclosure can be implemented by way of one or more algorithms. An algorithm can be implemented by way of software upon execution by the central processing unit 1505. The algorithm can, for example, identify a biological component, detect a barcode, generate a spatial modulating element (e.g., a mask), provide energy from an energy source, detect or measure a local parameter using a sensor, etc.

[0268] While some embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the invention be limited by the specific examples provided within the specification. While the invention has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. Furthermore, it shall be understood that all aspects of the invention are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is therefore contemplated that the invention shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims

WSGR Docket No. 59528-739601CLAIMSWHAT IS CLAIMED IS:

1. A method, compri sing:(a) providing a fluidic device, wherein:the fluidic device comprises at least 500 enclosures,each enclosure of the at least 500 enclosures has an interior volume, the interior volume comprises a fluid,a cell of the plurality of cells is entirely located within the interior volume of each enclosure of the at least 500 enclosures, andthe cell of a plurality of cells within each enclosure is not immobilized within the interior volume the enclosure; and(b) subsequent to (a), monitoring each enclosure of the at least 500 enclosures for at least about 10 minutes.

2. The method of claim 1, wherein the fluidic device comprises from about 1000 to about 100000 enclosures.

3. The method of claim 1, wherein the method comprises monitoring each enclosure of the at least 500 enclosures for about one day to about ten days.

4. The method of claim 1, wherein each of the at least 500 enclosures comprises a single cell of the plurality of cells.

5. The method of claim 1, wherein a distribution of the plurality of cells in the at least 500 enclosures is a non-Poisson distribution.

6. The method of claim 1, wherein the monitoring in (b) comprises: (i) imaging the at least 500 enclosures; (ii) performing an image-based phenotypic assay on the cell; or (iii) a combination thereof.

7. The method of claim 6, wherein the imaging-based phenotypic assay comprises monitoring a morphology, proliferation, surface marker expression, cytokine secretion, or a combination thereof of the cell of the plurality of cells.

8. The method of claim 6, wherein the imaging-based phenotypic assay comprises monitoring an interaction between the cell of the plurality of cells and an additional cell of the plurality of cells.

9. The method of claim 8, wherein:i) the interaction comprises killing,WSGR Docket No. 59528-739601ii) the interaction comprises activation,iii) the interaction comprises junction formation,iv) the interaction comprises phagocytosis, orv) a combination thereof.

10. The method of claim 8, wherein the cell and the additional cell are co-enclosed within an enclosure of the at least 500 enclosures.

11. The method of claim 8, wherein the cell is enclosed within a first enclosure of the at least 500 enclosures, and wherein the additional cell is enclosed within a second enclosure of the at least 500 enclosures.

12. The method of claim 8, wherein the cell is enclosed within a first enclosure of the at least 500 enclosures, and wherein the additional cell is not enclosed within an enclosure.

13. The method of claim 1, further comprising, subsequent to (b):(c) releasing a nucleic acid from the cell, wherein the nucleic acid is captured in the interior volume of the enclosure of the at least 500 enclosures.

14. The method of claim 13, further comprising:sequencing the nucleic acid, a derivative of the nucleic acid, or a complement of the derivative of the nucleic acid, andlinking data generated from the sequencing to data generated from the monitoring.

15. The method of claim 13, wherein the nucleic acid is captured on a nucleic acid capture probe, wherein the nucleic acid capture probe is entirely located within the interior volume of the enclosure, and wherein the nucleic acid capture probe comprises a barcode that is uniquely associated with the enclosure.

16. The method of claim 1, wherein each enclosure of the at least 500 enclosures is in fluidic communication with each other enclosure of the at least 500 enclosures.

17. The method of claim 1, wherein the at least 500 enclosures comprise fixed positions within the fluidic device.

18. The method of claim 1, wherein at least about 90% of the cells within the at least 500 enclosures are alive during the monitoring of (b).

19. The method of claim 1, wherein:the plurality of cells are from a human subject, andthe method further comprises identifying a health status of the human subject at least in part based on the monitoring.WSGR Docket No. 59528-73960120. The method of claim 1, wherein the interior volume of each enclosure is at least about 1 nanoliter.

21. The method of claim 1, wherein the fluid in each enclosure is in fluidic communication with an additional fluid outside of the enclosure.

22. The method of claim 1, wherein a first cell of the plurality of cells enclosed in a first enclosure of the at least 500 enclosures is in fluidic communication with a second cell of the plurality of cells enclosed in a second enclosure of the at least 500 enclosures.

23. The method of claim 1, wherein the cell of the plurality of cells is entirely located within the fluid of the interior volume.

24. The method of claim 1, wherein the forming generates the at least 500 enclosures at a rate of at least about 250 enclosures per minute.

25. The method of claim 1, wherein the monitoring comprises detecting a cell state transition of a cell of the plurality of cells located in an enclosure of the at least 500 enclosures.

26. The method of claim 1, wherein the monitoring comprises viewing the at least 500 enclosures through a plurality of fields of view.

27. The method of claim 1, wherein at least about 90% of cells of the plurality of cells located in the at least 500 enclosures are viable after the at least about 10 minutes.

28. The method of claim 1, wherein at least about 95% of cells of the plurality of cells located in the at least 500 enclosures are viable after the at least about 10 minutes.

29. The method of claim 1, wherein at least about 98% of cells of the plurality of cells located in the at least 500 enclosures are viable after the at least about 10 minutes.

30. A method, compri sing:(a) providing a fluidic device, wherein:the fluidic device comprises at least 500 enclosures,each enclosure of the at least 500 enclosures has an interior volume, the interior volume comprises a fluid,a cell of a plurality of cells is entirely located within the interior volume of each enclosure of the at least 500 enclosures, andthe cell of the plurality of cells within each enclosure is not immobilized within the interior volume of the enclosure comprises a cell of the plurality of cells;(b) subsequent to (a), performing an imaging assay in the at least 500 enclosures; and (c) subsequent to (b), performing a molecular assay on at least a subset of the plurality of cells.WSGR Docket No. 59528-73960131. The method of claim 30, wherein at least about 90% of the plurality of cells are alive during the imaging of (b).

32. The method of claim 30, wherein the at least 500 enclosures comprise from about 1000 to about 100000 enclosures.

33. The method of claim 30, wherein the method comprises monitoring an enclosure of the at least 500 enclosures for about 1 day to about 50 days.

34. The method of claim 30, wherein a distribution of the plurality of cells in the at least 500 enclosures is a non-Poisson distribution.

35. The method of claim 30, wherein the molecular assay comprises releasing a nucleic acid from the cell, wherein the nucleic acid is captured in the interior volume of the enclosure of the at least 500 enclosures.

36. The method of claim 35, wherein the nucleic acid is captured on a nucleic acid capture probe, wherein the nucleic acid capture probe is entirely located within the interior volume of the enclosure, and wherein the nucleic acid capture probe comprises a barcode that is uniquely associated with the enclosure.

37. The method of claim 35, further comprising:sequencing the nucleic acid, a derivative of the nucleic acid, or a complement of the derivative of the nucleic acid, andlinking data generated from the sequencing to data generated from the imaging assay.

38. The method of claim 30, wherein each enclosure of the at least 500 enclosures is in fluidic communication with each other enclosure of the at least 500 enclosures.

39. The method of claim 30, wherein the method further comprises performing an imagebased phenotypic assay on the cell.

40. The method of claim 30, wherein:the plurality of cells are from a human subject, andthe method further comprises identifying a health status of the subject at least in part based on the imaging assay, the molecular assay, or the combination thereof.

41. The method of claim 30, wherein the interior volume of each enclosure is at least about 1 nanoliter.

42. The method of claim 30, wherein the fluid in each enclosure is in fluidic communication with an additional fluid outside of the enclosure.WSGR Docket No. 59528-73960143. The method of claim 30, wherein a first cell of the plurality of cells enclosed in a first enclosure of the at least 500 enclosures is in fluidic communication with a second cell of the plurality of cells enclosed in a second enclosure of the at least 500 enclosures.

44. The method of claim 30, wherein the cell of the plurality of cells is entirely located within the fluid of the interior volume.

45. The method of claim 30, wherein the forming generates the at least 500 enclosures at a rate of at least about 250 enclosures per minute.

46. The method of claim 30, wherein the monitoring comprises detecting a cell state transition of a cell of the plurality of cells located in an enclosure of the at least 500 enclosures.

47. The method of claim 30, wherein the monitoring comprises viewing the at least 500 enclosures through a plurality of fields of view.

48. The method of claim 30, wherein at least about 90% of cells of the plurality of cells located in the at least 500 enclosures are viable after the at least about 10 minutes.

49. The method of claim 30, wherein at least about 95% of cells of the plurality of cells located in the at least 500 enclosures are viable after the at least about 10 minutes.

50. The method of claim 30, wherein at least about 98% of cells of the plurality of cells located in the at least 500 enclosures are viable after the at least about 10 minutes.

51. A method, compri sing:(a) introducing at least 100 cells to a channel of a fluidic device, wherein the introducing the at least 100 cells to the fluidic device comprises introducing the at least 100 cells through an inlet of the fluidic device;(b) selectively enclosing the at least 100 cells in a plurality of unique enclosures in the channel of the fluidic device such that each cell of the at least 100 cells is spatially constrained to a unique area of a plurality of unique areas of the channel of the fluidic device, wherein each unique area of the plurality of unique areas comprises a unique enclosure of the plurality of unique enclosures, wherein each unique area of the plurality of unique areas is no more than 285,000 square micrometers (μm2), and wherein the selectively enclosing is performed at a rate of at least 250 unique enclosures per minute;(c) subsequent to the selectively enclosing in (b), performing a cellular or molecular assay on the at least 100 cells to determine a cellular characteristic, wherein the cellular characteristic comprises cytotoxicity, proliferative capacity, proliferation rate, cellular identity, purity, gene expression profile, transcriptome, surface marker expression, soluble factor secretion, activation status, epigenetic profile, sequence copy number, morphology,WSGR Docket No. 59528-739601subcellular localization, intracellular protein expression, DNA sequence variation, or a combination thereof;(d) identifying at least a subset of the at least 100 cells; and(e) monitoring the at least 100 cells or the subset of the at least 100 cells in the plurality of unique enclosures for at least 10 minutes,thereby obtaining longitudinal data unique to each cell of the at least 100 cells or the subset of the at least 100 cells,wherein at least 90% of the at least 100 cells or the subset of the at least 100 cells are viable after the at least 10 minutes,wherein the monitoring comprises imaging the at least 100 cells or the subset of the at least 100 cells to generate a plurality of images across a plurality of fields of view of the channel of the fluidic device,wherein the longitudinal data comprises data from a first time point and a second time point of the at least 10 minutes, and wherein the first time point and the second time point are different.

52. The method of claim 51, wherein at least two of the at least 100 cells are spatially constrained to the same unique area of the plurality of unique areas.

53. The method of claim 51, wherein the at least 100 cells comprises from 2000 to 20000 cells.

54. The method of claim 51, wherein each unique area of the plurality of unique areas is 700 to 30000 μm2.

55. The method of claim 51, wherein:(i) the fluidic device comprises from 1000 to 100000 unique enclosures of the plurality of unique enclosures;(ii) at least a subset of the plurality of unique enclosures comprises a single cell of the at least 100 cells; or(iii) a combination thereof.

56. The method of claim 51, wherein the monitoring comprises performing an imagebased phenotypic assay on a cell of the at least 100 cells or the subset of the at least 100 cells.

57. The method of claim 1, wherein the monitoring comprises detecting an interaction between a first cell of the at least 100 cells or the subset of the at least 100 cells and a second cell of the at least 100 cells or the subset of the at least 100 cells.

58. The method of claim 57, wherein:i) the interaction comprises killing the first cell,WSGR Docket No. 59528-739601ii) the interaction comprises activation of the first cell,iii) the interaction comprises junction formation,iv) the interaction comprises phagocytosis of the first cell, orv) a combination thereof.

59. The method of claim 57, wherein the first cell and the second cell are co-located in a single unique enclosure of the plurality of unique enclosures.

60. The method of claim 57, wherein the first cell is located in a first unique enclosure of the plurality of unique enclosures, and wherein the second cell is located in a second unique enclosure of the plurality of unique enclosures.

61. The method of claim 51, further comprising, subsequent to (e): (f) releasing a nucleic acid from a cell of the at least 100 cells, wherein the nucleic acid is captured on a surface located in the unique area of the fluidic device that the cell of the at least 100 cells is spatially constrained to.

62. The method of claim 61, further comprising:sequencing the nucleic acid, a derivative of the nucleic acid, or a complement of the derivative of the nucleic acid, andlinking data generated from the sequencing to the longitudinal data obtained in (e).

63. The method of claim 51, wherein:the at least 100 cells are from a human subject, andthe method further comprises identifying a health status of the human subject at least in part based on the monitoring of (e).

64. A method, comprising:(a) introducing a plurality of cells to a channel of a fluidic device, wherein the introducing the plurality of cells to the fluidic device comprises introducing the plurality of cells through an inlet of the fluidic device, wherein the fluidic device comprises a surface;(b) selectively enclosing a subset of cells of the plurality of cells in a plurality of unique enclosures in the channel of the fluidic device such that each cell of the subset of cells is physically separated from other cells of the subset of cells of the plurality of cells, wherein at least about 1.5 cells are enclosed per micrometer squared (μm2) of the surface, and wherein the selectively enclosing is performed at a rate of at least 250 unique enclosures per minute; and(c) subsequent to the selectively enclosing in (b), performing a cellular or molecular assay on the plurality of cells or the subset of the plurality of cells to determine a cellular characteristic, wherein the cellular characteristic comprises cytotoxicity, proliferativeWSGR Docket No. 59528-739601capacity, proliferation rate, cellular identity, purity, gene expression profile, transcriptome, surface marker expression, soluble factor secretion, activation status, epigenetic profile, sequence copy number, morphology, subcellular localization, intracellular protein expression, DNA sequence variation, or a combination thereof.

65. The method of claim 64, wherein from 2 to 60 cells are enclosed per mm2of the surface.

66. The method of claim 64, wherein each unique enclosure of the plurality of unique enclosures comprises a cell of the subset of cells.

67. The method of claim 64, wherein during (b), an additional subset of cells of the plurality of cells are not selectively enclosed during (b), and wherein the method further comprises removing the additional subset of cells from the fluidic device.

68. The method of claim 64, wherein the subset of cells are in chemical communication following (b).

69. The method of claim 64, further comprising: (d) monitoring the subset of cells for at least 10 minutes, thereby obtaining longitudinal data unique to each cell of the subset of cells.

70. The method of claim 69, further comprising, subsequent to (d): (e) releasing a nucleic acid from the cell, wherein the nucleic acid is enclosed with the cell.

71. The method of claim 70, further comprising:sequencing the nucleic acid, a derivative of the nucleic acid, or a complement of the derivative of the nucleic acid, andlinking data generated from the sequencing to data generated from the monitoring in (d).

72. The method of claim 64, wherein the subset of cells comprises 2000 to 20000 cells.

73. The method of claim 69, wherein the monitoring in (d) comprises:(i) imaging a cell of the subset of cells;(ii) performing an image-based phenotypic assay on the cell; or(iii) a combination thereof.

74. The method of claim 69, wherein:the plurality of cells are from a human subject, andthe method further comprises identifying a health status of the human subject at least in part based the monitoring of (d).

75. The method of claim 51, further comprising screening a cell of the at least 100 cells for a genetic mutation.WSGR Docket No. 59528-73960176. The method of claim 51, wherein the monitoring of (e) comprises measuring a response of a cell of the at least 100 cells to an incubation condition.

77. The method of claim 51 or claim 64, wherein the plurality of unique enclosures comprise polymer matrices, wherein the selectively enclosing comprises projecting light into the channel of the fluidic device, and wherein the light causes a polymer precursor to crosslink to form the polymer matrices.

78. The method of claim 51, wherein the monitoring in (e) comprises monitoring the at least 100 cells or the subset of the at least 100 cells in the plurality of unique enclosures for at least 10 hours.

79. The method of claim 51, wherein the monitoring in (e) comprises monitoring the at least 100 cells or the subset of the at least 100 cells in the plurality of unique enclosures for at least 1 day.

80. The method of claim 51 or claim 64, wherein the cellular characteristic comprises cytotoxicity, proliferative capacity, proliferation rate, cellular identity, purity, gene expression profile, transcriptome, surface marker expression, soluble factor secretion, activation status, morphology, or a combination thereof.

81. The method of claim 51 or claim 64, wherein the selectively enclosing is performed at a rate of 250 unique enclosures per minute to 2500 unique enclosures per minute.

82. The method of claim 51 or claim 64, wherein each unique enclosure of the plurality of unique enclosures has an interior volume, wherein a cell of the at least 100 cells is entirely located within the interior volume of each unique enclosure of the plurality of unique enclosures, and wherein the cell of the at least 100 cells within each unique enclosure is not immobilized within the interior volume of the unique enclosure.

83. The method of claim 51 or claim 64, wherein at least 95% of the at least 100 cells or the subset of the at least 100 cells are viable after the at least 10 minutes.

84. The method of claim 51 or claim 64, wherein at least 98% of the at least 100 cells or the subset of the at least 100 cells are viable after the at least 10 minutes.

85. The method of claim 51, wherein the identifying of the at least the subset of the plurality of cells in (d) is based at least based in part on the cellular characteristic determined in (c).

86. The method of claim 85, wherein the identifying of the at least the subset of the plurality of cells in (d) occurs subsequent to the determining of the cellular characteristic in (c).

87. A method, comprising:WSGR Docket No. 59528-739601(a) selectively encapsulating at least 100 cells in a fluidic device such that each cell of the at least 100 cells is spatially constrained to a unique area of the fluidic device, wherein each of the unique areas is no more than 285,000 μm2; and(b) monitoring each cell of the at least 100 cells for at least 10 minutes, thereby obtaining longitudinal data unique to each cell of the at least 100 cells.

88. A method, comprising:(a) introducing a plurality of cells to a fluidic device comprising a surface; and (b) selectively encapsulating a subset of cells of the plurality of cells such that each cell of the subset of cells is physically separated from other cells of the subset of cells, wherein at least about 1.5 cells are encapsulated per mm2of the surface.

89. A method, comprising:(a) introducing a plurality of cells to a channel of a fluidic device, wherein the introducing the plurality of cells to the fluidic device comprises introducing the plurality of cells through an inlet of the fluidic device;(b) subsequent to (a), forming a plurality of unique enclosures in the channel of the fluidic device, wherein the plurality of unique enclosures comprises at least 1000 unique enclosures, wherein each unique enclosure of the plurality of unique enclosures comprises a cell of the plurality of cells, and wherein the plurality of cells are in a quiescent fluid during the forming of the plurality of unique enclosures;(c) subsequent to (b), performing a cellular or molecular assay on the plurality of cells or a subset of the plurality of cells to determine a cellular characteristic, wherein the cellular characteristic comprises cytotoxicity, proliferative capacity, proliferation rate, cellular identity, purity, gene expression profile, transcriptome, surface marker expression, secretion, activation status, morphology, or a combination thereof; and(d) monitoring each cell of the plurality of cells or the subset of the plurality of cells in the plurality of unique enclosures for at least 10 minutes, thereby obtaining longitudinal data unique to each cell of the plurality of cells or the subset of the plurality of cells, wherein at least 95% of the plurality of cells or the subset of the plurality of cells are viable after the at least 10 minutes, wherein the monitoring comprises imaging the plurality of cells or the subset of the plurality of cells to generate a plurality of images across a plurality of fields of view of the channel of the fluidic device, wherein the longitudinal data comprises data from a first time point and a second time point of the at least 10 minutes, and wherein the first time point and the second time point are different.

90. A method, comprising:WSGR Docket No. 59528-739601(a) introducing a plurality of cells to a channel of a fluidic device, wherein the introducing the plurality of cells to the fluidic device comprises introducing the plurality of cells through an inlet of the fluidic device;(b) subsequent to (a), forming a plurality of unique enclosures in the channel of the fluidic device, wherein the plurality of unique enclosures comprises at least 1000 unique enclosures, wherein each unique enclosure of the plurality of unique enclosures comprises a cell of the plurality of cells, and wherein the plurality of unique enclosures are configured to allow secretions from the plurality of cells to flow between the plurality of unique enclosures;(c) subsequent to (b), performing a cellular or molecular assay on the plurality of cells or a subset of the plurality of cells to determine a cellular characteristic, wherein the cellular characteristic comprises cytotoxicity, proliferative capacity, proliferation rate, cellular identity, purity, gene expression profile, transcriptome, surface marker expression, secretion, activation status, morphology, or a combination thereof; and(d) monitoring each cell of the plurality of cells or the subset of the plurality of cells in the plurality of unique enclosures for at least 10 hours, thereby obtaining longitudinal data unique to each cell of the plurality of cells or the subset of the plurality of cells, wherein at least 90% of the plurality of cells or the subset of the plurality of cells are viable after the at least 10 hours, wherein the monitoring comprises imaging the plurality of cells or the subset of the plurality of cells to generate a plurality of images across a plurality of fields of view of the channel of the fluidic device, wherein the longitudinal data comprises data from a first time point and a second time point of the at least 10 hours, and wherein the first time point and the second time point are different.

91. The method of any one of claim 89 or claim 90, wherein an additional subset of cells of the plurality of cells are not selectively enclosed during (b), and wherein the method further comprises removing the additional subset of cells from the fluidic device.

92. The method of any one of claim 89 or claim 90, wherein (b) comprises selectively enclosing at least 2000 cells of the plurality of cells.

93. The method of any one of claim 89 or claim 90, wherein a first cell of the plurality of cells in a first unique enclosure of the plurality of unique enclosures and a second cell of the plurality of cells in a second unique enclosure of the plurality of unique enclosures are in chemical communication following (b).

94. The method of any one of claim 89 or claim 90, further comprising releasing a nucleic acid from a cell of the plurality of cells or the subset of the plurality of cells, wherein theWSGR Docket No. 59528-739601nucleic acid is located in a unique enclosure of the plurality of unique enclosures with the cell.

95. The method of claim 94, further comprising sequencing the nucleic acid, a derivative of the nucleic acid, or a complement of the derivative of the nucleic acid, and linking data generated from the sequencing to data generated from the monitoring in (d).

96. The method of any one of claim 89 or claim 90, wherein:the plurality of cells are from a human subject, andthe method further comprises identifying a health status of the subject at least in part based on the cellular characteristic determined in (c) and the longitudinal data obtained in (d).

97. The method of claim 90, wherein during (b) the plurality of cells are disposed in a quiescent fluid.

98. The method of claim 90, wherein walls of the plurality of unique enclosures comprise pores, wherein the pores are sufficiently large to allow passage of the secretions through the walls of the plurality of unique enclosures, and wherein the pores block passage of the plurality of cells through the walls of the plurality of unique enclosures.

99. The method of claim 90, wherein the secretions comprise cytokines.

100. The method of any one of claim 89 or claim 90, wherein (b) comprises forming from 1000 to 100000 unique enclosures.

101. The method of claim 89 or 90, wherein the monitoring in (d) comprises monitoring a morphology, proliferation, surface marker expression, cytokine secretion, or a combination thereof of each cell of the plurality of cells or the subset of the plurality of cells.

102. The method of claim 94, wherein the nucleic acid is captured on a nucleic acid capture probe, and wherein the nucleic acid capture probe comprises a barcode that is uniquely associated with the unique enclosure of the plurality of unique enclosures.

103. The method of any one of claim 89 or claim 90, wherein:the plurality of cells are from a human subject, andthe method further comprises predicting a probability of a response from the human subject to a drug treatment or regimen.

104. The method of any one of claim 89 or claim 90, wherein the monitoring comprises measuring an intercellular interaction between two or more cells of the plurality of cells or the subset of the plurality of cells.

105. The method of any one of claim 89 or claim 90, further comprising screening the plurality of cells or the subset of the plurality of cells for a genetic mutation.WSGR Docket No. 59528-739601106. The method of any one of claim 89 or claim 90, wherein the plurality of unique enclosures comprise polymer matrices, wherein the forming comprises projecting light into the fluidic device, and wherein the light causes a polymer precursor to crosslink to form the polymer matrices.

107. The method of any one of claim 89 or claim 90, wherein the monitoring in (d) comprises monitoring the plurality of cells or the subset of the plurality of cells in the plurality of unique enclosures for at least 10 hours.

108. The method of any one of claim 89 or claim 90, wherein the monitoring in (d) comprises monitoring the plurality of cells or the subset of the plurality of cells in the plurality of unique enclosures for at least 1 day.

109. The method of any one of claim 89 or claim 90, wherein the plurality of unique enclosures are formed at a rate of at least 250 unique enclosures per minute.

110. The method of any one of claim 89 or claim 90, wherein each unique enclosure of the plurality of unique enclosures has an interior volume, wherein a cell of the plurality of cells is entirely located within the interior volume of each unique enclosure of the plurality of unique enclosures, and wherein the cell of the plurality of cells within each unique enclosure is not immobilized within the interior volume of the unique enclosure.

111. The method of any one of claim 89 or claim 90, wherein at least 95% of the plurality of cells or the subset of the plurality of cells are viable after the at least 10 minutes or the at least 10 hours.

112. The method of any one of claim 89 or claim 90, wherein at least 98% of the plurality of cells or the subset of the plurality of cells are viable after the at least 10 minutes or the at least 10 hours.

113. A method, comprising:(a) introducing a plurality of cells to a fluidic device; and(b) selectively encapsulating a subset of cells of the plurality of cells such that each cell of the subset of cells is physically separated from other cells of the subset of cells, wherein during the encapsulating, the plurality of cells are in a quiescent fluid.

114. A method, comprising:(a) introducing a plurality of cells to a fluidic device; and(b) subsequent to (a), forming a plurality of enclosures, wherein each enclosure of the plurality of enclosures comprises a cell of the plurality of cells, and wherein the plurality of enclosures are configured to allow secretions from the plurality of cells to flow between the plurality of enclosures.WSGR Docket No. 59528-739601115. A method for analyzing a plurality of cells over a period of time, comprising:collecting a first image of the plurality of cells,wherein the first image comprises a plurality of fields of view, and wherein the collecting the first image comprises moving a detector over the plurality of fields of view;applying annotations to at least a subset of the plurality of cells in the first image; collecting a second image of the plurality of cells,wherein the second image is collected after the first image,wherein the second image comprises the plurality of fields of view, and wherein the collecting the second image comprises moving the detector over the plurality of fields of view; andapplying the annotations to the plurality of cells or the subset of the plurality of cells in the second image,wherein each cell of the plurality of cells or the subset of the plurality of cells received the same annotation in the first image and the second image.

116. A method, comprising:(a) selectively encapsulating a subset of adherent cells of a plurality of adherent cells disposed on a surface of a fluidic device such that each adherent cell of the subset of adherent cells is physically separated from other adherent cells of the subset of adherent cells; and(b) monitoring the subset of adherent cells for at least 10 minutes.

117. The method of claim 116, wherein (a) comprises selectively encapsulating from about 2000 to about 20000 adherent cells.

118. The method of claim 116, wherein (a) comprises forming a plurality of enclosures, wherein each enclosure of the plurality of enclosures comprises an adherent cell of the subset of adherent cells.

119. The method of claim 118, wherein, during (a) the plurality of enclosures are formed at a rate of about 50 to about 1500 enclosures per minute.

120. The method of claim 116, wherein during (a), the subset of adherent cells are encapsulated at a rate of about 50 to about 1500 adherent cells per minute.

121. The method of claim 116, wherein an additional subset of adherent cells of the plurality of adherent cells are not selectively encapsulated during (a), and wherein the method comprises removing the additional subset of adherent cells from the fluidic device.WSGR Docket No. 59528-739601122. The method of claim 116, wherein the subset of adherent cells are in chemical communication following (a).

123. The method of claim 116, further comprising, subsequent to (c): (d) releasing a nucleic acid from an adherent cell of the subset of adherent cells, wherein the nucleic acid is selectively encapsulated with the adherent cell.

124. The method of claim 123, further comprising:sequencing the nucleic acid, a derivative of the nucleic acid, or a complement of the derivative of the nucleic acid, andlinking data generated from the sequencing to data generated from the monitoring in (b).

125. The method of claim 116, wherein the monitoring in (b) comprises:(i) imaging at least one adherent cell of the subset of adherent cells;(ii) performing an image-based phenotypic assay on an adherent cell of the subset of adherent cells; or(iii) a combination thereof.

126. The method of claim 116, wherein (a) comprises forming at least 1000 enclosures, wherein each enclosure of the at least 1000 enclosures comprises an adherent cell of the subset of adherent cells.

127. The method of claim 126, wherein in (b), at least 75% of the at least 1000 enclosures comprises a living adherent cell in its adherent state.

128. The method of claim 116, wherein the surface comprises (i) fibronectin, (ii) laminin, (iii) poly-L-ornithine, or (iv) a combination thereof.

129. A fluidic device, comprising: at least 1000 enclosures, wherein at least 75% of the 1000 enclosures comprise a living adherent cell in its adherent state.

130. The fluidic device of claim 129, wherein the living adherent cells are adhered to a surface of the fluidic device.

131. The fluidic device of claim 130, wherein the surface comprises (i) fibronectin, (ii) laminin, (iii) poly-L-ornithine, or (iv) a combination thereof.

132. The fluidic device of claim 129, wherein the living adherent cells are from a single human subject.

133. A method, comprising: performing at least 3 assays on a plurality of cells, wherein each of the at least 3 assays generates data associated with the plurality of cells, and wherein the method further comprises associating a subset of the data from each of the at least 3 assays with individual cells of the plurality of cells.WSGR Docket No. 59528-739601134. The method of claim 133, wherein the at least 3 assays are performed in about 1 to about 30 minutes.

135. The method of claim 133, wherein at least one assay of the at least 3 assays simultaneously generates data for at least a subset of the plurality of cells.

136. The method of claim 133, wherein the method comprises performing from 4 to 8 assays on the plurality of cells.

137. The method of claim 133, wherein the at least 3 assays comprise (i) an imaging assay and (ii) a molecular assay.

138. The method of claim 137, wherein the imaging assay comprises monitoring a morphology, proliferation, surface marker expression, cytokine secretion, or a combination thereof of at least one cell of the plurality of cells.

139. The method of claim 137, wherein the molecular assay comprises:releasing a nucleic acid from a cell of the plurality of cells, and sequencing the nucleic acid, a derivative of the nucleic acid, or a complement of the derivative of the nucleic acid.

140. The method of claim 137, wherein at least about 90% of the plurality of cells are alive during the imaging assay.

141. The method of claim 137, wherein the imaging assay comprises monitoring the plurality of cells for at least about 10 minutes.

142. The method of claim 133, wherein the at least 3 assays measure: cytotoxicity, proliferative capacity, proliferation rate, activation status, cellular identity, purity, gene expression profile, transcriptome, surface marker expression, soluble factor secretion, activation status, epigenetic profile, sequence copy number, morphology, subcellular localization, intracellular protein expression, or a combination thereof of at least one cell of the plurality of cells.

143. The method of claim 133, further comprising enclosing the plurality of cells within a plurality of enclosures.

144. The method of claim 133, wherein at least 2 assays of the at least 3 assays are performed at different times.

145. A method for analyzing a plurality of cells, comprising:(a) dispersing the plurality of cells over a planar surface;(b) while the plurality of cells is dispersed over the planar surface, imaging at least a subset of the plurality of cells, thereby generating a plurality of cell images, wherein a cell image of the plurality of cell images comprises an image of a cell of the plurality of cells,WSGR Docket No. 59528-739601wherein the plurality of cell images is collected over a plurality of fields of view of the planar surface;(c) while the plurality of cells is dispersed over the planar surface, releasing a nucleic acid molecule from the cell of the plurality of cells and capturing the nucleic acid molecule with a capture probe;(d) performing at least a portion of a nucleic acid assay on the nucleic acid molecule or a derivative thereof, thereby generating a nucleic acid assay result, wherein the nucleic acid assay result identifies at least a portion of the capture probe that is associated with the cell of the plurality of cells; and(e) associating the cell image with nucleic acid assay result via at least the capture probe.

146. The method of claim 145, wherein the imaging is performed at multiple time points, and wherein the multiple time points span at least 10 minutes.

147. The method of claim 145, wherein the plurality of cell images comprise cell images collected at different wavelengths.

148. The method of claim 145, wherein the plurality of cell images are collected at three or more wavelengths.

149. The method of claim 145, wherein the cell image is collected in about 0.2 to about 5 seconds.

150. The method of claim 145, further comprising enclosing the plurality of cells or the subset of the plurality of cells within a plurality of enclosures, wherein the cell is enclosed within an enclosure of the plurality of enclosures.

151. The method of claim 150, wherein the plurality of enclosures comprises from about 1000 to about 100000 enclosures.

152. The method of claim 150, wherein at least a subset of the plurality of enclosures comprise single cells of the plurality of cells.

153. The method of claim 150, wherein the plurality of enclosures comprise polymer matrices, and wherein the enclosing comprises projecting light into a fluidic device, wherein the fluidic device comprises the planar surface, and wherein the light causes a polymer precursor to crosslink to form the polymer matrices.

154. The method of claim 145, wherein the nucleic acid assay comprises screening the plurality of cells or the subset of cells for a mutation.

155. The method of claim 145, further comprising using the cell image, the nucleic acid assay result, or the combination thereof to measure a response of the cell to an incubation condition.WSGR Docket No. 59528-739601156. The method of claim 145, wherein at least two cell images of the plurality of cell images are generated simultaneously.

157. The method of claim 145, wherein the planar surface is a surface of a fluidic device, wherein the fluidic device comprises an additional planar surface that opposes the planar surface, and wherein the planar surface and the additional planar surface at least partially define a fluidic space that comprises the plurality of cells.

158. The method of claim 145, wherein the capture probe comprises a spatially addressable tag, and wherein associating the plurality of cell images with the nucleic acid result comprises detecting the spatially addressable tag.

159. The method of claim 145, wherein at least 90% of the plurality of cells are viable during (b).

160. The method of claim 145, wherein at least 90% of the plurality of cells are viable during (b).

161. The method of claim 145, wherein at least 90% of the plurality of cells are viable during (b).

162. The method of claim 158, wherein detecting the spatially addressable tag comprises sequencing the spatially addressable tag.

163. The method of claim 145, wherein the planar surface comprises a plurality of unique areas, wherein each cell of the plurality of cells is dispersed into a unique area of the plurality of unique areas, and wherein each unique area of the plurality of unique areas is no more than 285,000 square micrometers (“pm2”).

164. A method for isolating cells, comprising:(a) collecting an image of a plurality of cells;(b) using the image, identifying at least about 20 cells of the plurality of cells from the image; and(c) generating a plurality of enclosures, wherein the plurality of enclosures at least partially enclose the at least about 20 cells,wherein (a), (b), and (c) are performed in less than about 5 seconds.

165. A method for isolating cells, comprising:receiving a parameter relating to a characteristic of an enclosure;generating a plurality of instances of the enclosure, wherein the plurality of instances of the enclosure enclose at least 500 cells, and wherein each of the plurality of instances of the enclosure comprises the characteristic.